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ABSTRACT 
Objectives  
This thesis aimed to study the inter-relationship between the oral health status, aspects of 
the adaptive and innate immune response, and the oral microbiome of a well-defined cohort 
of Behçet’s syndrome (BS) patients.  
 
Methods 
Patients thought to have BS were referred to one of the two centres participating in this 
study (St Thomas’ Hospital and Royal London Hospital). Diagnosis was based on the 
International Study Group (ISG) criteria. Information about the frequency of the different 
symptoms of the disease along with the treatment protocol was collected on a data sheet 
and stored electronically in a database, in the period between January 2006 and August 
2012. The data were then analysed at the end of the study period.  
 
The quality of life (QoL) and oral health status of BS patients in the UK was compared to 
those from Turkey. Furthermore, the oral health status of BS patients in the UK was 
compared to that of healthy control (HC) volunteers and recurrent aphthous stomatitis 
(RAS) patients. Saliva and oral swabs were cultured and purified to homogeneity and 
bacteria were identified by matrix-assisted laser desorption/ionisation-time of flight 
(MALDI-TOF). Salivary viral load and the serum immunoglobulin (Ig) G of the different 
herpes viruses were also examined. 
 
In order to determine whether there were differences in the innate response efficacy in BS 
patients, the expression of key molecular determinants of pathogen recognition was also 
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analysed. Total ribonucleic acid (RNA) was purified from non-ulcerated buccal mucosal 
brush biopsies and analysed by real time polymerase chain reaction (qPCR) for the 
presence of toll-like receptor (TLR) 2 messenger RNA (mRNA) and TLR4 mRNA, and 
their splice variants. The functions of TLR2 and TLR4 were also investigated. 
 
Results  
In the investigated cohort of UK BS patients, all patients had a history of recurrent oral 
ulceration, 85.6% had dermatological lesions, 79.1% had rheumatological manifestations, 
73.9% had genital ulceration, 68.6% had ocular involvement, 15% had neurological 
manifestations, and 10.5% had vascular involvement. The most frequent treatment was 
colchicine (54.2%), followed by topical corticosteroid therapy (53.6%) then azathioprine 
(43.8%). 
 
The QoL of BS patients from the UK and Turkey was affected to a similar extent. The 
Turkish BS patients had generally poorer oral health status in comparison to the UK BS 
patients. Nevertheless, the UK BS patients had also generally poorer oral health status in 
comparison to HC volunteers. The oral health status of the UK BS patients was comparable 
to those suffering from RAS.  
 
The oral mucosal and salivary microbial profile was variable between individuals in the 
same group and between individuals in different groups. The orally active BS patients’ oral 
mucosa showed the highest microbial community complexity and diversity compared to all 
the other investigated groups. Moreover, the BS patients had statistically higher salivary 
Epstein-Barr virus (EBV) shedding compared to HC volunteers, but not to RAS patients. 
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Relapsed BS patients’ oral mucosa expressed higher levels of TLR2 and TLR4 mRNA. 
Investigation of the known splice variants of both receptors revealed that TLR2 mRNA 
variants b, d and e, and TLR4 variants 3 and 4 are significantly elevated in relapsed BS 
patients. A significant defect in the response to cognate agonists of TLR1/2 heterodimer 
and TLR4 was also observed in the whole BS patient cohort. Furthermore, BS patients 
expressed a lower cytomegalovirus (CMV) IgG level in comparison to all the investigated 
groups. 
 
Conclusion  
In conclusion, BS patients show higher levels of expression of some of the unusual splice 
variants of TLR2 and TLR4 mRNA, which might contribute to the observed functional 
defect in TLR1/2 heterodimer and TLR4. This defect in the key molecular determinants of 
pathogen recognition can lead to a failure in the adaptive immune responses’ modulation, 
resulting in the observed decrease in the expression of CMV IgG in BS patients and indeed 
the increase in susceptibility to oral infections. Furthermore, it is envisaged that the 
reported discrepancy in the oral microbiome of BS patients can be targeted in the future by 
probiotics to restore the balance of the oral microbial community, leading to better oral 
health which in turn will enable a better control of the BS immune response. 
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INTRODUCTION 
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1.1 OVERVIEW  
Behçet’s syndrome (BS) is one of the vasculitides with devastating multi-systemic 
symptoms. It is an immune-related disease that was first described more than fifty years 
ago by the dermatologist Helusi Behçet. The disease affects young adults and severely 
compromises their quality of life (QoL). It was thought that an environmental factor 
triggers the heightened immune response in these patients, leading to the multi-systemic 
presentation of the disease. 
 
There is consensus that the complex interplay between the commensal microbial 
community and the abnormal immune response is a fundamental root cause for triggering 
BS. Therefore, the expression of molecular determinants of pathogen recognition is a key to 
understanding the capacity of these patients to respond to microbial insult. In this thesis, the 
author aimed to facilitate the understanding of the disease by investigating the inter-
relationship between BS patients’ oral microbiome and the relevant aspects of their innate 
and adaptive immune response.  
 
The thesis embraces seven chapters: Introduction, Materials and Methods, Behçet’s 
Syndrome Patient Cohort in the UK, Oral Health Status and Quality of Life of Behçet’s 
Syndrome Patients, Oral Mucosal Expression of Toll-Like Receptors 2 and 4, The Oral 
Microbiome of Behçet’s Syndrome Patients, and Discussion. 
 
Chapter 1 (Introduction): this chapter begins with an overview of the whole thesis, 
summarising the main findings and conclusions of this study. A review of literature is 
included in this chapter, which focuses on BS and reviews the available English written 
32 
 
literature in relation to the following: BS historical background, definition and diagnosis, 
diagnostic tests and activity markers, epidemiology, clinical picture, deferential diagnosis, 
aetiology, pathogenesis, and treatment. The aims and hypothesis that drive the clinical and 
laboratory elements of this study are detailed at the end of this chapter.  
 
Chapter 2 (Materials and Methods): this chapter focuses on the methodology employed 
to study the clinical and laboratory elements of this thesis.  
 
In summary, the oral health status and QoL of BS patients was assessed. Bacteria in saliva 
and oral swabs were cultured and purified to homogeneity and bacteria were identified by 
matrix-assisted laser desorption/ionisation-time of flight (MALDI-TOF) mass 
spectrometry. Salivary viral load and the serum immunoglobulin (Ig) G antibody to the 
different herpes viruses [herpes simplex virus (HSV) 1, HSV2, cytomegalovirus (CMV), 
Epstein-Barr virus (EBV), varicella zoster virus (VZV), human herpes virus (HHV) 8] were 
also examined. 
 
In order to determine whether there were differences in the innate immune response 
efficacy in BS patients, the expression of key molecular determinants of pathogen 
recognition were also analysed. Total ribonucleic acid (RNA) was purified from non-
ulcerated buccal mucosal brush biopsies and checked by real time polymerase chain 
reaction (qPCR) for the presence of toll-like receptor (TLR) 2 messenger ribonucleic acid 
(mRNA), TLR4 mRNA and their splice variants. Total protein was purified from the same 
samples and checked for the presence of TLR2 and TLR4 protein using slot-blot and 
Western-blot. The functions of TLR2 and TLR4 were also investigated. 
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Chapter 3 (Behçet’s Syndrome Patient Cohort in the UK): this chapter analyses the BS 
cohort. The prevalence of the different signs of the disease was assessed in a cohort of 153 
BS patients from two main tertiary referral centres in the UK for BS patients’ management. 
Recurrent oral ulceration were observed in 100% of the cases, followed by dermatological 
lesions (85.6%), rheumatological manifestations (79.1%), genital ulceration (73.9%) and 
ocular involvement (68.6%). Only 15% of the BS patients had neurological manifestations 
and 10.5% had vascular involvement. 
 
Patients were prescribed multiple medications in 73.9% of the cases. A total of 3.3% of all 
BS patients were treated with topical corticosteroid as the sole treatment while 53.6% were 
treated with topical corticosteroid as part of their multiple therapies. Colchicine was the 
most frequent treatment, used in 54.2% of the BS patient cohort, followed by azathioprine 
(43.8%). 
 
Chapter 4 (Oral Health Status and Quality of Life of Behçet’s Syndrome Patients): 
this chapter presents data extracted from analysing the BS patient cohort, their QoL and 
oral health status. The QoL of BS patients from the UK and Turkey was affected to a 
similar extent. The Turkish BS patients had generally poorer oral health status compared to 
the UK BS patients. Nevertheless, the UK BS patients had also generally poorer oral health 
status compared to healthy control (HC) volunteers. The oral health status of the UK BS 
patients was comparable to those with recurrent aphthous stomatitis (RAS).  
 
Chapter 5 (Oral Mucosal Expression of Toll-Like Receptors 2 and 4): this chapter 
presents the data extracted from analysing the expressions and functions of TLR2 and 
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TLR4 in BS patients. Relapsed BS patients’ oral mucosa expressed a higher level of TLR2 
and TLR4 mRNA. Investigation of the known splice variants of both receptors revealed 
that TLR2 mRNA variant b, d, and e, and TLR4 variants 3 and 4 are significantly elevated 
in relapsed BS patients. A significant defect in the response to cognate agonists of TLR1/2 
heterodimer and TLR4 was also observed in the whole BS patient cohort. 
 
Chapter 6 (The Oral Microbiome of Behçet’s Syndrome Patients): this chapter presents 
data extracted from investigating the oral microbiome of BS patients. The oral mucosal and 
salivary microbial profile was variable between individuals in the same group and between 
individuals in different groups. The orally active BS patients’ oral mucosa showed the 
highest microbial community complexity and diversity compared to all the other 
investigated groups. Moreover, BS patients had statistically higher salivary EBV shedding 
compared to HC volunteers, but not to RAS patients. Furthermore, BS patients expressed 
lower CMV IgG level compared to all the investigated groups. 
 
Chapter 7 (Discussion): this chapter critically appraises the different aspects of the results 
obtained during this study and highlights the conclusion and scope for future work. The 
main points concluded from this study are as follows: (1) BS patients exhibit some innate 
immune dysfunction and/or dysregulation that can explain the observed abnormalities in 
some areas of the adaptive immune responses to oral infection; (2) It is envisaged that the 
reported discrepancy in the oral microbiome of BS patients can be targeted in the future by 
probiotics to restore the balance of the oral microbial community, leading to better oral 
health which in turn will enable a better control of the BS immune response. 
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1.2 REVIEW OF LITERATURE OF BEHÇET’S SYNDROME 
 
1.2.1 HISTORICAL BACKGROUND  
The constellate of the three clinical signs (orogenital ulceration and uveitis) which create 
the major components of what is now known as Behçet’s syndrome (BS) was first 
described by Hippocrates in the fifth century before Christ (BC) in his 3rd Epidemion book. 
Subsequently, Benediktos Adamantiades presented the first case of relapsing iritis with 
hypopyon to the Medical Society of Athens in 1930. He identified three major signs of the 
disease: oral ulceration, relapsing iritis and hypopyon. In 1946, he acknowledged 
thrombophlebitis as the fourth major sign of the same disease. Adamantiades was the first 
to classify the disease into ocular, mucocutaneous and systemic subclasses and contributed 
to the first classification and diagnostic criteria (Zouboulis, 2002).  
 
Dr Hulusi Behçet, a Turkish dermatologist born in Istanbul in 1889, graduated in 1910 
from the Gulham Military Medical School and subsequently specialized in dermatology 
and syphilology. He was the first to formally describe the various manifestations of the 
disease, in the Journal of Skin and Venereal Diseases in 1936, by reporting a series of three 
cases (Verity et al., 1999a) (Figure 1.1). He initially described a triad of oral aphthae, 
genital ulcers, and hypopyon uveitis, and called it Behçet’s triple complex syndrome (Gray, 
1950). Behçet’s triple complex syndrome was classically described at that time as a triad of 
the following signs: (1) recurrent oral ulceration ranging from small ulcers to large necrotic 
ulcers with inflamed sharp edges that heal with scar formation; (2) genital ulceration; (3) 
various eye lesions ranging from conjunctivitis and iritis to thrombosis of the central retinal 
vein (Gray, 1950). Behçet’s disease was internationally documented at the International 
Congress of Dermatology in 1947 (Verity et al., 1999a).  
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Figure 1.1: Dr Hulusi Behçet, the Turkish dermatologist who formally described the 
various manifestations of BS [source: www.tiphastaligi.com]. 
 
1.2.2 DEFINITION AND DIAGNOSIS  
Currently BS is classified with the vasculitides and defined as a chronic, relapsing, multi-
systemic, idiopathic, inflammatory vasculitis that possibly will involve most tissues of the 
body, such as the mucocutaneous, ocular, musculoskeletal, vascular and central nervous 
system (CNS) (Escudier et al., 2006, Evereklioglu, 2005). The highest morbidity and 
mortality rates are observed with cardiovascular, gastrointestinal and neurological 
involvement (Talarico et al., 2012, Verity et al., 1999c). 
 
The diagnosis of BS is based solely on a clinical expert opinion. It is well appreciated that 
the standardization of the diagnosis of BS is mandatory for accurate international 
epidemiological studies, treatment evaluation, and development of guidelines. Therefore, 
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The main criterion 
Recurrent episodes of ulceration on the oral mucosa (at least three times in a 12-
month period) 
The additional criteria 
1- Ocular involvement  
2- Recurrent episodes of genital ulceration 
3- Skin involvement  
4- Positive pathergy reaction 
sixteen different diagnostic and classification criteria have been proposed to date for the 
purpose of standardizing the diagnosis and classification of BS. Two out of these sixteen 
criteria are the product of an international collaboration (Davatchi, 2012, Lancet, 1990). 
The first diagnostic and classification criteria were developed in 1946 by Curth (Curth, 
1946). 
 
In the UK, researchers follow the International Study Group (ISG) diagnostic and 
classification criteria (sensitivity: 92% and specificity: 97%) to standardize the diagnosis of 
BS in research projects and ensure that only well-defined cases are included in the research 
(Lancet, 1990). The ISG criteria are the product of collaborative work between six different 
countries (France, Iran, Japan, Turkey, UK, and USA) and they aim to bring international 
consensus on BS diagnosis and classification. This diagnostic tool includes the main 
criterion and additional criteria. The diagnosis of BS is established when the main criterion 
and at least two of the additional criteria are satisfied (ISG, 1992, Lancet, 1990) (Table 
1.1). 
 
Table 1.1: The ISG diagnostic and classification criteria for BS (1990).  
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Some other criteria were developed subsequent to the ISG criteria to overcome their 
limitations, such as the inability to diagnose cases that have fewer than three episodes of 
recurrent oral ulceration per year, patients who do not have oral ulceration, and patients 
who do not develop oral ulceration until later in the disease. Furthermore, some countries 
with a high prevalence of BS did not take part in the international collaborative work 
leading to the development of the ISG criteria (Chang and Kim, 2003). 
  
The most recent criteria are the international criteria for Behçet’s disease (ICBD) which 
were proposed in 2006 and validated in 2010 (Davatchi et al., 2010a). The ICBD are the 
outcome of the collaboration of many countries including Austria, Azerbaijan, China, 
Egypt, Japan, Jordan, Libya, Morocco, Pakistan, Portugal, Russia, Saudi Arabia, Singapore, 
Spain, Taiwan, Thailand, Tunisia, Turkey, and USA. These criteria were created by 
analysing an international cohort of 2,556 BS patients and 1,163 controls. Initially, there 
were two formats for the ICBD: the traditional format and the classification tree. However, 
only the traditional format is currently recognized. According to the traditional ICBD, a 
patient is classified as having BS when scoring three or more points. Oral aphthous, skin 
manifestations, vascular manifestations, and a pathergy positive test each score one point in 
the ICBD system, while genital aphthous and ocular manifestations score two points each 
(Table 1.2). 
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Table 1.2: The ICBD diagnostic criteria for BS (2006). 
 
 
Davatchi et al. (2010) recently evaluated the sensitivity, specificity, and accuracy of several 
different diagnostic and classification criteria. The accuracy of the different criteria was as 
follows: 75.8% for Mason and Barnes criteria, 78.8% for O’Duffy criteria, 80.4% for 
Hewitt criteria, 84.3% for Hubault criteria, 85.3% for ISG criteria, 86% for Dilsen criteria, 
86.2% for Dilsen revised criteria, 88.8% for Japan criteria, 89.6% for Japan revised criteria, 
92.7% for Iran traditional criteria, 93.1% for Zhang criteria, 93.4% for Curth criteria, and 
97.1% for the classification tree. Furthermore, 98.2% sensitivity and 95.6% specificity were 
reported for the ICBD in the Iranian BS patient cohort (Davatchi et al., 2010a, Davatchi, 
2012). An international multi-centre study to examine the different criteria in different BS 
patient cohorts is mandatory to confirm these findings.  
 
In the author’s opinion, the ICBD criteria could be subject to criticism based on their 
potential for over diagnosing BS. For example, isolated idiopathic orogenital ulceration 
satisfy the ICBD criteria leading to a potential false positive diagnosis and therefore the 
specificity of the criteria is expected to be lower than the reported 95.6%. 
 
Criteria scoring one point: 
1- Oral aphthous 
2- Skin manifestations 
3- Vascular manifestations 
4- Pathergy positive test 
Criteria scoring two points: 
1- Genital aphthous 
2- Ocular manifestations 
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1.2.3 DIAGNOSTIC TESTS  
There is a lack of a universally recognized diagnostic laboratory test for BS. The pathergy 
test (reactivity of the skin to a needle prick or injection) forms a major component in the 
two sets of international diagnostic and classification criteria (ISG and ICBD). Classically, 
the pathergy test is performed by puncturing the skin with a 25- or 21-gauge needle, 
perpendicular to or diagonally to the skin, with or without the injection of normal sterile 
saline. Some centres use a set of three tests: 25-gauge needle with intradermal injection of 
one drop of normal sterile saline, 25-gauge needle without injection, and 21-gauge needle 
without injection (Davatchi et al., 2010b). The reaction is then monitored after 24 and 48 
hours. However, the fact that there is a lack of a standardized measuring method in the 
pathergy reaction makes its value as a sole diagnostic test for BS uncertain.  
 
Two different possible reactions are seen in the positive pathergy test: the classical 
papulopustular reaction, and the circular haemorrhagic reaction. The classical 
papulopustular reaction has sensitivity of 60%, specificity of 87%, and accuracy of 73% in 
an Iranian BS patient cohort, while the circular haemorrhagic reaction has sensitivity of 
12%, specificity of 98%, and accuracy of 55% in the same cohort (Davatchi et al., 2010b).  
 
Ozdemir et al. (2007) performed a study of a Turkish BS patient cohort to compare the 
results of the pathergy reaction in various body areas. This study concluded that no positive 
pathergy reaction was found in HC volunteers, but the pathergy test was positive in 18% of 
patients with RAS, and 85.7% of BS patients. In the above-mentioned patient cohort, the 
forearm was the most frequent site showing positive pathergy reaction, while the abdomen 
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was the least frequent site. At the same time, this study showed that multiple needle pricks 
increased the positive rate in BS (Ozdemir et al., 2007).  
 
The pathergy test was also investigated in another Turkish BS patient cohort (n: 31) 
compared to familial Mediterranean fever (FMF) patients and HC volunteers. The positivity 
rate was 41.9% in BS patients, 0% in FMF patients, and 0% in HC volunteers (Aydin et al., 
2009). In another study the positivity rate of the pathergy test was 8% in inflammatory 
bowel disease (IBD) patients (cohort of 93 Crohn’s disease patients, and 130 ulcerative 
colitis patients) (Hatemi et al., 2008b). This highlights a good specificity of the test; 
however, a standardized test protocol along with a well-designed multi-centre study to 
examine the reproducibility and validity of the test in different BS patient cohorts is 
mandatory. 
 
Davatchi et al. (2011) investigated the sensitivity and specificity of the pathergy test over 
time by analysing the test results recorded for BS patients enrolled in the registry of Tehran 
University of Medical Sciences (BS: n=6607 and HC: n=4292) during the last 35 years. 
They concluded that the test specificity has increased over time (from 86.6% to 98.4%) 
while the sensitivity has decreased over time (from 64.2% to 35.8%). The fact that the 
frequency of the positive pathergy reaction has declined over recent decades is undermining 
its value as a diagnostic test for BS (Davatchi et al., 2011, Davatchi et al., 2003). 
Interestingly, the rate of positive pathergy tests in the BS cohort from western countries 
such as the UK and Germany seems to be much lower than in the “Silk Road” countries 
such as Turkey and Iran. Currently, the rate of the pathergy test is 56% for patients from 
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Turkey, 54% for Iran, 53% for Morocco, 44% for Japan, 40% for Korea, 34% for Germany, 
and 32% for the UK (Davatchi et al., 2010b). 
 
The histopathology of the papulopustular skin lesion in BS patients was investigated as a 
diagnostic marker. However, in a recent study, vasculitis (leukoclastic vasculitis or 
lymphocytic vasculitis) was recorded in only 23.8% of the investigated cases (n: 42). 
Superficial, deep perivascular inflammation and/or interstitial dermatitis was encountered 
in 64.3% of cases (Kalkan et al., 2009).  
 
Other diagnostic markers were investigated, such as the thrombomoduline level for 
endothelial dysfunction in BS patients. However, the study was performed on a small 
number of patients and has not been substantiated by larger studies (Menashi et al., 2008).  
 
1.2.4 ACTIVITY MARKERS 
The availability of a reproducible and validated activity marker is of prime importance in 
monitoring and evaluating the different treatment strategies. This in turn will facilitate the 
development of evidence-based information that is useful for decision makers and guideline 
developers. This fact encouraged research aimed at establishing an activity scoring system 
and/or laboratory activity markers. Iranian and European scoring systems were suggested 
and refined, as a result and the International Scientific Committee approved the Behçet’s 
disease current activity form (BDCAF), which is based on the history of the disease’s 
clinical features. The BDCAF scores oral ulcerations, genital ulcerations, skin involvement, 
joint involvement, gastrointestinal involvement, fatigue, and headache in relation to the 
duration of symptoms. Large vessel and CNS involvement along with Behçet’s oculopathy 
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index is also recorded. Patients’ and clinicians’ opinions on the overall disease activity are 
rated on a 7-point scale (Bhakta et al., 1999).  
 
The BDCAF was validated and proven to have a good inter-observer reliability in assessing 
the general disease activity (Bhakta et al., 1999). A Turkish version of the BDCAF was also 
evaluated for reproducibility and validity (Hamuryudan et al., 1999). Subsequently, the 
score was subjected to re-evaluation in a multi-centre study (Turkey, Korea, and the UK) 
which led to a further refinement to allow comparison between countries and pooling of 
data (Lawton et al., 2004). However, the Iranian Behçet’s disease dynamic activity measure 
(IBDDAM) that is based on an interval scale, evaluation of symptom history in the 12 
months prior to the date of assessment, and an average activity score per month was 
preferred in some countries such as Turkey (Shahram et al., 2009). Recently, a disease 
activity index for intestinal Behçet’s disease (DAIBD) was suggested and validated by a 
Korean research group; nevertheless; an international consensus needs to be established 
(Cheon et al., 2011).  
 
C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and serum neopterin are 
significantly higher in active BS patients compared to inactive BS patients and HC 
volunteers; however, these activity markers are known to be elevated in other inflammatory 
as well as infectious diseases and hence they are not specific for BS (Coskun et al., 2005). 
Furthermore, the serum total level of homocysteine (a known risk factor for 
atherothrombogenesis) was also found to be elevated in active BS patients compared to 
inactive BS patients and HC volunteers (Sarican et al., 2007). Moreover, circulating 
endothelial cells and soluble tumour necrosis factor receptor (TNFR) 2 were suggested as 
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disease activity markers (Kutlay et al., 2008, Turan et al., 2008). However, to date there is a 
lack of international consensus on the use of a laboratory validated activity marker with an 
accurate positive/negative cut-off. Currently, BS activity determination is based solely on 
expert clinical judgement.  
 
1.2.5 EPIDEMIOLOGY  
A large proportion of BS patients live along the “Silk Road”, or their ancestors used to live 
in those countries through which the “Silk Road” passed; these include Turkey, Iraq, Iran, 
Korea, and Japan amongst others (Figure 1.2). However, the current thinking is that the 
global prevalence of BS is higher than was documented previously (Yazici et al., 2008). 
 
The “Silk Road” is a historical trade route that connected East, South and West Asia with 
the Mediterranean countries, the European world, and North and East Africa. The land road 
was supplemented by a sea route extending from the Red Sea to East Africa, India, China, 
and Southeast Asia. The classical concept of a single “Silk Road” is misleading as there 
were several routes that were frequently selected to transport a wide variety of commodities 
(Verity et al., 1999a). Not only had silk been traded from China along these routes since 
206 BC, but also other produce, technologies, religions, and philosophies were exchanged. 
Moreover, some diseases such as bubonic plague were disseminated in the same way 
(Figure 1.2).  
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Figure 1.2: The geographic distribution of the “Silk Road” which is indicated by the yellow 
line [source: www.maximizingprogress.org/2008/06/silk-road]. 
 
The frequency of BS in adults is very variable throughout the world. There is a consensus 
that the global incidence and prevalence of BS are more frequent than was reported earlier 
in the literature (Yazici et al., 2008). A prevalence of 380/100,000 was reported in Turkey, 
100/100,000 in Japan, 80/100,000 in Iran, 50-185/100,000 in the Druze populations (a 
unique religious community found primarily in Syria, Lebanon, Jordan, Israel, and the 
Palestinian territories), 7.1/100,000 in France, 5.2/100,000 in USA, 3.8/100,000 in Italy, 
2.4/100,000 in the northern region of Israel, 2.26/100,000 in Germany, 0.64/100,000 in 
England and 0.24/100,000 in Northwest Spain (Calamia et al., 2009, Davatchi et al., 2010b, 
Davatchi et al., 2010c, Dejaco et al., 2009, Gonzalez-Gay et al., 2000, Jaber et al., 2002, 
Klein et al., 2010, Krause et al., 2007, Mahr et al., 2008, Salvarani et al., 2007, Zouboulis et 
al., 1997). 
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BS generally affects young adults between the second and fourth decade of life. However, 
the onset can occur at any age (Kone-Paut et al., 2011, Mundy and Miller, 1978). Mean age 
at onset for BS patients in countries which have a national survey for BS (Iran, Japan, 
China, Korea, and Germany) is 26.2, 35.7, 33.8, 29, and 26 years respectively (Davatchi et 
al., 2010b, Davatchi et al., 2010c, Zouboulis et al., 1997). The mean age at diagnosis was 
33 in Italy, 31 in USA, 32.8 in Egypt, 29 in Korea, 25.6 in Turkey, 33.1 in India, 29.3 in 
Saudi Arabia, 29.4 in Iraq, 30.1 in Jordon, 26 in Lebanon, 30.7 in Israel, 20 in Greece, 25.7 
in Portugal, 33 in Sweden, 28.03 in Brazil, 20.8 in Ireland, and 24.7 in Yorkshire, UK 
(Calamia et al., 2009, Chamberlain, 1977, Davatchi et al., 2010b, El Menyawi et al., 2008, 
Sachetto et al., 2011, Salvarani et al., 2007). Juvenile disease was recorded in 6.9% of BS 
patients in the German BS patient cohort (Zouboulis et al., 1997). A younger age at 
diagnosis was considered to be associated with a more severe clinical course, especially in 
relation to intestinal BS (Jung et al., 2011). However, late-onset BS (BS diagnosed after the 
age of 40) was deemed to have a good prognosis, especially in relation to the ocular 
involvement (Sungur et al., 2010). 
 
The disease was classically described as being more prevalent in men than women in the 
ancient “Silk Road” countries, whereas the trend is reversed in Western Europe and the 
USA (Evereklioglu, 2005, Zouboulis et al., 1997). Currently, there seems to be almost no 
gender predilection in most BS patient cohorts. The male to female ratio of BS patients in 
countries which have a national survey for BS (Iran, Japan, China, Korea and Germany) is 
1.19, 0.98, 1.34, 0.63, and 1.40 to 1 respectively (Davatchi et al., 2010b, Zouboulis et al., 
1997). The male to female ratio was 1:1.19 in Brazil, 1:1 in Italy, 3.67:1 in Russia, 3.4:1 in 
Saudi Arabia, 3:1 in Iraq, 1.03:1 in Turkey, 1.8:21 in India, 0.64:1 in Israel, 2:1 in 
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Morocco, 1.4:1 in Greece, 1:1 in Portugal, 0.5:1 in Spain, and 0.67:1 in Sweden (Calamia 
et al., 2009, Davatchi et al., 2010b, Davatchi et al., 2010c, El Menyawi et al., 2008, 
Sachetto et al., 2011, Salvarani et al., 2007). Interestingly, late-onset BS was observed 
consistently to affect both genders equally (Sungur et al., 2010).  
 
1.2.6 CLINICAL PICTURE 
The major clinical manifestations of BS are reported in the literature as follows: ulcers in 
the oral cavity and on the genitals, acne-like papulopustular skin lesions, erythema 
nodosum, positive pathergy test, and ocular symptoms. Other symptoms that may occur 
include arthritis, venous thrombosis, gastrointestinal complications, and inflammation in 
the CNS, kidneys, lungs, and cardiovascular system (El Menyawi et al., 2008, 
Evereklioglu, 2004, Zouboulis et al., 2003). 
 
BS is characterized by a chronic course with unpredictable exacerbations and remissions. 
Male gender, the human leucocyte antigen (HLA) B51, and a younger age at onset are all 
associated with more severe disease. The main complications of the disease are 
neurological, pulmonary, large vessel involvement, and bowel perforation (Zouboulis et al., 
2003). 
 
BS does not affect the life expectancy of the affected patients. However, mortality due to 
severe CNS involvements, pulmonary involvements, catastrophic bleeding from large 
vessels, bowel perforation, or as a complication of immunosuppressive therapy has been 
reported. Furthermore, the risk of visual loss was shown as 23% in an international multi-
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centre study, despite the availability of modern treatment modalities (Evereklioglu, 2004, 
Evereklioglu, 2005, Kitaichi et al., 2007). 
 
1.2.6.1 ORAL ULCERATION 
Oral ulceration was typically found in almost all patients with BS. Interestingly, the initial 
presentation of the disease is by oral ulceration in most BS cases. In Iran, 82.1% of BS 
patients presented with oral ulceration as the initial disease manifestation (Davatchi et al., 
2010c). Likewise, in Italian BS patients the primary finding was oral ulceration in 88% of 
the investigated cases (Salvarani et al., 2007).  
 
Oral ulceration are usually round or oval, surrounded with a well-defined inflamed red 
margin, and with a yellowish white necrotic base. Minor (<10 mm in diameter), 
herpetiform (multiple 1–2 mm in diameter ulcerations that coalesce, forming a big ulcer 
with a ragged margin), and major (10–30 mm in diameter) aphthous ulcer-like lesions may 
present in BS patients (Figures 1.3–1.5). In addition, a mixed pattern was observed and 
documented in the literature. Major aphthous-like lesions are more common in BS patients 
than in RAS patients (Krause et al., 1999). Small ulcerations usually heal without scarring; 
however, large ulcerations are more prone to heal with scar formation (64%) (Davatchi et 
al., 2010b). 
 
Oral ulceration of BS are typically associated with increased tissue oedema and are 
surrounded with a large erythematous border, compared to RAS oral ulcerations. BS also 
involves the soft palate and the oropharynx more often (Kokturk, 2012, Main and 
Chamberlain, 1992).  
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The global rate of oral ulcerations in BS patients is 94.5% (Kitaichi et al., 2007). However, 
a relatively higher percentage was reported in population-based studies (97% in Iran, 98% 
in Japan, 98% in China, 99% in Korea, 99% in Germany, 100% in USA, 100% in Italy, and 
100% in Egypt) (Calamia et al., 2009, Davatchi et al., 2010b, Davatchi et al., 2010c, El 
Menyawi et al., 2008, Salvarani et al., 2007, Zouboulis et al., 1997). 
 
 
Figure 1.3: Oral ulceration (minor aphthous ulcer-like lesion) in BS patient [source: Royal 
London Hospital with patient consent]. 
 
 
Figure 1.4: Oral ulceration (herpetiform aphthous ulcer-like lesion) in BS patient [source: 
Royal London Hospital with patient consent]. 
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Figure 1.5: Oral ulceration (major aphthous  ulcer-like lesion) in BS patient [source: Royal 
London Hospital with patient consent]. 
 
The histopathological picture of the BS oral ulceration is nonspecific, with lymphocyte, 
macrophage, and neutrophils infiltration at the base of the ulcer. Leukocytoclastic and 
lymphocytic vasculitis were also observed (Chun et al., 1990, Kokturk, 2012). 
 
Oral ulcerations can be caused by a number of different oral conditions, therefore the 
clinician should be aware of the relevant differential diagnosis. Traumatic ulceration, RAS, 
hematinic deficiency, infections (herpes simplex, syphilis, tuberculosis, human 
immunodeficiency virus (HIV), herpangina, and hand–foot–mouth disease), squamous cell 
carcinoma, necrotizing sialometaplasia, cyclic neutropenia, graft versus host disease, 
radiotherapy-induced mucositis, osteoradionecrosis, lichen planus, lichenoid reaction, 
systemic lupus erythematosis, pemphigus, pemphigoid, mouth and genital ulcers with 
inflamed cartilage (MAGIC) syndrome, Reiter’s syndrome, Sweet’s syndrome, and IBD 
(Table 1.3).  
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Table 1.3: Differential diagnosis of the oral ulceration of BS. 
CONDITIONS PRESENTING WITH ORAL ULCERATIONS 
Traumatic ulceration Osteoradionecrosis 
RAS Lichen planus 
Hematinic deficiency Lichenoid reaction 
Herpes simplex SLE 
Syphilis Pemphigus 
Tuberculosis Pemphigoid 
HIV MAGIC 
Herpangina Reiter’s syndrome 
Hand–foot–mouth disease Sweet’s syndrome 
Radiotherapy-induced mucositis Inflammatory bowel disease 
HIV: Human immunodeficiency virus; IBD: inflammatory bowel disease; MAGIC: mouth 
and genital ulcers with inflamed cartilage syndrome; RAS: recurrent aphthous stomatitis; 
SLE: systemic lupus erythematosis 
 
1.2.6.2 GENITAL ULCERATION 
Genital ulceration are considered to be the second most common manifestation of BS and 
sometimes they are the initial finding of the disease. In Iran, 10% of BS patients presented 
with genital ulceration as the initial disease manifestation (Davatchi et al., 2010c). 
Likewise, 16% of the Italian BS patients reported genital ulceration as the initial finding of 
their disease (Salvarani et al., 2007). 
 
The clinical picture of genital ulceration resembles the oral ulceration. The main 
differences are that genital ulceration recur less frequently, take longer to heal, heal with 
scar formation, and are usually bigger in size. In females suffering from BS, genital 
ulceration might be seen on the vulva, vagina, and cervix. Interestingly, genital ulceration 
are observed more prominently during the premenstrual or menstrual phases of the ovarian 
cycle. Furthermore, genital ulceration recur less frequently during pregnancy but activity 
increases during the post-partum period. In male BS patients, genital ulceration are 
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observed mainly on the scrotum and less often on the shaft of the penis or the meatus 
(Davatchi et al., 2010b, Kokturk, 2012) (Figure 1.6). 
 
The frequency of genital ulceration in BS patients is as follows: 61.4% in a multi-centre 
study, 65% in Iran, 73% in Japan, 76% in China, 83% in Korea, 75% in Germany, 77% in 
Italy, 62% in USA, and 96.8% in Egypt (Calamia et al., 2009, Davatchi et al., 2010b, 
Davatchi et al., 2010c, El Menyawi et al., 2008, Kitaichi et al., 2007, Salvarani et al., 2007, 
Zouboulis et al., 1997). 
 
 
Figure 1.6: Genital ulceration in a male BS patient [source: Royal London Hospital with 
patient consent]. 
 
1.2.6.3 OTHER FORMS OF ULCERATION 
BS patients may also suffer from anal ulceration, with very similar characteristics to the 
genital ulceration. Moreover, conjunctival ulceration were reported in the literature 
(Davatchi et al., 2010b). 
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1.2.6.4 CUTANEOUS MANIFESTATIONS 
Cutaneous manifestations of BS may present in the form of papulopustular, erythema 
nodosum-like lesion, superficial thrombophlebitis, pathergy reaction, or skin ulcer. The 
frequency of cutaneous manifestations is as follows: 69.5% in a multi-centre study, 66% in 
Iran, 87% in Japan, 69% in China, 84% in Korea, 81.5 in Germany, 100% in Italy, 100% in 
USA, and 55.5% in Egypt (Calamia et al., 2009, Davatchi et al., 2010b, Davatchi et al., 
2010c, El Menyawi et al., 2008, Kitaichi et al., 2007, Salvarani et al., 2007, Zouboulis et 
al., 1997). It is the second most common initial manifestation in the Italian BS patient 
cohort (33.3%) (Salvarani et al., 2007).  
 
Papulopustular lesions are the most common cutaneous lesion in BS patients and typically 
present with elevated erythema and a dome-shaped pustule in the centre. They are believed 
to be a type of vasculitis with a sterile pustule. Papulopustular lesions are observed mainly 
in the lower limbs and pubis. However, they can affect anywhere in the body including 
palms, soles, face, trunk, and the back. Their frequency is as follows: 57% in Iran, 31% in 
China, and 62% in Germany (Davatchi et al., 2010b) (Figures 1.7 and 1.8). 
  
 
Figure 1.7: Papulopustular lesions in BS patient [source: Royal London Hospital with 
patient consent]. 
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Figure 1.8: Papulopustular lesions in BS patient [source: Royal London Hospital with 
patient consent]. 
 
Erythema nodosum-like lesions are the second most common cutaneous manifestation of 
BS. They are painful, subcutaneous nodules of different sizes and are characterized by 
severe oedema and erythema around them (Figures 1.9 and 1.10). They frequently affect 
the lower limbs. However, they may affect anywhere in the body including buttocks, face, 
and neck. These lesions take a few weeks to heal and subsequently leave hyperpigmented 
areas. The erythema nodosum-like lesions frequency in BS is as follows: 22% in Iran, 38% 
in China, and 42% in Germany (Davatchi et al., 2010b, Davatchi et al., 2010c, Kokturk, 
2012). The histological appearance of an erythema nodosum-like lesion is variable 
including leukocytoclastic vasculitis, neutrophil vascular reaction, lymphocytic vasculitis, 
lymphohistocytic septal/lobular panniculitis, granulomatous panniculitis, or acute 
necrotizing panniculitis (Kim and LeBoit, 2000, Lee et al., 1997). 
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Figure 1.9: Erythema nodosum-like lesion in BS patient [source: Royal London Hospital 
with patient consent]. 
 
 
Figure 1.10: Ulcerated erythema nodosum-like lesion in BS patient [source: Royal London 
Hospital with patient consent]. 
 
Superficial thrombophlebitis is also one of the characteristic cutaneous lesions of BS. It 
presents as a recurrent painful subcutaneous nodule with erythema of the overlying skin. It 
is observed mainly in the lower extremities and classically heals in a few days (Kokturk, 
2012, Lee et al., 1997). 
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1.2.6.5 OCULAR MANIFESTATIONS 
Uveitis (involving the anterior segment, posterior segment, or both) is the main ocular 
manifestation in BS patients. The intraocular inflammation is usually bilateral and occurs as 
the initial manifestation of BS in only 8.7% of the cases. Uveitis frequency in BS is as 
follows: 55% in Iran, 69% in Japan, 63.5% in China, 45.1% Korea, 53% in Germany, 
55.6% in Italy, 47.6% in Egypt, and 62% in USA (Calamia et al., 2009, Davatchi et al., 
2010b, Davatchi et al., 2010c, El Menyawi et al., 2008, Kitaichi et al., 2007, Salvarani et 
al., 2007, Zouboulis et al., 1997).  
 
Anterior uveitis is an inflammation of the anterior chamber of the eye leading to pain, 
photophobia, and visual disturbance. Hypopyon is the most classical form of anterior 
uveitis in BS patients, presenting as visibly whitish thick exudates with sediment in the 
lower part of the anterior chamber of the eye (Figure 1.11). Recurrent attacks of anterior 
uveitis can lead to cataract or glaucoma (Davatchi et al., 2010b, Soloway and Weissgold, 
1996).  
 
 
Figure 1.11: Hypopyon in BS patient [source: (Soloway and Weissgold, 1996)]. 
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Recurrent posterior uveitis and retinal vasculitis are the most important causes of visual 
loss in BS patients. Men tend to have posterior uveitis more frequently than women. 
Consequently, poor visual acuity as a complication of BS ocular manifestations is seen in 
men more often than women (24.8% versus 18.9%). Unfortunately, despite of the 
availability of the modern treatment modalities, a quarter of BS patients who suffer from 
ocular manifestations go blind at one point of their disease course (Kitaichi et al., 2007). 
 
1.2.6.6 JOINT MANIFESTATIONS 
Arthralgia, arthritis and synovitis are the main articular manifestations in BS patients. Joint 
manifestations frequency in BS is as follows: 33% in Iran, 57% in Japan, 30% in China, 
38% in Korea, 59% in Germany, 50% in Italy, 36.5% in Egypt, and 46% in USA (Calamia 
et al., 2009, Davatchi et al., 2010b, Davatchi et al., 2010c, El Menyawi et al., 2008, Kitaichi 
et al., 2007, Salvarani et al., 2007, Zouboulis et al., 1997).  
 
BS patients’ joint manifestations are typically non-erosive, non-deforming, and recurrent, 
and each attack takes a few weeks to resolve. Rarely, chronic polyarticular arthritis, 
osteonecrosis, and ankylosing spondylitis are seen in BS patients (Kokturk, 2012).  
 
1.2.6.7 GASTROINTESTINAL MANIFESTATIONS 
Ulcerations affecting the gastrointestinal tract at any site from the oesophagus to the anus 
can occur in BS patients. However, the terminal ileum and the caecum are the sites most 
affected, by deeply penetrating ulcerations that carry a high tendency to perforation. BS 
gastrointestinal manifestations present with acute abdominal pain, diarrhoea, constipation, 
or proctorrhagia. The frequency of gastrointestinal manifestations in BS is as follows: 7% 
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in Iran, 15.5% in Japan, 9% in China, 7.3% in Korea, 12% in Germany, and 19% in Egypt 
(Davatchi et al., 2010b, Davatchi et al., 2010c, El Menyawi et al., 2008, Kokturk, 2012). 
 
1.2.6.8 VASCULAR MANIFESTATIONS 
BS is classified as systemic vasculitis affecting all vessels. It can easily be differentiated 
from other vasculitis by following one of the international criteria for BS diagnosis and 
classification. BS arterial involvement is very rare, but very similar to that of Takayasu’s 
arteritis. However, neutophils and lymphocytes infiltration of the vasa vasorum is 
significantly higher in BS compared to Takayasu’s arteritis (Kokturk, 2012, Talarico et al., 
2012) (Table 1.4).  
 
Table 1.4: BS is a vasculitis that can affect all types of vessels (large, medium, and small).  
LARGE VESSEL 
VASCULITIS 
MEDIUM VESSEL 
VASCULITIS 
SMALL VESSEL 
VASCULITIS 
Behçet’s Syndrome Behçet’s Syndrome Behçet’s Syndrome 
Polymyalgia rheumatica Kawasaki disease Wegener’s granulomatosis 
Takayasu’s arteritis Cutaneous vasculitis Cutaneous vasculitis 
Giant cell arteritis Polyarteritis nodosa Polyarteritis nodosa 
  Henoch-Schönlein purpura 
  Churg-Stauss syndrome 
 
The clinical vascular manifestation frequency is as follows: 8.9% in Iran, 8.9% in Japan, 
7.7% in China, 1.8% in Korea, and 13% in Germany. However, a colour duplex 
sonography study showed that vascular involvement is about 79% in the 100 BS patients 
studied (63% arterial involvement, 55% venous involvement, and 39% both arterial and 
venous) (Davatchi et al., 2010b, Morelli et al., 1997). 
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Venous involvement including superficial thrombophlebitis, deep venous thrombosis and 
large venous thrombosis was documented in BS patients. Occlusion of the suprahepatic 
vein (Budd-Chiari syndrome) carries a high risk of mortality. Likewise, thromboses of the 
superior and inferior vena cava and the dural sinuses have poor prognosis. Arterial 
involvements including thrombosis, aneurysms, and pulse weakness were observed in BS 
patients (Kokturk, 2012) 
 
1.2.6.9 PULMONARY MANIFESTATIONS 
Pulmonary manifestations of BS are rare but carry a high risk of morbidity and mortality. 
Vasculitis of the pulmonary arteries, veins, and septal capillaries is the main cause of the 
pulmonary manifestation in BS patients, leading to aneurysm, thrombotic occlusion, 
haemorrhage, pleural effusion, pulmonary infarct, or pulmonary fibrosis. The main 
pulmonary symptom in BS patients is haemoptysis. The frequency of pulmonary 
manifestations in BS patients is as follows: 0.3% in Iran, 2.2% in China, 11% in Italy, 33% 
in USA and 3.6% in Germany (Calamia et al., 2009, Davatchi et al., 2010b, Davatchi et al., 
2010c, Kokturk, 2012, Salvarani et al., 2007). 
 
1.2.6.10 CARDIAC MANIFESTATIONS 
Cardiac manifestations of BS are very rare. Myocarditis, valvular lesions, pericarditis, 
ventricular aneurysms, intracardiac thrombosis, and coronary vasculitis were reported in the 
literature. The frequency of the cardiac manifestations is as follows: 0.5% in Iran, 4% in 
China, and 3.2% in Germany (Davatchi et al., 2010b, Davatchi et al., 2010c, Kokturk, 
2012). 
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1.2.6.11 NEUROLOGICAL MANIFESTATIONS 
 Neurological manifestations of BS are rare but carry considerable risk of morbidity and 
mortality. Aseptic meningoencephalitis is the classical manifestation observed in Neuro-
Behçet. However, behavioural changes, seizures, headache, benign intracranial 
hypertension, diencephalic dysfunction, aphasia, pseudobulbar palsy, brainstem syndromes, 
cranial nerve palsies, hemiplegia, cerebellar syndromes, myelopathy, and mononeuritis 
were reported in the literature as BS neurological manifestations. The frequency of 
neurological manifestations of BS is as follows: 9% in Iran, 11% in Japan, 6.4% in China, 
4.6% in Korea, and 11% in Germany (Davatchi et al., 2010b, Davatchi et al., 2010c, 
Kokturk, 2012).  
 
1.2.7 TREATMENT  
The aim of the current treatment recommendations in BS is to prevent irreversible damage 
that mostly occurs early in the course of the disease, especially in the high-risk groups such 
as young age of onset, male gender, and HLA-B51. Treatment should also aim to prevent 
exacerbations of mucocutaneous and joint involvement that usually does not cause damage 
but affects the QoL (Calamia and Kaklamanis, 2008, Evereklioglu, 2004, Fresko and 
Yazici, 2008, Hatemi et al., 2008a, Kappen et al., 2008). 
 
1.2.7.1 EULAR RECOMMENDATIONS 
Several treatment recommendations were recently developed by a multi-disciplinary 
committee of the European League Against Rheumatism (EULAR), based on the best 
available evidence (Hatemi et al., 2008a): 
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1. Azathioprine and systemic corticosteroids are the treatment of choice for BS 
patients suffering from inflammatory eye disease affecting the posterior segment. 
2. If the eye disease is severe, and that is defined as 0.2 lines of drop in visual acuity 
on a 10/10 scale and/or retinal disease (retinal vasculitis or macular involvement), it is 
recommended that either ciclosporin or infliximab is prescribed in combination with 
azathioprine and corticosteroids; alternatively interferon alpha (IFNα) with or without 
corticosteroids is another appropriate treatment strategy. 
3. There is no evidence-based guideline for the management of major vessel disease in 
BS. In case of acute deep vein thrombosis in BS, immunosuppressive agents such as 
corticosteroids, azathioprine, cyclophosphamide or ciclosporin are recommended. 
However, for the management of pulmonary and peripheral arterial aneurysms, 
cyclophosphamide and corticosteroids are recommended. 
4. Similarly, there is no evidence of the benefit of anticoagulants, anti-platelet or anti-
fibrinolytic agents in the management of deep vein thrombosis or the arterial lesions of BS. 
5. There is no evidence-based recommendation for the management of gastrointestinal 
involvement of BS. Sulfasalazine, corticosteroids, azathioprine, TNFα antagonists and 
thalidomide should be tried as a first line therapy before proceeding to surgical treatment, 
except in emergencies. 
6. Colchicine is the drug of choice for BS patients with arthritis. 
7. There is no evidence-based guideline for the management of CNS involvement in 
BS. For parenchymal involvement, corticosteroids, IFN, azathioprine, cyclophosphamide, 
methotrexate, and TNFα antagonists can be tried. For dural sinus thrombosis, 
corticosteroids are recommended. 
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8. Ciclosporin should not be used in BS patients with CNS involvement unless 
necessary for intraocular inflammation. 
9. The decision to treat skin and mucosa involvement will depend on the severity of 
the lesions. Topical therapy such as local corticosteroids should be the first line of 
treatment for isolated oral and genital ulcers, and acne-like lesions. Colchicine should be 
preferred when the dominant lesion is erythema nodosum-like lesions. To note, leg ulcers 
in BS might have different causes. Therefore, treatment should be designed in relation to 
the cause. Azathioprine, INF, and TNFα antagonists may be considered in resistant cases.  
 
1.2.7.2 THE UK’S BS CENTRES OF EXCELLENCE RECOMMENDATIONS 
A new treatment guidelines were suggested in 2012 by the three BS centres of excellence in 
the UK (unpublished). The drug pathway is as follows: 
 
1.2.7.2.1 MUCOCUTANEOUS DISEASE 
1. The initial therapy (oral cochicine, topical steroid, topical non-steroidal therapy, or 
mixed topical steroid and antimicrobial therapy) is expected to be effective in 70% 
of the cases. 
2.  If the initial therapy was ineffective, the step up therapy (azathioprine, 
mycophenolate, tacrolimus, or steroid) is expected to be effective in 66% of the 
cases. 
3. If the step up therapy was ineffective, a 6 months course of TNF inhibitor therapy 
(infliximab 5mg/kg for 4 doses then swap to either adalimumab 40mg once a week 
or etanercept 50mg once a week) is expected to be effective. TNF inhibitor therapy 
should be re-initiated during flare up periods.  
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1.2.7.2.2 BS EYE DISEASE  
1. The initial therapy (topical, intraocular, intavenous, or oral steroid) followed by 
maintenance therapy (oral steroid, azathioprine, or ciclosporin) is expected to be 
effective in 80% of the cases. 
2.  If the initial therapy was ineffective, a 24 months course of TNF inhibitor therapy 
(infliximab 5mg/kg for 4 doses then swap to either adalimumab 40mg once a week 
or etanercept 50mg once a week) is expected to be effective. TNF inhibitor therapy 
should be re-initiated during flare up periods. 
3. If the TNF inhibitor therapy was ineffective, a 6 months course of INF-α should be 
considered.  
 
1.2.7.2.3 MAJOR ORGAN DISEASE 
Major organ disease is defined as BS with CNS involvements, peripheral neurological 
disease, or major vessel thrombosis. 
  
1. The initial therapy (intavenous steroid and azathioprine) is expected to be effective 
in 50% of the cases. 
2.  If the initial therapy was ineffective, a 6 months course of TNF inhibitor therapy 
(infliximab 5mg/kg for 4 doses then swap to either adalimumab 40mg once a week 
or etanercept 50mg once a week) is expected to be effective. TNF inhibitor therapy 
should be reinitiated during flare up periods. 
3. If the TNF inhibitor therapy was ineffective, cyclophosphamide or INF-α should be 
considered.  
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1.2.8 AETIOLOGY AND PATHOGENESIS  
The aetiology of BS remains obscure. Bacterial and viral aetiology were suggested in the 
literature from over fifty years ago (Denman et al., 1980, Gray, 1950). However, 
epidemiologic and molecular studies proved that both genetic and environmental factors 
contribute to the disease susceptibility (Evereklioglu, 2005). 
 
BS is one of the chronic, relapsing, multi-systemic, idiopathic, inflammatory problems. 
Therefore, it is crucial to understand precisely how the inflammation is initiated and to 
trace the activation events that occur within the cells of the innate immune system. It is also 
necessary to identify individual molecules of environmental origin that act as inducers of 
the inflammatory process, and the host receptor molecules that detect them (Huyton et al., 
2007). 
 
1.2.8.1 HYPOTHESIS 
Lehner (1999) postulated that microbial infection induces a stress response that leads to 
upregulation of the heat shock protein (HSP) as well as the major histocompatibility 
complex class I chain-related (MIC) gene A product, which in turn will stimulate gamma 
delta (γδ) and alpha beta (αβ) T cell receptor positive (TCR+) cells, neutrophils and B cells. 
These activated T cells, B cells and neutrophils will induce cytokines to modulate the 
immune response. The end result of these complex cellular and cytokine immune 
interactions in HLA-B51 or genetically related subjects is to induce pathological changes 
consistent with BS (Lehner, 1999) (Figure 1.12). 
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Figure 1.12: Lehner’s Hypothesis for BS aetiology and pathogenesis [source: redrawn from 
(Lehner, 1999)]. 
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1.2.8.2 GENETICS 
The major histocompatibility complex (MHC) genes are the most polymorphic genes 
present in the genome, explained by the fact that more than 250 alleles have been identified 
for some HLA loci by serologic assays. Moreover, the molecular sequencing has shown 
that a single serologically defined HLA allele may consist of slightly different multiple 
variants (Abbas and Lichtman, 2005) (Figure 1.13). There are 21 different alleles from 
B5101 to B5121 serving to encode MHC class I, which participates during the presentation 
of endogenous antigens to CD8
+
 cytotoxic-suppressor T lymphocytes (Abbas and 
Lichtman, 2005). Additionally, the HLA-B51 gene plays a role in neutrophil function 
(Fortune, 2003, Lehner, 1999, Yamashita, 1997).  
 
Interestingly, the MHC class I HLA genotype B5 and its subclass (split antigen) B51 allele 
on chromosome 6p21 (HLA-B5101) is strongly associated with the susceptibility to BS 
(Bettencourt et al., 2008, Krause and Weinberger, 2008, Mizuki et al., 2002, Takemoto et 
al., 2008). Furthermore, HLA-Cw16 was also associated with BS susceptibility, while 
HLA-B27 was associated with the severity of the disease in a Portuguese BS cohort 
(Bettencourt et al., 2008). Indeed, the HLA-B51 genotype and BS have a close geographic 
distribution. However, around a third of BS patients do not possess the gene. HLA-B51 was 
considered to be a strong risk factor for developing severe ocular BS in particular (Verity et 
al., 1999c). However, other genes such as Factor V Leiden were also implicated as an 
additional risk factor for the development of ocular disease in BS patients (Verity et al., 
1999b). 
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To date, it is still not clear whether HLA-B51 is pathogenic to BS or whether it is in linkage 
disequilibrium to the causative gene (Ahmad et al., 2003, Mizuki et al., 1995) (Figure 
1.13). Therefore, recent studies have focused on studying MICA, TNFα and HSP genes as 
these genes are located on chromosome 6 in close proximity to HLA-B51 (Ahmad et al., 
2003, Akman et al., 2008b, Arayssi et al., 2008, Durrani and Papaliodis, 2008, Hughes et 
al., 2005, Karasneh et al., 2005, Mizuki et al., 1995).  
 
Figure 1.13: The proximity of Class I and Class II MHC Locus in chromosome 6p21 
[source: (Abbas and Lichtman, 2005)]. 
 
The MIC genes occupy the region between the HLA-B and TNF genes. Seven MIC loci 
exist (A–G), with only MICA and MICB encoding proteins which show homology with the 
classical HLA molecule. MIC encoded proteins do not combine with ß2 microglobulin and 
are not expressed on normal circulating lymphocytes but they are expressed on the surface 
of freshly isolated gastric epithelium and endothelial cells, and fibroblasts. MICA and 
MICB act as ligands for activating the natural killer-cell G2D (NKG2D) receptor which is 
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also found on γδ T cells and αß CD8+ T cells (Abbas and Lichtman, 2005). Interestingly, a 
triplet repeat microsatellite polymorphism in the transmembrane region of the MICA gene 
has been found in Caucasian BS patients and other patients with Turkish, Korean, Italian, 
and Iranian origins (Hughes et al., 2005, Mizuki et al., 2002, Park et al., 2002, Picco et al., 
2002). 
 
Recent genetic investigations suggested that TNF genes are an important risk factor in BS 
pathogenesis. Two extended HLA haplotypes which contain the TNF promoter 
polymorphism-1031C gene were identified and correlated to BS. The TNF promoter 
polymorphism-1031C allele was found to be associated with BS even in individuals who 
did not carry either HLA-B51 or HLA-B5701 (Ahmad et al., 2003, Arayssi et al., 2008). 
 
A comparison between patients with BS and HC volunteers revealed no significant 
difference in the frequency of polymorphism in one of the HSP 70 genes HUM70t (HSP70-
Hom) (Mizuki et al., 1995). Furthermore, the single-nucleotide polymorphism (SNP) 
analysis of TLR2 and TLR4 genes was not significantly associated with BS in Caucasian, 
Turkish, and Tunisian cohorts (Bacanli et al., 2006b, Ben Dhifallah et al., 2009, Durrani et 
al., 2011, Tomiyama et al., 2009). However, one SNP in the TLR4 gene but not TLR2 was 
associated with BS and six other SNPs had an effect on its clinical features in the Japanese 
BS patient cohort (Meguro et al., 2008, Tomiyama et al., 2008). Likewise, TLR4 haplotype 
TAGCGGTAA was considered a susceptibility gene for HLA-B51 positive BS patients and 
for the complication of arthritis in the Korean cohort (Horie et al., 2009). 
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Polymorphisms in other genes were also suggested as being associated with the risk of 
developing BS, such as the increased frequency of E469 in the intercellular adhesion 
molecule-1 gene, increased frequency of IL-1α-889C, and the decreased frequency of 
620W in the gene encoding protein tyrosine phosphatase type 22 (Akman et al., 2008a, 
Baranathan et al., 2007, Verity et al., 2000).  
 
Recently, an association at the IL10 and IL23R-IL12RB2 locus was identified. 
Furthermore, BS was found to be associated with the IL10 gene variant (rs1518111A 
allele), which is known to cause a diminished mRNA expression and a low protein 
production (Mizuki et al., 2010, Remmers et al., 2010, Xavier et al., 2012). IL10 is a known 
suppressor for inflammatory cytokines; therefore, desregulation of its production will lead 
to a status of heightened inflammatory response. Interestingly, the same variant was 
previously associated with severe juvenile rheumatoid arthritis (Crawley et al., 1999) 
 
1.2.8.3 INFECTIOUS AETIOLOGY 
The aetiology of BS has not been completely identified. However, an infectious aetiology 
was postulated more than fifty years ago (Denman et al., 1980, Eglin et al., 1982, Gray, 
1950). A viral cause for BS was first postulated by Hulusi Behçet, and later Denman et al. 
(1980) and then Eglin et al. (1982) showed by in situ DNA-DNA hybridization that part of 
the HSV1 genome is transcribed in mononuclear cells of some patients with BS (Denman 
et al., 1980, Eglin et al., 1982, Gray, 1950).  
 
The current evidence in the literature suggests that the herpes virus family is the most 
probable virus associated with BS. Herpes virus DNA and serum antibodies against the 
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virus have been found in a higher proportion of patients with BS than in HC volunteers. 
However, none of these viral infectious agents were proven to cause BS and no study was 
able to establish whether the organisms were the cause or consequence of the lesions 
(Direskeneli, 2001).  
 
The level of IgG antibody against HSV1 was found to be significantly increased in patients 
who had BS (Lee et al., 2005). However, no statistical significance was observed between 
PCR results of HSV1 DNA in the saliva of BS patients and of HC volunteers (Lee et al., 
1996). At the same time, administration of high doses of acyclovir in association with 
plasma exchanges failed to produce positive treatment results, and treatment with acyclovir 
alone failed to alleviate the frequency and severity of oral and genital ulceration or other 
BS features in a randomized, double-blind, placebo-controlled, crossover trial (Davies et 
al., 1988). 
 
In addition to HSV1, the CMV has been studied in relation to BS. The mean titre of IgG 
and IgA antibodies to CMV was significantly lower in BS patients than in HC volunteers. 
However, the number of patients having IgM antibody against CMV was similar in both BS 
patients and HC volunteers (Lee et al., 2005). In a recent study, CMV DNA was detected in 
biopsy specimens from the oral mucosa of BS patients (Sun et al., 1996). 
 
The involvement of streptococcus infection has also been suggested (Lehner et al., 1991, 
Mumcu et al., 2007b). The serum antibody titre and delayed hypersensitivity of patients 
with BS against Streptococcal antigens were reported to be significantly higher than those 
of HC volunteers (Kaneko et al., 1997, Kaneko et al., 2008). An increase in the 
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concentration of oral streptococci in BS patients has been demonstrated, more especially 
the uncommon serotypes of Streptococcus sanguis (KTH-1, strain BD113-20) (Lehner et 
al., 1991, Yoshikawa et al., 1998). Interestingly, some streptococcal antigens that are 
associated with HSP can be recognized by human γδ T cell lines. Indeed, the previous 
research in this field proved that the microbial HSP65 shows homology with the human 
mitochondrial HSP60 and shares antigenicity with this oral mucosal antigen (Lehner et al., 
1991, Lehner, 1997). 
 
In a recent study, Staphylococcus aureus, Moraxella spp., and Streptococcus spp. were 
found to colonize the conjunctiva of BS patients more significantly than those of the HC 
volunteers (Gunduz et al., 2008). Staphylococcus aureus and Prevotella spp. were also 
found to colonize the pustular lesions of BS patients more frequently than HC volunteers 
(Hatemi et al., 2004). Furthermore, treatment of eight BS patients suffering from active 
mucocutaneous symptoms with azithromycin for four weeks was reported to be effective in 
decreasing folliculitic lesions and speeding up the healing of oral ulcers (Mumcu et al., 
2005). 
 
Interestingly, the incidence of bacteraemia and viraemia was also investigated in relation to 
BS patients. No bacterial DNA was isolated from the collected blood samples from BS 
patients. However, EBV, CMV and HHV8 were detected more frequently in the BS patient 
cohorts (Irschick et al., 2011).  
 
It is still not entirely clear whether the change in the microbial community triggers the 
heightened immune response in BS patients, or whether the increase in the detected 
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imbalance in the microbial diversity and load results from a raised host susceptibility to 
infection due to a defect in the immune response (Fortune, 2003). However, the speculation 
that an infectious antigen might contribute to the aetiology of BS is supported by the 
following facts:  
1. The HLA-B51 gene, which has an association with BS, encodes MHC class I that 
participates during the presentation of endogenous antigens to CD8
+
 cytotoxic-
suppressor T lymphocytes (Bettencourt et al., 2008, Krause et al., 2008, Takemoto 
et al., 2008).  
2. Recently, BS was found to be associated with the IL10 gene variant (rs1518111A 
allele), which is known to cause a diminished mRNA expression and a low protein 
production, and potentially leads to heightened inflammatory response to microbial 
insult (Mizuki et al., 2010, Remmers et al., 2010, Xavier et al., 2012).  
3. The major part of the immunopathogenesis in BS is believed to be a T-cell-
mediated immune response, especially by γδ T cells; they are a fascinating 
population of T cells that participate in early responses against microorganisms by 
identifying a wide variety of antigens and they can respond to non-peptide antigens 
in a non-MHC restricted fashion (Fortune et al., 1990). 
4. There is an increase in the concentration of oral streptococci and increase in the IgG 
antibody against HSV1 in BS, which remains an area of interest for further research 
as no causative correlation has been established yet (Hamza et al., 1990, Yoshikawa 
et al., 1998).  
 
73 
 
1.2.8.4 HEAT SHOCK PROTEIN 
HSPs form the most abundant group of proteins inside cells and are expressed in a variety 
of intracellular locations, such as cytosol of prokaryotes and in the cytosol, nuclei, 
endoplasmic reticulum, mitochondria and chloroplasts of eukaryotes. Their expression can 
be induced as a result of heat shock or other forms of stress, including exposure to toxins, 
oxidative stress and glucose deprivation (Srivastava, 2002).  
 
There are ten families of HSPs. Each family consists of anywhere from one to five closely 
related proteins, whereas there is no obvious homology among the individual HSP families. 
The proposed function of HSPs is folding and unfolding of proteins, degradation of 
proteins, assembly of multi-subunit complexes, thermo-tolerance, and buffering of 
expression of mutations. Furthermore, HSP molecules are peptide binding proteins and are 
associated with antigenic epitopes (Srivastava, 2002) (Figure 1.14).  
 
HSPs are highly conserved immunogenic proteins synthesized in large amounts when cells 
are exposed to stressful stimuli. They are often immunodominant antigens produced in 
bacteria and mammalian cells by a variety of stresses. In infections, HSP release could 
support induction of immunity. Extensive sequence homology between microbial and 
human HSPs has led to the concept that HSPs might be involved in the aetiology and 
pathogenesis of autoimmune disorders. It has long been suspected that these proteins act as 
danger signals and act as endogenous immune stimulators that are released during 
infections by intrinsic cells of the body, and that alert the immune system to the need to 
induce immune responses (Lang et al., 2005).  
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Figure 1.14: Different members of HSPs family contain a highly conserved N-terminal 
ATPase domain, a conserved C-terminal hydrophobic peptide binding domain and more 
variable alpha-helical domains [source: (Dollins et al., 2007)]. 
 
When a pathogen infects the cells, it replicates in the infected cells and can destroy them, 
releasing abundant HSPs that carry information about the internal environment. The 
released HSPs in turn can bind to specific receptors on the antigen presenting cell (APC) 
such as CD91, TLRs, CD36, CD40, LOX1 (Srivastava, 2002). Endocytosis of HSP-peptide 
complexes occurs after the HSPs interact with APCs through one of the above-mentioned 
receptors. Endocytosis will be followed by the processing of the HSP-peptide complex and 
their presentation by MHC class I (MHC I) molecules to CD8
+
 T cells or by MHC class II 
(MHC II) molecules to CD4
+
 T cells. HSPs can also activate the antigen nonspecific 
pathway, which lead to innate immune response activation (Srivastava, 2002). 
 
The MHC I or the MHC II pathway will be activated if HSPs bind to CD91 or LOX1 
receptors on the APC. However, when the HSPs interact with the APC through TLRs, 
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CD40 or CD36, the antigen nonspecific pathway will be activated, which leads to 
translocation of nuclear factor kappa B (NFκβ) into the nuclei of macrophages and 
dendritic cells (DCs) (Srivastava, 2002). 
 
HSPs can act as an adjuvant to exogenous antigen and induce the activation of the APC 
through the classical MHC I antigen processing pathway, a phenomenon known as cross-
presentation that can be used in vaccine development (Susumu et al., 2008). 
 
Nevertheless, the release of HSPs is not specific to infections only but also occurs in 
response to physical stimuli, such as heat or irradiation, and in non-infectious inflammatory 
diseases. It is known now that HSPs released from injured tissue may aggravate 
autoimmune responses (Srivastava, 2002). 
 
Many research groups have indicated that HSPs have been implicated in the aetiology of 
BS. Indeed, a significant increase in serum IgA antibodies to the mycobacterial HSP65 was 
found in BS. Furthermore, the HSP65 of Mycrobacterial tuberculosis shows significant 
homology with human HSP60 and cross-reacts with that produced by strains of 
Streptococcus sanguis. These observations are consistent with the presence of an increased 
population of γδ T cells, which could recognize and respond to HSPs and which were found 
in the peripheral blood of patients with BS. Furthermore, γδ T cells increased during 
periods of active disease (Direskeneli et al., 1996, Fortune, 2003, Pervin et al., 1993). 
Moreover, HSP60 is a known ligand for TLR2 and TLR4 and possibly acts as an 
endogenous danger signal to the immune system, with rapid inflammatory cytokine release 
and the enhancement of adaptive Th1-type responses (Takeda et al., 2003). 
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Two types of immune responses to HSPs have been proposed. One type has foreign 
epitopes not shared by self-HSP, inducing a conventional response to infection, and the 
other has conserved epitopes recognized by a tightly regulated autoreactive T cell 
population. Both the T cell and B cell responses in BS fall into the second type, as immune 
responses were detected against both foreign and homologous human determinants 
(Direskeneli et al., 1996, Pervin et al., 1993). 
 
Recently, T cell epitope mapping has identified four peptides (p111-125, p154-172, p219-
233 and p311-325) derived from the sequence of the HSP65. Interestingly, p336-351 is 
significantly associated with BS in Britain, Japan and Turkey. These peptides can 
specifically stimulate TCR γδ+ lymphocytes from BS patients and they show significant 
homology with the corresponding peptides derived from the human HSP60 (Lehner, 1997). 
 
A rat model of uveitis was investigated and the development of uveitis was successfully 
prevented by oral tolerization with the 336-351 peptide linked to recombinant cholera toxin 
B subunit (CTB) (Lehner et al., 2003). This strategy was adopted in a phase I/II clinical 
trial by oral administration of p336-351 three times a week, followed by gradual 
withdrawal of all immunosuppressive drugs used to control the disease in eight patients 
with BS. Oral administration of p336-351-CTB had no adverse effect and withdrawal of the 
immunosuppressive drugs showed no relapse of uveitis in five out of the eight patients. 
After tolerization was discontinued, three patients remained free of relapsing uveitis for 10–
18 months after cessation of all treatment (Stanford et al., 2004). 
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The human HSP70 protein and anti-HSP70 antibodies were also investigated and both were 
found to be elevated in the serum of BS patients. HSP70 mediates innate and adaptive 
immune responses and may participate in pro-inflammatory cytokine activation and tissue 
destruction in BS. It also can take a role in the cross-presentation process previously 
explained (Birtas-Atesoglu et al., 2008). 
 
Based on the above background information, one can conclude that a heightened 
responsiveness to microbial antigens in genetically susceptible hosts might be the best 
hypothesis to explain BS aetiology. It is possible that microbial HSPs stimulate the 
production of self-HSPs. This, in turn, may serve as an endogenous danger signal with 
rapid augmentation of the inflammatory reaction (Lehner, 1999).  
 
1.2.8.5 TOLL-LIKE RECEPTORS 
TLRs are a receptor-based system for the recognition and discrimination of microbial 
pathogens by sensing their Pathogen-Associated Molecular Patterns (PAMP). TLR1, the 
first TLR, was identified in 1994, and was so named because of its close homology with the 
known Drosophila Toll receptor system (Gay and Gangloff, 2007). TLR4 was identified in 
1997, and TLRs 2, 3, and 5 were cloned shortly thereafter. TLRs are mainly expressed on 
the cells associated with innate immunity such as granulocytes, monocytes, macrophages 
and dendritic cells. However, some TLR expression was demonstrated on epithelial and 
endothelial cells (Takeda et al., 2003). 
 
TLRs act as surface proteins that sense the presence of microbial infection by binding to the 
characteristic patterns within molecules on the outside of bacteria, fungi and viruses, and 
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even to forms of DNA and RNA. This receptor system is thought to provide the specificity 
for the innate immunity, allowing it to recognize and differentiate between gram negative 
(–ve) bacteria, gram positive (+ve) bacteria or fungal infection (Takeda et al., 2003). 
 
The TLRs are type I integral membrane glycoprotein, consisting of a characteristic 
extracellular leucine-rich repeat (LRR) domain and intracellular toll/interleukin-1 receptor 
(TIR) domain. These conserved domains have helped to identify and classify 13 distinct 
mammalian TLRs, 10 of which are found in humans (Huyton et al., 2007) (Figure 1.15). 
 
 
Figure 1.15: Structure of TLR [source: (Goodsell, 2006)]. 
 
TLR2 and TLR4 jointly act as two of the major innate immune receptors recognizing most 
of the oral microbial commensals and pathogens. It is known that some HSP families, 
which might play a pivotal role in BS pathogenesis, are ligand to TLR2 and TLR4 (Binder 
Extracellular domain 
Intracellular domain 
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et al., 2004). Therefore, Table 1.5 focuses on the description of the TLR2 and TLR4 
distribution, their activators, ligand and adaptors.  
 
Table 1.5: TLR2’s and TLR4’s distribution, activators, ligand, and adaptors [source: 
(Takeda et al., 2003)]. 
TOLL-
LIKE 
RECEPTOR 
CELL 
TYPES 
ACTIVATORS LIGAND ADAPTORS 
TLR2 Macrophage  
Dendritic cell 
Granulocyte 
Gram +ve 
bacteria 
Fungi 
Parasite 
Self 
Viruses 
 
Β-glucans 
HSP70 
Necrotic cells 
Peptidoglycan 
Porins 
Posphalipomannan 
Teichoic acid 
Zymosan 
Mal 
MyD88 
 
TLR4 Macrophage 
Dendritic cell 
T cell 
Granulocyte 
B cell 
 
Gram –ve 
bacteria 
Fungi 
Self 
Viruses 
 
Chamydia 
pneumonia 
CMV 
Glycoproteins 
Human HSP60/70 
HSP60 
LPS 
Mannan 
O-linked 
mannosyl residue 
Teichoic acid 
RSV 
Mal/TIRAP and 
MyD88 
TRAM and TRIF 
HSP: heat shock protein; LPS: lipopolysaccharide; Mal: MyD88 adaptor-like; 
Mal/TIRAP: MyD88 adaptor-like/TIR domain-containing adaptor molecule; MyD88: 
myeloid differentiation primary response protein 88; RSV: respiratory syncytial virus; 
TRAM: tumour necrosis factor receptor-associated factor; TRIF: TIR domain-containing 
adaptor protein inducing interferon-β 
 
Activation of TLRs triggers a cascade of protein kinases that result in a well-characterized 
innate host recognition pathway leading to the nuclear translocation of NF-κB and 
transcription of cytokine-encoding genes (Takeda et al., 2003). The NF-κB pathway is of 
great significance because it is involved in the regulation of about 40% of human genes and 
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is particularly involved in the production of pro-inflammatory cytokines, chemokines, and 
Growth Factors (GF) as well as inducible enzymes, including the inducible Nitric Oxide 
Synthase (iNOS) (Takeda et al., 2003) (Figure 1.16). 
 
 
Figure 1.16: The cascade of protein kinases triggered by activation of TLRs [source: (Zhu 
and Mohan, 2010)]. 
 
The first step in TLR signalling is stimulus-induced dimerization or oligomerization. The 
next step is the recruitment of adaptors to the TIR domains of the dimerized receptor. There 
are a total of five adaptors which are: myeloid differentiation primary response protein 88 
(MyD88); MyD88 adaptor-like/TIR domain-containing adaptor molecule (Mal/TIRAP); 
tumour necrosis factor receptor-associated factor (TRAM); TIR domain-containing adaptor 
protein inducing interferon-ß (TRIF); and sterile alpha and HEAT/Armadillo motif protein 
(SARM). MyD88 is used by TLRs 5, 7, 8 and 9. However, TLR2 requires Mal and MyD88, 
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whereas TLR4 can use either Mal/TIRAP and MyD88 or TRAM and TRIF to signal to NF-
κB or antiviral responses mediated through interferon response factor (IRF) 3 respectively. 
At the same time, TLR3 uses TRIF exclusively for IRF3-directed signals (Gay and 
Gangloff, 2007). 
 
Next in the signalling hierarchy are the interleukin-1 receptor-associated kinases (IRAKs). 
There are four IRAKs; IRAK2 and IRAKM are not active phosphotransferases and function 
as negative regulators, whereas IRAK4 and IRAK1 autophosphorylate and are recruited by 
association with MyD88 into the post receptor signalling complex (Gay and Gangloff, 
2007). The precise events thereafter which lead to downstream signalling are not 
completely understood: they lead either to releases of NF-κB which then relocalize to the 
nucleus or to the activation of the second branch of the TLRs’ pathway leading to antiviral 
responses such as the production of interferons, chemokines and anti-inflammatory 
cytokines. Interestingly, TLR4 and TLR3 can activate the antiviral response pathway. In 
doing so, TLR4 requires the adaptor molecules TRAM and TRIF, whereas TLR3 requires 
TRIF alone (Gay and Gangloff, 2007).  
 
More interestingly, the activation of different TLRs can result in different reactions within 
the cell. As an example, activation of TLR2 induces the transcription of genes encoding 
TNF-α and IL-1ß less effectively than those binding to TLR4, and results in no 
transcription of genes encoding IFN-γ or IL-12. Moreover, TLR2 signalling can also 
activate pro-apoptotic pathways resulting in inflammatory cell death (Takeda et al., 2003). 
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An elevated expression of TLR4 (mRNA and protein) but not TLR2 in peripheral blood 
mononuclear cells (PBMCs) of BS patients was initially observed, irrespective of the 
disease activity (Kirino et al., 2008). Later on, TLR2 and TLR4 expression in the PBMCs 
of active BS patients were highly elevated compared to HC volunteers. Interestingly, in the 
same study the serum vitamin D levels were found to be lower in active BS patients. 
Therefore, vitamin D levels were inversely correlated with the expressions of TLR2, TLR4, 
and with the clinical indicators (Do et al., 2008). In a functional study, vitamin D was found 
to suppress the protein and mRNA expression of both receptors (Do et al., 2008). 
Furthermore, decreased TLR2 expression was noted in PBMCs of BS patients after 
stimulation with HSP60 and lipopolysaccharide (LPS) (Yavuz et al., 2008). The total 
expression of TLR2 and TLR4 was also found to be elevated in the intestinal and buccal 
mucosa of BS patients and broncho-alveolar lavage (BAL) (Durrani et al., 2011, Hamzaoui 
et al., 2012, Nara et al., 2008).  
 
Because of the essential role of TLRs in innate immune recognition, these receptors are 
currently being explored as possible therapeutic targets. The use of antibodies or small 
molecules that block recognition or signalling by the TLRs may play a role in damping the 
exaggerated inflammatory responses in diseases such as sepsis and autoinflammatory or 
autoimmune diseases (Goodsell, 2006). 
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1.3 AIMS AND HYPOTHESIS 
1.3.1 CLINICAL AIMS 
1. To analyse the frequency of the different signs and symptoms of the BS patient 
cohort in the UK and compare it to the international published data. To analyse the 
treatment protocol used to treat the BS patient cohort in the UK. 
2. To correlate the QoL to the oral health status and disease activity in the UK’s BS 
patient cohort and compare it to a Turkish BS patient cohort. 
3. To compare the oral health status of the UK’s BS patient cohort with RAS patients 
and HC volunteers.  
 
1.3.2 LABORATORY AIMS 
1. To investigate aspects of the oral mucosal innate immune response in BS patients 
by focusing on the difference in expression of TLR2 and TLR4, mRNA and protein 
in the buccal mucosa of BS patients, RAS patients, and HC volunteers. Moreover, 
to determine the difference in expression of TLR2 and TLR4, mRNA and protein, 
in the oral mucosa of BS patients during inactive and relapsed periods. 
2. To investigate the level of expression of the different splice variants of TLR2 and 
TLR4 in the oral mucosa of BS patients, RAS patients, and HC volunteers. 
Understanding the difference between inactive and relapsed periods of BS activity 
was of great interest.  
3. To investigate the function of TLR2 and TLR4 in vitro upon treatment with 
different agonists. 
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4. To determine the difference in buccal mucosal and salivary microbiome between 
BS patients, RAS patients, and HC volunteers. Moreover, to investigate any 
difference in the ulcerated and non-ulcerated mucosal microbiome in BS patients.   
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1.3.3 HYPOTHESIS 
It was hypothesized that the complex interplay between the oral microbiome 
(environmental factors) and aspects of the innate immune responses such as TLRs in 
genetically susceptible patients leads to enhanced inflammatory responses and 
consequently the amplified tissue damage observed in BS patients (Figure 1.17).  
 
 
Figure 1.17: BS is caused by the interaction of a number of factors leading to amplified 
tissue damage. 
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This study attempted to examine the following null hypothesis: 
1. There are no differences in the QoL, oral health status and disease activity in the 
UK’s BS patient cohort compared to a Turkish BS patient cohort.  
2. There are no differences in the oral health status of the UK’s BS patients, RAS 
patients, and HC volunteers.  
3. There are no differences in the expression of TLR2 and TLR4, mRNA, and protein 
in the buccal mucosa of BS patients, RAS patients, and HC volunteers.  
4. There are no differences in the expression of TLR2 and TLR4, mRNA, and protein 
in the buccal mucosa of BS patients during inactive and relapsed periods. 
5. There are no differences in the level of expression of the different mRNA splice 
variants of TLR2 and TLR4 in the buccal mucosa of BS patients, RAS patients, and 
HC volunteers.  
6. There are no differences in the level of expression of the different mRNA splice 
variants of TLR2 and TLR4 in the buccal mucosa of inactive and relapsed BS 
patients.  
7. There are no differences in the function of TLR2 and TLR4 expressed on BS 
patients’ PBMC compared to HC volunteers.  
8. There are no differences in the buccal mucosal and salivary microbiome between 
BS patients, RAS patients, and HC volunteers.  
9. There are no differences in the ulcerated and non-ulcerated mucosal microbiome in 
the BS patient cohort.   
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 SECTION 1: CLINICAL METHODS 
This clinical study investigated aspects of the oral health status of Behçet’s syndrome (BS) 
patients and compared it to recurrent aphthous stomatitis (RAS) patients and healthy 
control (HC) volunteers. BS patients were accessible through specialized clinics in the 
Royal London Hospital and St Thomas’ Hospital. These clinics specialize in diagnosing, 
managing, and investigating patients who are classified according to the International Study 
Group (ISG) criteria for BS diagnosis (The Lancet, 1990). A small cohort of Turkish BS 
patients was also compared to the UK patients in the quality of life (QoL) and oral health 
analysis part of the study. The RAS patients and HC volunteers were accessible through the 
Oral Medicine Clinic at the Royal London Hospital. 
 
2.1.1 ETHICAL APPROVAL  
The project is part of the immunoregulation at the mucosal barrier programme, with ethical 
approval granted by the East London and The City Research Ethics Committee, Reference 
P/03/122. Ethical approval has been granted for St Thomas’ Hospital, and the Turkish 
centre independently. 
 
2.1.2 SUBJECTS  
There are three groups in this clinical study, namely BS patients, RAS patients and HC 
volunteers. 
 
2.1.2.1 GROUP NUMBER 1: BS PATIENTS 
BS patients were recruited mainly from the two UK centres mentioned above. The Turkish 
cohort was included in the QoL and oral health status analysis only.  
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2.1.2.1.1 UK COHORT 
 To avoid selection bias, all patients attending the research clinic who were over 18 years 
old were invited to take part in the study. If the patient wished to consider participation in 
the study, it was explained to them and they were provided with full details. An informed 
consent was subsequently obtained (Appendix 1). 
 
2.1.2.1.2 TURKISH COHORT 
Similarly to the UK cohort, all patients attending the research clinic who were over 18 
years old were invited to take part in the study. Patient recruitment and investigation in 
Turkey were conducted by the Turkish collaborators. 
 
2.1.2.1.3 BS PATIENTS’ INCLUSION CRITERIA  
All BS patients were diagnosed and classified according the ISG criteria for BS patient 
diagnosis (Lancet, 1990).  
 
2.1.2.1.4 BS PATIENTS’ EXCLUSION CRITERIA 
1. Not fulfilling the ISG criteria for BS patient diagnosis 
2. Pregnancy 
3. Age under 18 years. 
 
2.1.2.1.5 BS PATIENTS’ STRATIFICATIONS 
BS patients were clinically assessed in a consultant-led examination and then classified 
according to the overall activity of the disease into the following groups:  
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1. Relapsed status that was defined as severe disease activity in more than two of the 
BS symptoms despite treatment.  
2. Minor activity status that was defined as some disease activity in less than three of 
the BS symptoms. 
3. Inactive status that was defined as the absence of any symptoms at the time of 
sampling.  
  
BS patients were further stratified according to the oral activity into orally active and orally 
inactive groups. 
1. Orally active BS is a state of oral activity where patients presented to the clinic with 
oral ulcerations.  
2. Orally inactive BS is a state of oral inactivity where patients presented to the clinic 
with no oral ulcerations.  
 
The different disease activities, other than the oral ulceration, were also examined along 
with the treatment protocol.  
  
2.1.2.2 GROUP NUMBER 2: HC VOLUNTEERS  
This group consists of HC volunteers, recruited using advertisements displayed on 
appropriate notice boards in the Dental Institute of The Royal London Hospital and the 
Centre of Clinical and Diagnostic Oral Sciences of Barts and The London School of 
Medicine and Dentistry. Every effort has been made to match the age and gender of the 
control group to that of the patient group.  
 
91 
 
2.1.2.2.1 HC VOLUNTEERS’ INCLUSION CRITERIA 
1. Healthy individuals who do not suffer from chronic diseases or do not receive 
regular medications. 
2. Healthy individuals who matched the BS patient group in age and gender.  
 
2.1.2.2.2 HC VOLUNTEERS’ EXCLUSION CRITERIA 
1. Chronic disease 
2. Regular medications 
3. Pregnancy 
4. Age under 18 years 
5. History of recurrent oral ulceration. 
 
2.1.2.3 GROUP NUMBER 3: RAS PATIENTS  
This group consists of RAS patients who experience recurrent oral ulcerations but do not 
fulfil the ISG criteria of BS patient diagnosis. 
 
2.1.2.3.1 RAS PATIENTS’ INCLUSION CRITERIA 
The RAS patient group includes patients who have a history of recurrent oral ulcerations of 
indefinable cause. 
  
2.1.2.3.2 RAS PATIENTS’ EXCLUSION CRITERIA 
1. Patients with a history of recurrent oral ulcerations accompanied by any other 
systemic manifestation such as skin lesions, eye problems or genital ulcerations. 
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2. Patients with a history of recurrent oral ulcerations with identifiable cause such as 
trauma, mucocutaneous disease, or vitamin deficiency. 
3. Age under 18 years. 
4. Pregnancy.  
 
2.1.3 QUESTIONNAIRES 
2.1.3.1 CLINICIAN’S OBSERVATION FORM FOR DISEASE ACTIVITY 
The clinician’s observation form for disease activity was used to record the activity of the 
disease in each session after a consultant-led clinical assessment (Appendix 2). Oral, 
genital, dermatological, ophthalmological, vascular, and neurological activities were 
recorded. The clinician’s opinion on the overall activity of the disease was also recorded 
and each case was classified as relapsed or inactive.  
 
2.1.3.2 QoL AND ORAL HEALTH STATUS QUESTIONNAIRE 
QoL was assessed using the oral health impact profile-14 (OHIP-14) while the oral health 
status was assessed by dental examination using dental and periodontal indices. This 
questionnaire aimed to highlight the correlation between QoL, oral health, and disease 
activity. 
 
2.1.3.2.1 OHIP-14 
A 5-point Likert-type scale was used in scoring each item of the OHIP-14. Responses were 
coded 0=never, 1=hardly ever, 2=occasionally, 3=fairly often, 4=very often. Patients’ 
responses were added up to produce an OHIP-14 total score. Total OHIP-14 scores ranged 
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from 0 (no impact) to 56 (all of the oral health problems were experienced very often). 
High scores indicated a poor oral health-related QoL (Appendix 3).  
 
2.1.3.2.2 DENTAL AND PERIODONTAL INDICES 
Oral health was evaluated by dental and periodontal indices including the decayed, missing, 
filled teeth (DMFT) index, plaque index (PI), gingival index (GI), sulcus bleeding index 
(SBI), periodontal probing depth (PPD) and attachment level (AL) (Appendix 4). 
 
2.1.3.2.2.1 DMFT INDEX 
The DMFT index is a general indicator of the dental health status of a population: the lower 
the index, the better the dental health. The DMFT score for any individual can range from 0 
to 32, in whole numbers. The index gives equal weight to missing, untreated, decayed, and 
well-restored teeth (Miyamoto et al., 2006).  
 
2.1.3.2.2.2 PI 
The PI is a general indicator of oral hygiene. The score ranges from 0 to 3. Score 0 means 
no plaque, score 1 means a film of plaque adhering to the free gingival margin and adjacent 
area of the tooth, score 2 means moderate accumulation of soft deposits within the gingival 
pocket of the tooth and gingival margin which can be seen with the naked eye, and score 3 
means an abundance of soft matter within the gingival pocket and/or on the tooth and 
gingival margin.  
 
The PI was calculated for each examined tooth by adding the plaque scores for the 4 
different surfaces (buccal, lingual/palatal, mesial, and distal) and dividing the score by 4. 
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The index for each patient was then calculated by adding the indices for all teeth and 
dividing by the number of teeth (Loe, 1967). 
 
2.1.3.2.2.3 GI 
The GI was developed more than 40 years ago to describe the clinical severity and location 
of gingival inflammation (Table 2.1) (Loe, 1967). The GI score ranges from 0 to 3 with 
score 0 representing clinically normal gingiva with no bleeding on probing, and score 3 
corresponding to severe gingival inflammation evidenced by marked redness, hypertrophy, 
oedema, ulceration, and spontaneous bleeding. Score 1 indicates mild gingival 
inflammation while score 2 points towards the presence of moderate gingival inflammation. 
 
Table 2.1: Loe (1967) GI scoring system.  
APPEARANCE BLEEDING INFLAMMATION SCORE 
Normal No bleeding None 0 
Slight change in colour, and mild 
oedema with slight change in texture 
No bleeding Mild 1 
Redness, hypertrophy, oedema, and 
glazing 
Bleeding on 
probing/pressure 
Moderate 2 
Marked redness, hypertrophy, oedema, 
ulceration 
Spontaneous 
bleeding 
Severe 3 
[source: (Loe, 1967)] 
 
 
 
2.1.3.2.2.4 SBI 
The SBI was used to supplement the data obtained from the GI in assessing the presence of 
gingivitis (Table 2.2) (Muhlemann and Son, 1971). The SBI score ranges from 0 to 5 with 
score 5 indicating severe gingival inflammation while score 0 represents clinically normal 
gingiva.  
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Table 2.2: Muhlemann and Son (1971) SBI scoring system. 
APPEARANCE SULCUS PROBING SCORE  
Healthy No bleeding  0 
Apparently healthy with no change in colour and 
no swelling 
Bleeding on probing 1 
Change in colour due to inflammation; no 
swelling or macroscopic oedema 
Bleeding on probing 2 
Change in colour due to inflammation; slight 
oedematous swelling 
Bleeding on probing 3 
Obvious swelling Bleeding on probing 4 
Spontaneous bleeding; changes in colour; marked 
swelling with or without ulceration 
Bleeding on probing 5 
[source: (Muhlemann and Son, 1971)] 
 
2.1.3.2.2.5 PPD 
The PPD was measured between the gingival margin and the base of the pocket in six 
points (mesiobuccal, mid buccal, distobuccal, distolingual, mid lingual, mesiolingual) of 
each examined tooth (Figure 2.1). An average of the six readings was calculated for each 
tooth. 
 
2.1.3.2.2.6 AL 
The AL was measured between the cemento-enamel junction (CEJ) and the base of the 
pocket in six points (mesiobuccal, mid buccal, distobuccal, distolingual, mid lingual, 
mesiolingual) of each examined tooth (Figure 2.1). An average of the six readings was 
calculated for each tooth. 
 
2.1.3.2.2.7 RECESSION 
Recession was calculated by subtracting the PPD from the AL. 
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Figure 2.1: The difference between PPD and AL. PPD is the measurement between the 
gingival margin and the base of the pocket while AL is the measurement between the CEJ 
and the base of the pocket [source: www.medscape.com].  
 
2.1.4 TYPE OF SAMPLES COLLECTED 
2.1.4.1 SALIVA 
Un-stimulated, whole saliva samples (1ml) were collected from BS patients, RAS patients, 
and HC volunteers. Samples were collected in a sterile universal container and processed 
using the following protocol: the saliva samples were centrifuged at 3300 rpm at 4 °C for 
15 minutes. The supernatant was divided into 200 l aliquots in eppendorfs and stored at -
80 °C.  
 
Salivary sediments were either re-suspended in 1 ml of Amies liquid transport medium and 
stored at 4 °C to be cultured on different bacteriological culture media within 48 hours of 
97 
 
collection or they were lysed by adding 600 µl of lysis buffer (Purescript, Qiagen, UK). For 
the purpose of deoxyribonucleic acid (DNA) purification, the salivary sediment samples 
were mixed with the lysis buffer by pipetting up and down, then they were incubated at 65 
°C for 15 minutes and stored at -80 °C until further analysis. 
 
2.1.4.2 BRUSH BIOPSY 
 The base of the ulcer and the non-ulcerated buccal mucosa from BS patients, RAS patients, 
and HC volunteers were brush biopsied with a nylon bristle buccal cytology brush 
(Flowgen, UK) using 10 strokes with 2 different brushes. Brushes were dipped up and 
down 10 times in a 1.5 ml eppendorf containing 600 µl of cell lysis solution (Purescript-
Gentra, Qiagen, UK) or 600 µl of normal saline. The samples in the lysis buffer were 
incubated at 65 °C for 15 minutes then stored at -80 °C until DNA, ribonucleic acid (RNA), 
and protein isolation was carried out. The samples in normal saline were used to grow 
mycobacterium according the protocol described later on.  
 
2.1.4.3 ORAL MUCOSAL SWABS 
Amies liquid transport medium swabs (Copan, UK) were collected from ulcerated and non-
ulcerated oral mucosa of the same cohorts of patients and controls. Swabs were stored at    
4 °C and processed within 48 hours of collection by culturing on different culture media, 
following the protocol detailed below. 
 
2.1.4.4 SERUM SAMPLES 
Blood samples were collected from the same cohorts of BS patients, RAS patients, and HC 
volunteers in tubes coated with pro-coagulant to shorten the coagulation time. The tubes 
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also contained separation gel that solidifies and forms a barrier to separate serum from red 
blood cells. Serum was obtained from clotted blood by centrifugation at 3300 rpm at 4 °C 
for 15 minutes. Samples were divided into 200 l aliquots and stored at -80 °C. The serum 
samples were then tested for the presence of herpes viruses immunoglobulin (Ig) G 
according to the protocol detailed in chapter 2, section 2.2.3.4.  
 
2.1.4.5 WHOLE BLOOD SAMPLES  
Whole blood samples were collected in tubes coated with ethylenediaminetetraacetic acid 
(EDTA) to avoid coagulation of the blood during transport time from the clinic to the 
laboratory. Upon reaching the laboratory, the peripheral blood mononuclear cells (PBMC) 
were isolated by density gradient centrifugation over ficoll-hypaque (F-H) (1700 rpm for 35 
minutes). The cells were then tested according to the toll-like receptor (TLR) function study 
protocol detailed in chapter 2, section 2.2.5.  
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2.2 SECTION 2: LABORATORY METHODS 
2.2.1 SAMPLE PREPARATION  
2.2.1.1 DNA, RNA, AND PROTEIN EXTRACTION FROM BRUSH BIOPSIES AND 
SALIVARY SEDIMENTS  
DNA, RNA, and protein were isolated using the Purescript kit (Gentra, Qiagen, UK) 
following the manufacturer’s protocol as follows. 
 
2.2.1.1.1 PROTEIN AND DNA PRECIPITATION 
A 200 μl protein-DNA precipitation solution was added to the cell lysate prepared as 
mentioned above from saliva sediments and brush biopsies. The content of the tube was 
mixed by inverting it gently about 10 times and it was then placed on ice for 5 minutes. The 
samples were subsequently centrifuged at 15,000 rpm for 3 minutes to allow the formation 
of tight pellets of protein and DNA. 
  
2.2.1.1.2 RNA EXTRACTION 
 RNA in the supernatant fluid was poured into a sterile 1.5 ml eppendorf containing 600 μl 
of 100% isopropanol (propan-2-ol) and 1 μl of glycogen solution (Gentra, Qiagen, UK). 
The sample was mixed by inverting the tube almost 50 times and centrifuged at 15,000 rpm 
for 3 minutes; the RNA and glycogen mixture was visible at the end of this step as a small 
translucent pellet. The supernatant was poured off and the tube drained on clean absorbent 
paper. 100 μl of 70% ethanol (v/v) was then added to the tube, which was inverted several 
times to wash the pellet, followed by centrifuging the samples at 15,000 rpm for 1 minute. 
The ethanol was poured off and the samples allowed to air dry at an angle for 15 minutes. 
A 20 μl RNA hydration solution was added and the tube was placed on ice for at least 30 
100 
 
minutes. The sample was centrifuged for 5 seconds to spin down the entire sample and then 
stored at -80 °C until the complementary Deoxyribonucleic Acid (c-DNA) preparation. 
 
2.2.1.1.3 HUMAN DNA AND PROTEIN EXTRACTION 
A 600 μl cell lysis solution was added to the cell pellet and gently pipetted up and down 
until the cells were suspended then 3 μl of RNAse A (4mg/ml) was added and the sample 
mixed by inverting the tube 25 times. It was then incubated at 37 °C for 15 minutes to 
degrade the RNA. The samples were allowed to cool by placing them on ice for 1 minute 
then 200 μl of protein precipitation reagent were added and the samples vortexed 
vigorously at high speed for 20 seconds to mix the protein precipitation reagent uniformly 
with the cell lysate.  
 
The samples were then incubated on ice for 30 to 60 minutes and were centrifuged at 
13,000 rpm for 3 minutes to allow the protein to form a tight pellet. Supernatant containing 
DNA was carefully removed into fresh tubes. The protein pellets were then re-suspended in 
200 μl of sterile protease inhibitor cocktail solution (Roche Applied Science, UK). The 
supernatant samples were centrifuged at 13,000 rpm for 1 minute in 600 μl of 100% 
isopropanol (propan-2-ol). The supernatant was then discarded and 600 μl of 70% ethanol 
were added to the DNA pellets to wash the samples. The samples were centrifuged as 
before. The supernatants were carefully discarded and samples left to air dry. Each DNA 
sample was dissolved in 20 μl of DNA hydration solution and was rehydrated by incubating 
it for 1 hour at 65 °C or alternatively overnight at room temperature. All samples were 
stored at -80 °C until further analysis. 
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2.2.1.1.4 BACTERIAL DNA EXTRACTION 
For the purpose of bacterial DNA purification, the following steps followed the steps 
detailed in section 2.2.1.1.2, as follows: 
A 600 μl cell lysis solution was added to the cell pellet and gently pipetted up and down 
until the cells were suspended. A 1.5 μl lytic enzyme solution was then added and the tube 
inverted about 25 times to mix its contents. The samples were incubated at 37 °C for 1 hour 
to digest the cell walls and were occasionally inverted during the incubation. Then 3 μl of 
RNAse A (4mg/ml-wt/v) were added and the sample mixed by inverting the tube 25 times 
and incubating it at 37 °C for 1 hour to degrade the RNA. The samples were allowed to 
cool by placing them on ice for 1 minute then 200 μl of protein precipitation reagent were 
added and the samples vortexed vigorously at high speed for 20 seconds to mix the protein 
precipitation reagent uniformly with the cell lysate.  
 
The samples were then incubated on ice for 30 to 60 minutes and were centrifuged at 
13,000 rpm for 3 minutes to allow the protein to form a tight pellet. Supernatant containing 
DNA was carefully removed into fresh tubes. The protein pellets were then discarded 
(Roche Applied Science, UK). The supernatant samples were centrifuged at 13,000 rpm for 
1 minute in 600 μl of 100% isopropanol (propan-2-ol). The supernatant was then discarded 
and 600 μl of 70% ethanol were added to the DNA pellets to wash the DNA. The samples 
were centrifuged as before. The supernatants were carefully discarded and samples left to 
air dry. Each DNA sample was dissolved in 20 μl of DNA hydration solution and was 
rehydrated by incubating it for 1 hour at 65 °C or alternatively overnight at room 
temperature. All samples were stored at -80 °C until further analysis. 
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2.2.1.2 NUCLEIC ACID PURIFICATION FROM SALIVA SAMPLES 
Nucleic acid in 300 μl of all the saliva samples was simultaneously purified along with 6 
water samples as a negative control. All samples were processed in the BioRobotMDx 
workstation using the QIAamp DNA extraction kit, following the manufacturer’s protocol 
(Qiagen, UK) (Figure 2.2). This method utilized the selective binding properties of a silica-
based membrane to purify DNA samples. Purified DNA samples were then eluted in 
elusion buffer (AE) (10 mM Tris Cl, 0.5 mM EDTA, pH 9) and were free from protein, 
nucleases, and other contaminants or inhibitors. All samples were subsequently spiked with 
phocine herpes virus (PHV) DNA to act as an internal control during the real time 
polymerase chain reaction (qPCR) test. Samples were then stored at -80 °C until further 
analysis.  
 
 
Figure 2.2: BioRobotMDa workstation employed for automated nucleic acid purification 
from salivary supernatant samples (Qiagen, UK) [source: Virology Unit at Barts and The 
London NHS Trust]. 
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2.2.1.3 QUANTIFICATION OF DNA, RNA, AND PROTEIN 
DNA, RNA, and protein quantification were determined by using the NanoDrop 
spectrophotometer, according to the manufacturer’s protocol (Labtech, UK) (Figure 2.3). 
Using fibre optic technology and surface tension, the NanoDrop spectrophotometer holds   
1 µl of sample between two optical surfaces to define the path length in a vertical 
orientation.  
 
The upper and lower optical surfaces of the microspectrophotometer sample retention 
system were cleaned at the beginning of each reading session by pipetting 1 µl of clean 
deionised water onto the lower optical surface. The lever arm was then closed and tapped a 
few times to bathe the upper optical surface, followed by reopening the lever arm to allow 
meticulous cleaning with a clean tissue.  
 
The NanoDrop software was opened on the required module, followed by initiation of the 
spectrophotometer by placing 1 µl of deionised water onto the lower optic surface, 
lowering the lever arm, and selecting “initialize” in the NanoDrop software. A blank 
measurement was performed by loading 1 µl of the buffer used to re-suspend the DNA, 
RNA, or protein samples before the first sample measurement and between every 5 
measurements. Both optical surfaces were cleaned before measuring the first sample and in 
between each sample.  
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Figure 2.3: NanoDrop spectrophotometer [source: Labtech, UK]. 
 
2.2.1.4 c-DNA PREPARATION 
RNA was transcribed to c-DNA by using the high-capacity c-DNA reverse transcription kit 
(Applied Biosystems, UK) according to the kit protocol. To synthesize single-stranded      
c-DNA from the previously purified RNA, a 10 µl reverse transcription master mix was 
prepared for each RNA sample, as shown in table 2.3, then 10 µl of RNA sample was 
added. The reverse transcription was performed in the thermal cycler using the thermal 
cycler conditions shown in table 2.4. c-DNA samples were then stored at -80 °C until 
further analysis. 
 
Table 2.3: Master mix for c-DNA preparation.  
COMPONENT VOLUME REACTION PER 
SAMPLE 
10x RT Buffer 2.0 µl 
25x dNTP Mix (100 mM) 0.8 µl 
10x RT Random Primers 2.0 µl 
MultiScribeReverse
TM
Transcriptase 1.0 µl 
RNase Inhibitors 1.0 µl 
Nuclease-free H2O 3.2 µl 
Total 10.0 µl 
dNTP: deoxyribonucleotide triphosphate; H2O: water; RT: reverse transcriptase 
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Table 2.4: The thermal cycler condition for c-DNA preparation. 
 STEP 1 STEP 2 STEP 3 STEP 4 
Temperature 
(°C) 
25 °C 37 °C 85 °C 4 °C 
Time 10 min 120 min 5 sec ∞ 
°C: degree Celsius; min: minutes; sec: seconds; ∞: until removing the samples from the 
cycler  
 
2.2.2 ORAL MUCOSAL EXPRESSION OF TLR2 AND TLR4  
2.2.2.1 qPCR FOR TLR2 AND TLR4 mRNA DETECTION  
2.2.2.1.1 PRIMERS FOR THE qPCR  
TaqMan probe was used for the detection of TLR2, TLR4 and 18S ribosomal RNA (18S 
rRNA) in general (TLR2 Hs00152932_m1, TLR4 Hs00370853_m1 and 18S rRNA 
Hs99999901_s1). The TaqMan probe for TLR2 mRNA was a general TLR2 probe for the 
common 5´ untranslated region (5´UTR) region of the five transcripts on the 2–3 exon 
boundaries, while for TLR4 mRNA the general TLR4 probe for the common 5´UTR region 
of the three transcripts on the 1–2 exon boundary was employed (Applied Biosystems, 
UK). 18S rRNA was used as a housekeeping gene for the purpose of calculating the relative 
expression of TLR2 and TLR4 mRNA. 
 
These probes are a sequence detection system applying TaqMan chemistry, also known as 
fluorogenic 5´ nuclease chemistry. The TaqMan chemistry uses a fluorogenic probe to 
enable the detection of a specific PCR product as it accumulates during PCR cycles. By 
using these probes, a specific hybridization between probe and target generates a 
fluorescent signal which is considered one of the advantages of this technology. TaqMan 
probes can also be labelled with different distinguishable reporter dyes that allow 
amplification of two distinct sequences in one reaction tube. This property leads to post-
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PCR processing elimination and reduces assay labour and material costs. However, the 
disadvantage of TaqMan chemistry is that the synthesis of different probes is required for 
different sequences. 
 
2.2.2.1.2 THE THERMAL CYCLE PROTOCOL 
The cycle used in this experiment was composed of three stages, namely denaturation, 
annealing and extension/elongation. Stage one is 1 cycle at 50 °C for 2 minutes, stage two 
is 1 cycle at 95 °C for 10 minutes, and stage three is composed of 50 cycles, with each 
cycle formed of two steps, 95 °C for 0.15 minutes followed by a cooling step at 60 °C for 1 
minute (Figure 2.4). Samples were tested in triplicate to confirm the reliability of the 
technique at the Barts and the London School of Medicine and Dentistry’s Genome Centre.  
 
 
 
Figure 2.4: The thermal cycle protocol used in the TaqMan qPCR experiment for the 
detection of TLR2, TLR4, and 18s rRNA. 
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2.2.2.2 qPCR FOR THE DETECTION OF TLR2 AND TLR4 mRNA SPLICE 
VARIANTS  
2.2.2.2.1 PRIMERS FOR THE qPCR   
Specific primers designed and validated in-house were used in this experiment to detect the 
relative expression of TLR2 and TLR4 mRNA splice variants in relation to glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). All primers were designed to pass by exon 
boundaries and examined for its ability to amplify a single product (Table 2.5). Validation 
steps proved that each primer pair detected a single product and that negative control is 
consistently negative (Figure 2.5).  
 
SYBR Green master mix was used, which contains a fluorescent DNA binding dye that 
helps in quantifying the amount of c-DNA in the examined sample by measuring the 
increased fluorescence through the PCR cycle (Roche Applied Science, UK). Each reaction 
consisted of 7 μl of x1 SYBR Green master mix, 1 μl of the primer mix that consisted of 
the forward and the reverse primers, and 2 μl of the sample c-DNA. Each qPCR cycle 
included at least one negative control and five positive controls in serial dilutions, creating 
the standard curve used for the quantification (Figures 2.6 and 2.7). Samples were tested in 
duplicate to test the reliability of the technique.  
 
2.2.2.2.2 THE THERMAL CYCLE PROTOCOL 
The thermal cycle was composed of three stages, namely denaturation, amplification and 
melting analysis. Stage one consisted of 1 cycle at 95 °C for 5 minutes. Stage two consisted 
of 45 cycles with each cycle formed of three steps: melting at 95 °C for 10 seconds, 
annealing at 60 °C for 10 seconds, and extension at 72 °C for 10 seconds, followed by the 
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three stages of the melting analysis (95 °C for 5 seconds, 60 °C for 60 seconds, 60 °C to 99 
°C gradual heating, and finally 40 °C for 20 seconds). 
Table 2.5: q PCR primers for GAPDH, TLR2 and TLR4 splice variants.  
TOLL-LIKE 
RECEPTOR 
MRNA 
PRIMER PRODUCT 
SIZE 
START STOP 
TLR2 variant a 
(AF424051.1) F  
GAGTTCTCCCAGTTTCTCT
TTTAAC 
110 98 122 
TLR2 variant a 
(AF424051.1) R  
CCCACAGGTACCTTCACT
TGG 
110 207 187 
TLR2 variant b  
(AF424049) F  
CCCTTTTGCTTACTTCCTA
GTCCCG 
107 1 25 
TLR2 variant b  
AF424049) R 
GGGAGAACTCCGAGCAGT
CACCT 
107 107 85 
TLR2 variant c 
(AF424053.1) F 
CCCTTTTGCTTACTTCCTA
GTCCC 
206 1 24 
TLR2 variant c 
(AF424053.1) R  
GTGCTTCAACCTTCACTTG
GTCAC 
206 206 183 
TLR2 variant d 
(AF424052.1) F 
CCCTTTTGCTTACTTCCTA
GTCCC 
119 1 24 
TLR2 variant d  
(AF424052.1) R 
CCTTTGGATCCTGGGAGA
ACTCC 
119 119 97 
TLR2 variant e  
(AF424050) F 
CCCTTTTGCTTACTTCCTA
GTCCCG 
114 1 25 
TLR2 variant e  
AF424050) R  
TCAACCTGGGAGAACTCC
GAGCAG 
114 114 91 
TLR4 variant 1 
(NM_138554.3) F 
GCCCTGCGTGGAGGTGGT
TC 
292 372 391 
TLR4 variant 1 
(NM_138554.3) R 
TCCAGAAAAGGCTCCCAG
GGCT 
292 663 642 
TLR4 variant 3 
(NR_024168.1) F 
CCTGCGTGGAGACTTGGC
CC 
203 374 393 
TLR4 variant 3 
(NR_024168.1) R  
TGAGAAGGGGAGGTTGTC
GGGG 
203 576 555 
TLR4 variant 4 
(NR_024169.1) F 
AGCCCTGCGTGGAGGTGT
GA 
126 371 390 
TLR4 variant 4  
(NR_024169.1) R  
TCCAGAAAAGGCTCCCAG
GGCT 
126 496 475 
GAPDH  
(NM_002046.3) F 
TGACGCTGGGGCTGGCAT
TG 
143 987 1006 
GAPDH  
(NM_002046.3) R 
GGCTGGTGGTCCAGGGGT
CT 
143 1129 1110 
F: forward; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; R: reverse; TLR: toll-
like receptor 
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Figure 2.5: Melting temperatures of five positive controls and one negative control, 
showing single product amplification from the positive control samples and no product 
amplified from the negative control sample.  
 
 
Figure 2.6: Serial dilutions of five positive control samples and one negative control 
sample. 
 
 
Figure 2.7: Standard curve created from five positive control samples and one negative 
control sample. 
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2.2.2.3 SLOT-BLOT FOR TLR2 AND TLR4 PROTEIN DETECTION 
2.2.2.3.1 ANTIBODIES 
Two different primary antibodies were used for TLR4: TLR4 (H-80), a rabbit polyclonal 
antibody raised against amino acids 242-321 of TLR4 of human origin (Santa Cruz 
Biotechnology, USA) and polyclonal goat anti-human TLR4 which was produced in goats 
immunized with purified, recombinant human TLR4 (rh TLR4) extracellular domain (R&D 
Systems, UK). Simultaneously, two different antibodies were used for TLR2: TLR2 (H-
175), a rabbit polyclonal antibody raised against amino acids 180-354 mapping near the N-
terminus of TLR2 of human origin (Santa Cruz Biotechnology, USA) and TLR2.1, a mouse 
monoclonal antibody raised against TLR2 cells of human origin which can be used in 
Western-blot, flow cytometry and immunofluorescence. The TLR2.1 antibody was 
generated using either full-length fusion proteins or transfected cell lines; therefore, the 
exact amino acid sequences of the epitopes it recognizes are not mapped or reported 
(eBioscience, USA). ß-Actin antibody (Sigma-Aldrich, USA), a rabbit antibody raised to ß-
Actin of human origin, was used as a control antibody. 
 
The optimization stage proved that the following antibodies are more specific in detecting 
the tested proteins: 
1. Monoclonal mouse anti-human TLR2.1 antibody (eBioscience, USA) 
2. Polyclonal goat anti-human TLR4 antibody (R&D Systems, UK) 
3. Rabbit anti-human ß-Actin antibody (Sigma-Aldrich, USA) 
Three different species-specific secondary antibodies were used: donkey anti-goat IgG-
horseradish peroxidase (HRP) (Santa Cruz Biotechnology, USA), anti-rabbit-HRP (Pierce, 
USA), and anti-mouse-HRP (Pierce, USA). 
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2.2.2.3.2 POSITIVE CONTROLS 
Three types of positive control cells were used: Hel 92.1.7 cell lysate for TLR4 (Insight 
Biotechnology Limited, UK), Caco-2 cell lysate for TLR2 (Insight Biotechnology Limited, 
UK), and peripheral blood mononuclear cells (PBMC) used as a control for the two 
receptors.  
 
2.2.2.3.3 SLOT-BLOT ANALYSIS 
Protein samples were quantified using the NanoDrop spectrophotometer as mentioned 
above (Labtech, UK). 12.5% (w/v) purified protein samples were prepared in a sodium 
dodecyl sulphate (SDS) buffer composed of 0.32 M Tris-HCl pH 6.8, 3.5% SDS, 8.7% 
glycerol, 1.8% 2-mercaptoethanol and 0.1% bromophenol blue. The Bio-Dot SF (Bio-Rad, 
USA) apparatus was assembled according to the manufacturer’s instructions and a 
nitrocellulose membrane was placed in the apparatus after pre-wetting it in Tris-buffered 
saline (TBS; 20 mM Tris, pH 7.5 and 500 mM NaCl). The membrane was rehydrated with 
100 μl of TBS per well to ensure uniform binding of the antigen. The wells were filled with 
200 μl of the 12.5% (w/v) purified protein in SDS buffer (25 μg/200 μl). The samples were 
allowed to filter through the membrane under vacuum. The wells were then washed with 
200 μl of TBS using a gentle vacuum. The membrane was removed from the apparatus and 
blocked by incubating it in a blocking buffer containing dried milk powder (5% wt/v), 0.32 
M Tris-HCl pH 8.0 (1% v/v), 5 M NaCl (3% v/v) and Tween 20 (0.05% v/v) for at least 1 
hour at room temperature with agitation. 
 
TLR2 and TLR4 were detected by incubating the membrane with the primary antibody 
(TLR2 at 1:500 and TLR4 at 1:1000: eBioscience, USA and R&D systems, USA 
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respectively) overnight at 4 °C. The membrane was washed with TBS-Tween (TBST) 
buffer containing 0.32 M TRIS-HCL pH 8.0 (1% v/v), 5 M sodium chloride (3% v/v), and 
Tween 20 (0.05% v/v) for 60 minutes. A bound antibody was detected using an HRP 
conjugated species-specific antibody at 1:1000 for 1 hour at room temperature with 
agitation.  
 
The membrane was developed by using chemiluminescent detection reagents such as the 
enhanced chemiluminescent plus (ECL plus, BioRad, UK) reaction, which is based on the 
enzymatic generation of an acridinium ester. This technique produces more light emission 
of longer duration than the ECL reaction, which was based on the oxidation of the cyclic 
Diacylhydrazide. The signal generated by the ECL reaction was then quantified by using 
densitometry analysis and expressed as a relative expression in relation to the negative 
control. 
 
2.2.2.4 WESTERN-BLOT FOR TLR2 AND TLR4 PROTEIN 
2.2.2.4.1 ANTIBODIES 
The same primary and secondary antibodies used in the slot-blot analysis were also used in 
the Western-blot analysis. 
 
2.2.2.4.2 POSITIVE CONTROLS 
The same positive controls used in the slot-blot analysis were also used in the Western-blot 
analysis. 
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2.2.2.4.3 WESTERN-BLOT ANALYSIS 
All proteins samples were quantified by using the NanoDrop spectrophotometer (Labtech, 
UK). The samples were prepared for loading in the sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) by adding buffer composed of 0.32 moles 
(M) Tris-HCl pH 6.8 (28% v/v), SDS (3.5% w/v), glycerol (8.7% v/v), 2-mercaptoethanol 
(1.8% v/v) and bromophenol blue (0.1% v/v). 1 µg/µl protein samples were prepared (25 
µg protein in a 25 µl reducing buffer) in order to load equal volumes of protein to each 
well. All protein samples were allowed to denature at 100 °C for 5 minutes. Proteins were 
separated by SDS-PAGE in a 4–20% linear gradient ready-casted gel (Invitrogen, UK) by 
using electrophoresis at 150 volts (constant voltage) for 1–2 hours. Separated protein 
samples were transferred to a polyvinylidenedifluoride (PVDF) membrane (Immobilon 
membrane, Sigma-Aldrich, USA) at 30 volts (constant voltage) for 1 hour at 4 °C in the 
cold room or on ice (Corbett and Dunn, 1993, Dunn and Bradd, 1993). The membrane was 
blocked by incubating it in a blocking buffer containing dried milk powder (5% wt/v), 0.32 
M Tris-HCl pH 8.0 (1% v/v), 5 M NaCl (3% v/v) and Tween 20 (0.05% v/v) for at least 1 
hour at room temperature with agitation. 
 
Detection of TLR2 and TLR4 was achieved by incubating the membrane with the primary 
antibody overnight at 4 °C. The TLR2 and TLR4 antibody was prepared by adding it to the 
blocking buffer in the desired concentration (TLR2 at 1:500 v/v, and TLR4 at 1:1000 v/v). 
The membrane was then washed by using a wash buffer containing 0.32 M Tris-HCl pH 
8.0 (1% v/v), 5 M NaCl (3% v/v), and Tween 20 (0.05% v/v) for 60 minutes. After 
washing, the membrane was incubated with the species-specific secondary antibody 
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engaged to a HRP at a concentration of 1:1000 v/v for 1 hour at room temperature with 
agitation. The membrane was developed by using ECL plus (ECL plus-BioRad, UK).  
 
2.2.2.4.4 OPTIMIZATION 
The Western-blot optimization took a substantial amount of time and effort. The 
optimization experiment was as follows: Hel 92.1.7 cell lysate was used as positive control 
for TLR4 (Insight Biotechnology Limited, UK), Caco-2 cell lysate was used as positive 
control for TLR2 (Insight Biotechnology Limited, UK), and PBMC were used as positive 
control for both proteins. The first lane was used for the molecular weight ladder 
(Kaleidoscope marker, Bio-Rad, USA), then Hel 92.1.7 cell lysate in 20, 50, 100 and 150 
µg/25 µl were added, each in a different lane, followed by PBMC in 20, 25 and 50 µg/25 
µl, followed by another molecular weight ladder, then Caco-2 cell lysate in 20, 50, 100 and 
150 µg/25 µl were added, each in a different lane, followed by PBMC lysate in 20, 25 and 
50 µg/25 µl, then finally a last molecular weight ladder (Tables 2.6 and 2.7).  
 
Table 2.6: Optimization experiment for TLR4 using positive control samples. 
LANE LYSATE PRIMARY 
ANTIBODY 
SECONDARY 
ANTIBODY  
1 Molecular weight marker Polyclonal goat anti-
human TLR4 
antibody (1:1000) 
 
Donkey anti-
goat antibody-
HRP (1:1000) 
2 Hel 92.1.7 – 20 µg 
3 Hel 92.1.7 – 50 µg 
4 Hel 92.1.7 – 100 µg 
5 Hel 92.1.7 – 150 µg 
6 Monocytes-20 µg 
7 Monocytes-25 µg 
8 Monocytes-50 µg 
9 Molecular weight marker 
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Table 2.7: Optimization experiment for TLR2 using positive control samples. 
LANE LYSATE PRIMARY 
ANTIBODY 
SECONDARY 
ANTIBODY 
9 Molecular weight marker Monoclonal mouse 
anti-human TLR2.1 
antibody (1:500) 
  
 
Anti-mouse 
antibody-HRP 
(1:1000) 
10 Caco-20 µg 
11 Caco-50 µg 
12 Caco-100 µg 
13 Caco-150 µg 
14 Monocytes-20 µg 
15 Monocytes-25 µg 
16 Monocytes-50 µg 
17 Molecular weight marker 
 
The membrane was cut into two and the first half was incubated with TLR4 antibody, while 
the second half was incubated with TLR2 antibody. Multiple bands were observed for 
TLR2 and TLR4 in each experiment, which was repeated twice with the first set of 
antibodies then a third time with the second set of antibodies from a different company 
(Figure 2.8). 
 
Figure 2.8: Western-blot analysis of TLR2 and TLR4 protein showing multiple bands, 
which may represent multiple splice variants.  
 
90 kDa 
70 kDa 
50 kDa 
35 kDa 
25 kDa 
TLR4  TLR2  
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2.2.2.5 TLR FUNCTIONAL STUDY  
PBMC were isolated by density gradient centrifugation over F-H (1700 rpm for 35 
minutes). The isolated cells were incubated at 37 °C overnight. Each sample was plated in 
twelve different wells of a 96 well plate in a density of 2x10
5
/well. The incubated cells 
were treated by different agonists such as 0.1 µg of Pam3CSK4, 10
8 
HKLM, 0.2 µg E.coli 
K12 LPS and 1 µg FSL-1 (InvivoGen, USA) to examine the function of TLR1/2 
heterodimer, TLR2, TLR4, and TLR2/6 heterodimer respectively. Two wells of each 
sample were treated with phytohaemagglutinin (PHA) as a positive control. Another two 
wells were performed as a negative control and were not treated by any agonist. The cells 
plus agonists were incubated at 37 °C overnight. The level of tumour necrosis factor alpha 
(TNF-α) in the culture supernatant was quantified by using enzyme-linked immunosorbent 
assay (ELISA) following the manufacturer’s instructions (R&D Systems, UK). The 
stimulation index was calculated for each treatment by dividing the level of TNF-α 
produced after treatment by the spontaneous TNF-α secretion.  
 
2.2.3 THE ORAL MICROBIOME  
2.2.3.1 MALD-TOF ANALYSIS 
The oral and salivary microbiome was analysed by matrix-assisted laser 
desorption/ionisation-time of flight (MALDI–TOF) analysis after culturing the samples on 
different bacteriological culture media in different environments to recover the maximum 
number of cultivable bacteria. 
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2.2.3.1.1 CULTURE TECHNIQUES 
Amies transport medium swabs (Copan, UK), collected from ulcerated and non-ulcerated 
oral mucosa, and re-suspended salivary sediments samples were diluted in sterile saline at 
10
2
 and 10
4
 and cultured on 7 different culture media: blood agar, chocolate agar, colistin 
nalidixic acid agar, MacConkey agar, gonococcus agar, Sabouraud agar and fastidious 
anaerobic agar (Figures 2.9–2.11).  
 
Blood agar, chocolate agar, and gonococcus agar plates were incubated at 37 °C for 48 
hours in a CO2 enriched environment. Colistin nalidixic acid agar, MacConkey agar, and 
Sabouraud agar plates were incubated at 37 °C for 48 hours in an O2 enriched environment. 
The fastidious anaerobic agar plates were incubated at 37 °C for 7 days in an anaerobic 
environment.  
 
 
Figure 2.9: Two different Candida species grow on Candida chromogenic agar. 
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Figure 2.10: Mixed oral flora grows on chocolate agar plate. 
 
 
Figure 2.11: Mixed oral flora grows on blood agar plate. 
 
2.2.3.1.2 BACTERIAL QUANTIFICATION 
Bacteria which have grown on blood agar plates were quantified in colony-forming units by 
using the standard plate count. The 10
2
 dilution was obtained by transferring 100 µl of the 
initial sample into 9.9 ml of sterile saline. The 10
2 
dilution was then manually vortexed to 
distribute the bacteria evenly by grasping the tube between the palms of both hands and 
rotating quickly. The 10
4
 was created by the transfer of 100 µl of the 10
2 
dilution sample 
into 9.9 ml of sterile saline and mixing the sample as mentioned above. 100 µl of each 
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dilution was aseptically transferred to the surface of the blood agar plate and distributed 
evenly using a sterile bacteriological spreader.  
 
The blood agar plates were incubated at 37 °C for 48 hours in a CO2 enriched environment. 
At the end of the incubation period, all plates containing 30 to 300 colonies were selected 
and the colonies were counted. Plates with fewer than 30 colonies or more than 300 
colonies were considered unquantifiable. 
 
Further dilutions were prepared in cases when the 10
4
 dilution grew more bacterial colonies 
than the maximum quantifiable colony number. The original sample was used in cases 
when the 10
2
 dilution grew fewer bacterial colonies than the minimum quantifiable colony 
number.  
 
2.2.3.1.3 BACTERIAL PURIFICATION 
Isolated colonies were re-cultured in the same culture environments to homogeneously 
purify them before peptide isolation.  
 
2.2.3.1.4 BACTERIA PEPTIDE PURIFICATION  
Peptides were purified by the acetonitrile precipitation method according to the 
manufacturer’s instructions (Bruker Daltonics, Germany). Five colonies from each purified 
bacteria were placed into an eppendorf tube and mixed with 300 µl of sterile deionised 
water by briefly vortexing the tube. 900 µl of absolute ethanol were added to each tube and 
mixed gently by inverting the tube several times.  
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A tight pellet was created by centrifuging at maximum speed for 2 minutes. The 
supernatant was removed and all the residual ethanol was allowed to evaporate by leaving 
the eppendorf tube open for 10–15 minutes. The pellet was thoroughly re-suspended in 25 
µl of formic acid. 25 µl of acetonitrile was then added to each sample and mixed carefully 
by inverting the tube several times. The tubes were centrifuged at maximum speed for 2 
minutes. The supernatant containing the purified bacterial peptides was transferred to a 
sterile tube and saved at -80 °C until further analysis. 
 
2.2.3.1.5 MALDI-TOF MATRIX PREPARATION 
250 µl of the basic organic solvent (2.5% (v/v) tri-fluoro-acetic-acid (TFA), 50% (v/v) 
acetonitrile and deionised water) was added to 10 mg/ml alpha cyanohydroxycinnamic acid 
(Bruker Daltonics, Germany) and vortexed thoroughly until the crystals were completely 
dissolved. 
 
2.2.3.1.6 MALDI-TOF TARGET PLATE PREPARATION 
The polished steel 96 target plate was thoroughly cleaned by overlaying its surface with 
70% aqueous ethanol for 5 minutes at room temperature (Figure 2.12). The target plate was 
then rinsed with tap water and wiped with a paper towel moistened with 70% aqueous 
ethanol. Subsequently, sterile deionised water was used to wipe the plate, followed by 
overlaying it with 100 µl of 80% TFA and quickly wiping it scrupulously. Lastly, the target 
plate was rinsed with sterile deionised water, wiped with a paper towel and left to air dry 
for 15 minutes.  
 
 
121 
 
2.2.3.1.7 MALDI-TOF ANALYSIS 
A MALDI–TOF analysis using the MALDI Biotyper was conducted on a 96 target plate by 
applying 1 μl of each peptide sample to a different target, followed by 1 μl of the 
crystallised molecules in the MALDI matrix (Bruker Daltonics, Germany) to protect the 
peptides and help in the ionisation process by the laser beam (Figure 2.12).  
 
 
Figure 2.12: Target plate of the MALDI-TOF machine (Bruker Daltonics, Germany) 
[source: Medical Microbiology Unit at Barts and the London NHS Trust]. 
 
 
MALDI–TOF applies nitrogen-pulsed laser ionisation to the peptide samples to ionise and 
separate them based on their mass/charge ratio (Figure 2.13). The resulting spectra 
formulate the protein finger print (2,000–20,000 Dalton range) which is then compared to a 
database of known spectra to identify and type the different bacteria being analysed. A 
match factor for each sample was automatically calculated by the MALDI Biotyper based 
on the number and amplitude of the peaks that match.  
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Figure 2.13: MALDI-TOF (Bruker Daltonics, Germany) [source: Medical Microbiology 
Unit at Barts and The London NHS Trust]. 
 
2.2.3.1.8 MALDI-TOF DATA INTERPRETATION 
A score of 1.7 or above was considered a reliable identification of the investigated 
microorganism (Tables 2.8 and 2.9). Scores below 1.7 were a driver for repeating the 
peptide isolation or checking the purity of the isolated organism. In cases when no peaks 
were found, 1:10 and 1:100 dilutions were prepared from the peptide sample to exclude the 
possibility that the sample was much too concentrated to be read by the MALDI–TOF 
analysis. Due to the reported inability of MALDI-TOF in identifying S. mitis from S. 
pneumoniae, optochin susceptibility and bile solubility tests were used to check the 
identification accuracy of any microorganism reported as S. pneumoniae by MALDI-TOF 
(Kok et al., 2011). 
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Table 2.8: MALDI-TOF data interpretation. 
Analyte 
Name 
Analyte 
ID 
Organism  
(best match) 
Score 
Value 
Organism  
(second best match) 
Score 
Value 
A1 ( ++ )    Neisseria flavescens 2.097  Neisseria flavescens 1.99  
A2 ( + )    
Lactobacillus 
rhamnosus 
1.89  
Lactobacillus 
rhamnosus 
1.857  
A3 ( + )    Kingella denitrificans 1.857  Kingella denitrificans 1.732  
 
 
Table 2.9. The MALDI-TOF typing data for one microorganism investigated. 
Rank (Quality) Matched Pattern Score Value NCBI Identifier 
1 ( ++ ) Neisseria flavescens DSM 17633T DSM 2.097 484  
2 ( + ) Neisseria flavescens C1 2 PGM 1.99 484  
3 ( + ) Neisseria perflava DSM 18009T DSM 1.956 33053  
4 ( + ) Neisseria subflava DSM 17610T DSM 1.878 28449  
 
 
2.2.3.2 MYCOBACTERIAL ANALYSIS 
Brush biopsies (Flowgen Bioscience, UK) from ulcerated and non-ulcerated oral mucosa 
and unstimulated saliva samples were investigated in the mycobacterial analysis. 
 
2.2.3.2.1 SAMPLE DECONTAMINATION 
Saliva samples were decontaminated using the NaOH-NALC [2% sodium hydroxide 
(NaOH), 1.45% trisodium citrate and 0.5% N-acetyl-L-cysteine (NALC)] decontamination 
method as follows: 6 ml of the prepared NaOH-NALC were added to each salivary sample 
in a 50 ml Falcon tube and mixed by briefly vortexing and inverting the tube several times. 
The sample was allowed to be incubated with the NaOH-NALC for 30 minutes with 
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periodic gentle vortexing. Subsequently, each sample was diluted (1:40 dilution) with 
phosphate buffer (pH 6.8) followed by centrifugation at 3000 xg for 30 minutes. The 
supernatant was discarded and 1.5 ml of sterile phosphate buffer was added to re-suspend 
the pellet.  
 
 Brush biopsy samples were treated with the 4% sulphuric acid decontamination method as 
follows: 2 ml of the acid was mixed with the brush biopsy sample by vortexing and then 
incubated for 30 minutes with periodic gentle mixing. Subsequently, each sample was 
diluted (1:40 dilution) with phosphate buffer and processed as mentioned above for the 
salivary samples.  
 
2.2.3.2.2 CULTURING TECHNIQUES 
0.25 ml of each decontaminated sample was cultured on Lowenstein-Jensen (LJ) slopes 
(Figure 2.18) and 0.5 ml was inoculated into mycobacterial growth indicator tubes (MGIT) 
which contained 4 ml of Middlebrook 7H9 broth base with a fluorescent indicator (Figures 
2.14 and 2.15) (Becton Dickinson Diagnostic Instrument Systems, USA). MGIT bottles 
were incubated on the MGIT instrument which reads each tube hourly and triggers an alarm 
when growth is detected (Figure 2.16) (Becton Dickinson Diagnostic Instrument Systems, 
USA). All samples were allowed to be incubated for 6 weeks. 
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Figure 2.14: LJ culture media [source: The National Mycobacterium Reference 
Laboratory]. 
 
 
 
Figure 2.15: MGIT bottles (Becton Dickinson Diagnostic Instrument Systems, USA) 
[source: The National Mycobacterium Reference Laboratory]. 
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Figure 2.16: MGIT instrument (Becton Dickinson Diagnostic Instrument Systems, USA) 
[source: http://www.bd.com/ds]. 
 
2.2.3.2.3 MYCOBACTERIAL IDENTIFICATION  
The isolated mycobacterium was identified by the PCR and DNA-DNA hybridization 
technique using the GenoType Mycobacterium Common Mycobacterial (CM) kit, 
following the manufacturer’s instructions (Hain Lifescience, Germany). 
 
The above-mentioned kit allows the identification of the following Mycobacterial species: 
M. avium, M. chelonae, M. abscessus, M. fortuitum, M. gordonae, M. intercellulare, M. 
scrofulaceum, M. interjectum, M. kansasii, M. malmoense, M. peregrinum, M. marinum, M. 
ulcerans, M. tuberculosis complex and M. xenopi. 
 
The identification procedure was divided into three stages: DNA isolation, multiplex 
amplification with biotinylated primes, and reverse hybridization.  
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2.2.3.2.3.1 DNA ISOLATION 
DNA was isolated from bacteria grown on LJ slopes or MGIT tubes. Bacterial colonies that 
had grown on LJ slopes were diluted directly with 300 µl of sterile deionised water. In the 
case of Mycobacteria grown on MGIT tubes, pellets were created by centrifuging 1 ml of 
the medium for 15 minutes at 10000 xg prior to the dilution step. Diluted samples were 
incubated for 20 minutes at 95 °C then for 15 minutes in an ultrasonic bath. Subsequently, 
the samples were centrifuged for 5 minutes at full speed and 5 µl of the supernatant were 
used in the PCR reaction.  
 
2.2.3.2.3.2 DNA AMPLIFICATION 
To amplify the isolated DNA, 45 µl of master mix were prepared for each DNA sample, as 
shown in table 2.10, then 5 µl of DNA sample were added. The amplification was 
performed in the thermal cycler using the thermal cycler conditions shown in table 2.11. 
  
Table 2.10: Master mix for mycobacterial DNA amplification. 
COMPONENT VOLUME REACTION PER 
SAMPLE 
PNM 35 µl 
10 x polymerase incubation buffer 5 µl 
MgCl2 1 µl (1.5 mM final concentration) 
Thermostable DNA polymerase 1 µl 
Nuclease-free H2O 3 µl 
 MgCl2: magnesium chloride; PNM: primer-nucleotide mix  
 
Table 2.11: Thermal cycler conditions for mycobacterial DNA amplification. 
 STEP 1 
1 CYCLE 
STEP 2 
10 CYCLES 
STEP 3 
20 CYCLES 
STEP 4 
1 CYCLE 
Temperature  95 °C 95 °C 58 °C 95 °C 53 °C 70 °C 70 °C 
Time 5 min 30 sec 2 min 25 sec 40 sec 40 sec 8 min 
ºC: degree Celsius; min: minutes; sec: seconds 
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2.2.3.2.3.3 HYBRIDIZATION 
The hybridization stage included the following steps: chemical denaturation of the 
amplified product, hybridization of the single-stranded, biotin-labelled amplicons to 
membrane-bound probes, stringent washing, streptavidin conjugated alkaline phosphatise 
(AP) conjugation and AP mediated staining reaction. 
 
2.2.3.2.3.3.1 CHEMICAL DENATURATION STEP 
The chemical denaturation was created by mixing 20 µl of the amplified sample with 20 µl 
of the denaturation solution then incubating the mixture at room temperature for 5 minutes. 
1 ml of warm hybridization buffer (45 °C) was added to each denatured sample and shaken 
gently until a homogeneous colour was created.  
 
2.2.3.2.3.3.2 HYBRIDIZATION OF THE SINGLE-STRANDED, BIOTIN-
LABELLED AMPLICONS TO MEMBRANE-BOUND PROBES STEP 
A GenoType Mycobacterium CM DNA strip was added to each sample and allowed to be 
completely covered with the solution. The strips were incubated for 30 minutes at 45 °C in 
a shaking water bath.  
 
2.2.3.2.3.3.3 STRINGENT WASHING STEP 
At the end of the incubation period, all the hybridization solution was aspirated and 1 ml of 
the stringent wash solution (STR) was incubated with the DNA strip for 15 minutes at      
45 °C. The DNA strip was then removed and rinsed with 1 ml of rinse solution for 1 minute 
at room temperature. 
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2.2.3.2.3.3.4 AP CONJUGATION STEP 
1 ml of the diluted conjugate containing AP was added to each DNA strip and incubated for 
30 minutes at room temperature on a shaking platform. The DNA strip was then washed 
twice for 1 minute each time with 1 ml of deionised water on a shaking platform at room 
temperature.  
 
2.2.3.2.3.3.5 AP MEDIATED STAINING STEP 
1 ml of the diluted substrate containing dimethyl sulfoxide was added to each DNA strip 
and incubated at room temperature in the dark for 20 minutes. The reaction was then 
stopped by rinsing the DNA strip twice with deionised water.  
 
Each DNA strip contains 16 DNA probes, conjugate control (CC) and marker (Mr) (Figure 
2.17). The first strip is the CC followed by the universal control (UC), which indicates the 
presence of bacteria, then the genus control (GC) that indicates the presence of 
mycobacteria in the tested sample. The other 14 bands are specific DNA probes used to 
identify the isolated mycobacterium. The hybridized strips were interpreted according to 
the manufacturer’s instructions, as illustrated in Figure 2.18.  
 
CC UC GC               Mr 
Figure 2.17: DNA strip with 16 DNA probes, CC and Mr. 
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Figure 2.18. GenoType Mycobacterium CM kit (source: Hain Lifescience, Germany). 
 
 
2.2.3.3 qPCR OF THE HERPES VIRUSES 
2.2.3.3.1 HSV1, HSV2 AND VZV qPCR 
Multiplex real time amplification of herpes simplex virus (HSV) 1, HSV2 and varicella 
zoster virus (VZV) DNA using glycoprotein B-specific primers was performed. The 143 
bp, 140 bp and 97 bp products were detected in qPCR by the use of TaqMan probes that are 
labelled at the 5´ end with FAM fluorophore (FAM), JOE fluorophore (JOE) and 
cyclohexyl fluorophore (Cy.) respectively and at the 3´ end with the quencher BHQ 
fluorophore  (BHQ) 3 (Table 2.12). The condition of the qPCR was as follows: 2.5 μl of 1x 
PCR buffer contained 1.5 mmol/L MgCl2 (Qiagen, UK), 5 μl of MgCl2 (25 mmol/L), 7.5 μl 
of dNTPs (6.25 mmol/L of each nucleotides), 1 μl of the forward and reverse primers (15 
pmol/μl), 1 μl of TaqMan probe (5 pmol/L) and 0.25 μl of HotStarTaq polymerase (0.25 
IU/μl) made up to a final volume of 20 μl with sterile water (Applied Biosystems, UK). 5 μl 
of extracted DNA were added to each reaction. The PCR cycling condition was 2 minutes 
at 50 °C, 10 minutes at 95 °C and 60 cycles of 15 seconds at 95 °C and 15 seconds at 60 
°C. All samples were analysed in duplicate and the average viral load was calculated by 
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using the sequence detection system software available on the ABI 7700 platform (Applied 
Biosystems, UK).  
 
2.2.3.3.2 CMV qPCR 
Real time amplification of cytomegalovirus (CMV) DNA using glycoprotein B-specific 
primers was performed. The 150 bp product was detected in qPCR by the use of a TaqMan 
probe which is labelled at the 5´ end with 6-carboxyfluorescein-FAM and at the 3´ end with 
the quencher tetramethylrhodamine (TAMRA) (Table 2.12). The conditions of the PCR 
were as follows: 2.5 µl of MgCl2 (25 mmol/L), 7.5 µl of dNTPs (96.25 mmol/L each 
nucleotide), 1 µL of each primer and 0.25 µL of HotStarTaq polymerase (0.25 IU/µl) 
(Applied Biosystems, UK) made up to a final volume of 20 µl with sterile water. 5 µl of 
sample DNA, positive control or negative control were added to each reaction. Each qPCR 
run included positive control, negative control and dilution series of cloned CMV DNA in 
triplicate of 1-10
4
 genomes. PCR cycling conditions were 2 minutes at 50 °C, 10 minutes at 
95 °C, and 60 cycles of 15 seconds at 95 °C and 15 seconds at 60 °C (Mattes et al., 2005). 
 
2.2.3.3.3 EBV qPCR 
Real time amplification of Epstein-Barr virus (EBV) DNA using glycoprotein B-specific 
primers was performed. The 96 bp product was detected in qPCR by the use of a TaqMan 
probe which is labelled at the 5´ end with JOE and at the 3´ end with BHQ1 (Table 2.12). 
The conditions of the PCR were as described above in the CMV qPCR experiment.  
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2.2.3.3.4 HHV8 qPCR  
Primers and probes for the detection of human herpes virus (HHV) 8 nucleic acid were 
chosen according to the previously published data (Stamey et al., 2001) (Table 2.12). They 
were synthesized by the standard phosphoramide chemistry techniques. Probes were 
labelled at the 5' end with the reporter molecule 6-carboxyfluorescein-FAM and at the 3' 
end with the quencher 6-carboxyletramethylehodamine. TaqMan probes were synthesized 
with a 3' phosphate group to block extension by Taq polymerase (Applied Biosystems, 
UK). The qPCR conditions were as described above in the CMV qPCR experiment. 
 
2.2.3.3.5 PHV qPCR 
Real time amplification of PHV DNA using glycoprotein B-specific primers was performed 
as an internal control. The 101 bp product was detected in qPCR by the use of a TaqMan 
probe which is labelled at the 5´ end with 6-carboxyfluorescein-FAM and at the 3´ end with 
the quencher BHQ1 (Table 2.12). The condition of the PCR and the PCR cycling condition 
were as described above in the CMV qPCR experiment.  
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Table 2.12: qPCR primers for HSV1, HSV2, CMV, EBV, HHV8 and PHV. 
TARGET PRIMERS AND PROBES  PRODUCT 
SIZE/BP 
HSV1 F TATTGGTGCGATGGCGACAC 143 
R CTTTCCGCATGTGGGCTCTC  
P FAM-CCCCGCCCCATACCCTACCCGC-BHQ1  
HSV2 F AGCATCCCGATCACTGTGTACTA 140 
R GCGATGGTCAGGTTGTACGT  
P JOE-CAGTGCTGGAACGTGCCTGCCGC-BHQ1  
VZV F GCCCGTCTATTCCATTCAGCAA 97 
R CCCGCAAACTTGTAGAACTGTTG  
P Cy-CACACGACGCCTCCGCCGCAG-BHQ3  
CMV F GAGGACAACGAAATCCTGTTGGGCA 150 
R TCGACGGTGGAGATACTGCTGAGG  
P FAM-CAATCATGCGTTTGAAGAGGTAGTCCACG-
BHQ1 
 
EBV F GGCCAGAGGTAAGTGGACTTTAAT 96 
R GGGGACCCTGAGACGGG  
P JOE-CCCAACACTCCACCACACCCAGGC-BHQ1  
HHV8 F TCGGTGGCGATGCTTTAGAC 97 
R TGAAGCAGACGATGCTTTGC  
P TCGTAACCCCCGTCTACTTTCCCCG  
PHV F CGTTCCAACAACACAACCTACTG 101 
R CTCTCATATCATCATTCAACTCAGTGT  
P JOE-ACCACCAATTACTCCTAGTCCACCACCG-
BHQ1 
 
BP: base pair; CMV: cytomegalovirus; EBV: Epstein-Barr virus; F: forward; HHV8: 
human herpes virus 8; HSV: herpes simplex virus; P: probe; PHV: phocine herpes virus; R: 
reverse; VZV: varicella zoster virus. 
 
 
 
2.2.3.4 IMMUNOASSAYS FOR THE DETECTION OF IgG TO HERPES VIRUSES 
2.2.3.4.1 HSV1 ELISA 
A 100 μl of the 1/101 diluted serum samples were added to the readymade recombinant-
gG1-antigen coated wells (Biokit, Spain). The antibodies in the samples were allowed to 
combine with the antigens attached to the well during a one hour incubation period at       
37 °C. The wells were then washed to remove all residual test specimens and then enzyme-
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labelled antibodies to human IgG (conjugate) were added. The wells were incubated for 30 
minutes at 37 °C to allow the conjugate to bind immunologically to the anti-HSV1 IgG 
antibodies that had combined with the antigen in the well during the first incubation period. 
After another wash to eliminate the unbound material, an enzyme substrate solution 
containing a chromogen was added. If the sample contained anti-HSV1 IgG, the solution 
developed a blue colour and the intensity of the colour was proportional to the number of 
antibodies in the specimens.  
 
The samples were tested in duplicate and seven control samples were tested simultaneously 
to validate the assay and extract quantifiable data. The mean absorbance of the low positive 
control was calculated and considered to be the cut-off value, followed by dividing the 
sample absorbance by the cut-off value to give a ratio absorbance/cut-off, which is 
proportional to the concentration of the HSV1 IgG antibodies in each tested specimen.  
 
2.2.3.4.2 HSV2 ELISA  
HSV2 IgG was detected and quantified using a similar method to the HSV1 IgG ELISA. 
However, the wells of the HSV2 IgG ELISA kit were coated with recombinant-gG2-
antigen instead of recombinant-gG1-antigen (Biokit, Spain). 
 
2.2.3.4.3 VZV ELISA  
VZV IgG was detected and quantified using a similar method to the HSV1 IgG ELISA. 
However, the wells of the VZV IgG ELISA kit were coated with VZV antigen from 
partially purified extract of human fibroblast infected with VZV, strain ELLEN (ATCC) 
(Diamedix, USA). To determine the ELISA unit (EU)/ml, the following formula was used 
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following the manufacturer’s instructions (absorbance of calibrator x absorbance of sample 
= EU/ml of sample). 
 
2.2.3.4.4 CMV ELFA 
CMV IgG was quantified by an automated quantitative two-step enzyme immunoassay 
sandwich method with a final fluorescent detection, enzyme-linked fluorescent assay 
(ELFA) (bioMérieux, France).  
 
All the assay steps were performed automatically by the vitek immuno-diagnostic assay 
system (VIDAS) instrument, according to the manufacturer’s instructions (Figure 2.19). 
The solid phase receptacle (SPR) coated internally by the CMV antigen (strain AD169) 
acted also as a pipetting device for the assay. Fluorescence was measured twice for each 
sample tested; the first reading was a background reading of the serum and the second one 
was taken after the incubation period with the antigen. The instrument, using calibration 
curves that are stored by the machine, automatically calculated the results and expressed 
them in AU/ml. The samples were tested in duplicate, along with calibrator and control 
samples to validate the assay. 
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Figure 2.19: VIDAS instrument (bioMérieux, France) [source: Virology Unit at Barts and 
The London NHS Trust]. 
 
2.2.3.4.5 EBV CHEMILUMINESCENT IMMUNOASSAY  
EBV viral capside antigens (VCA) IgG was quantified in the investigated serum samples 
by the LIAISON analyzer, following the manufacturer’s instructions. The samples were 
tested in duplicate, along with calibrator and control samples, to validate the assay 
(DiaSorin, Italy). 
 
The fully automated LIAISON immunoassay was used with its magnetic microparticle 
technology, chemiluminescence with flashlight kinetics, and an isoluminol derivative as 
labels. The p18 synthetic peptide is the major component used for coating magnetic 
particles (solid phase) and a mouse monocolonal antibody is linked to an isoluminol 
derivative (isoluminol-antibody conjugate). The cycle has two incubation periods: VCA 
antibodies in the sample were allowed to bind to the solid phase during the first incubation 
period, while the antibody conjugate reacted with VCA IgG already bound to the solid 
phase during the second incubation period. The unbound material was removed in a wash 
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cycle after each incubation period. Subsequently, the starter reagents were added and a 
flash chemiluminescence reaction was induced. The light signal was measured by a 
photomultiplier as relative light units (RLU) indicating VCA IgG concentration in tested 
samples. 
 
30 µL of each sample were used for this analysis. All reagents required for the assay 
(magnetic particles, luminescence-labelled tracer, two calibrators, diluent and assay buffer) 
were provided ready to use and assembled in one integrated reagent cartridge identifiable 
by a bar-coded label providing information such as lot number, expiry date and 
recalibration data (Figure 2.20). The analyzer automatically calculated the antibody 
concentrations and expressed it as U/ml.  
 
 
Figure 2.20: LIAISON analyzer (DiaSorin, Italy) [source: Virology Unit at Barts and The 
London NHS Trust]. 
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2.2.3.4.6 HHV8 INDIRECT FLUORESCENT ASSAY  
An indirect fluorescent antibody staining method was employed to semi-quantify the 
HHV8 IgG antibodies in the serum samples (Advanced Biotechnologies, Columbia). The 
1:40 diluted serum samples were incubated with HHV8 infected cells on a slide, allowing 
the antibody in the serum sample, if present, to bind with the antigen present in the infected 
cells, forming immunological complex. Incubation was done in a moist chamber for 30 
minutes at 37 °C. After the wash step (5–10 minutes in a wash buffer), the anti-human IgG 
conjugated to the dye fluorescein isothiocyanate (FITC) was added to each well on the slide 
and allowed to bind to the antibody-antigen complexes for 30 minutes at 37 °C.  
 
The slides were then washed (5–10 minutes in wash buffer), mounted and blindly evaluated 
under a fluorescent microscope by two different investigators. Each slide contained ten 
tests; the positive and negative controls and wash buffer were tested simultaneously with 
the seven patients’ samples to validate the assay. The positive control was given a semi-
quantitative score equal to 4 and the negative control was given a score of 0 (Figures 2.21 
and 2.22). Each patient’s samples were scored relative to the positive and negative controls. 
The results were checked for consistency and re-evaluated if there were any discrepant 
results between the two investigators. 
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Figure 2.21: HHV8 indirect fluorescent assay (positive control sample). 
 
 
 
Figure 2.22: HHV8 indirect fluorescent assay (negative control sample). 
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2.2.4 STATISTICAL ANALYSIS 
The statistical power calculation was investigated using StateMate 2 software to determine 
the minimum number of samples required in each part of the study. This practice ensured 
avoiding type I statistical error (rejecting the potentially true null hypothesis), and type II 
statistical error (failure to reject the potentially false null hypothesis) (GraphPad, USA).  
 
Mean, median, range, minimum, maximum, standard deviation (SD), standard error of 
mean (Sem), and percentage (%) were used in the descriptive statistics. The obtained data 
were analysed by Mann-Whitney-U when comparing quantitative data of two groups, 
Kruskal-Wallis when comparing quantitative data of more than two groups, and non-
parametric multivariate analysis of variance (MANOVA) with Bonferroni post tests when 
comparing multiple variants in relation to different groups. Differences in the rate were 
analysed using Chi-square tests and the correlation was analysed by using Spearman test. 
The GraphPad Prism® statistical package was used (GraphPad, USA).  
 
 
 
 
 
 
 
 
 
 
 
141 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
BEHÇET’S SYNDROME PATIENT COHORT IN THE UK 
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3.1 ABSTRACT 
3.1.1 BACKGROUND 
Classically, Behçet’s syndrome (BS) was considered more prevalent in the Far East and the 
Mediterranean region along what historically was known as the “Silk Road” (between the 
30th and 45th degree latitudes in Asian and European countries). BS’s highest prevalence is 
still along the “Silk Road”, especially in Turkey (380/100,000). However, recently, a higher 
than expected prevalence was reported in France (7.1/100,000), proving that this syndrome 
is not as rare outside the “Silk Road” boundaries as was previously thought.  
 
3.1.2 OBJECTIVES 
To analyse the clinical picture and treatment protocol of BS in a cohort of patients from two 
of the largest tertiary referral centres in the UK for BS patient management and care. The 
clinical picture of the UK BS patients was then compared to the published large series from 
other countries.  
 
3.1.3 METHODS 
Patients thought to have BS were referred to one of the two centres participating in this 
study (St Thomas’ Hospital and Royal London Hospital). Patients were then examined and 
classified according to the International Study Group (ISG) criteria by a multi-disciplinary 
team including consultants from Oral Medicine, Ophthalmology, Rheumatology, and 
Immunology. Information about the frequency of the different symptoms of the disease 
along with the treatment protocol was collected on a data sheet and stored electronically in 
a database in the period between January 2006 and August 2012. The information was then 
analysed at the end of the study period.  
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3.1.4 RESULTS  
The male/female (M/F) ratio was 0.5:1.0. All BS patients had a history of recurrent oral 
ulceration, 85.6% had dermatological lesions, 79.1% had rheumatological manifestation, 
73.9% had genital ulcerations, 68.6% had ocular involvement, 15% had neurological 
manifestations, and 10.5% had vascular involvement. The most frequent treatment was 
colchicine (54.2%) followed by topical corticosteroid therapy (53.6%) then azathioprine 
(43.8%). 
 
3.1.5 CONCLUSION 
BS in the UK is more prevalent in females. The most frequent symptoms are 
mucocutaneous, rheumatological, and ocular manifestations. In this study, the rate of ocular 
and rheumatological manifestations is higher than expected, which might highlight a 
referral bias due to the nature of the study centres (Oral Medicine, Rheumatology, 
Ophthalmology, and Immunology multi-disciplinary clinic). 
 
3.1.6 DECLARATION 
The ethical approval application was performed by Professor Fortune. The evaluation and 
diagnosis of patients were undertaken in a consultant-led examination.  
 
The author has performed the data analysis in this chapter, and contributed to the data 
collection and management. The research and clinical team of the Centre for Clinical and 
Diagnostic Oral Sciences also contributed to data collection and management.   
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3.2 INTRODUCTION  
A syndrome can be defined as a collection of signs and symptoms that frequently emerge 
together despite the lack of a known cause. Behçet's syndrome (BS) is a collection of 
mucocutaneous, ocular, rheumatological, vascular, and neural symptoms with mysterious 
cause; therefore, we prefer to describe this condition as a syndrome rather than a disease. 
The underlying pathological mechanism of BS is vasculitis that affects all types and sizes 
of vessels (Talarico et al., 2012). 
  
Currently, there are five nationwide surveys of BS (Iran: 5,059 patients; Japan: 3,316 
patients; China: 1,996 patients; Korea: 1,527 patients; Germany: 590 patients) (Davatchi et 
al., 2010b). In Europe, the highest prevalence of BS was reported recently in France 
(7.1/100,000 adults) highlighting increasing prevalence outside the “Silk Route” boundaries 
(Mahr et al., 2008). The male/female (M/F) ratio is almost equal in the five nationwide 
surveys; however, the classically reported trend was pointing towards an increase 
predelection for men than women in countries along the “Silk Route” (Davatchi et al., 
2010b, El Menyawi et al., 2008). On the other hand, a reverse pattern was reported in 
countries outside the ancient “Silk Route” boundaries (Chamberlain, 1977, Jankowski et 
al., 1992). Mucous membrane manifestations are the most prevalent manifestations of the 
syndrome, followed by dermatological, ocular, rheumatological, neurological, 
gastrointestinal, vascular, pulmonary, and cardiac manifestations (Davatchi et al., 2010b, 
Davatchi et al., 2010c, El Menyawi et al., 2008, Salvarani et al., 2007, Zouboulis et al., 
1997).  
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To date there is no curative treatment for BS. However, good control over the disease flare 
up can be established by using immunosuppressive medications aiming at preventing 
damage caused by recurrent episodes of inflammation during the flare up attacks. In 2008 
the European League Against Rheumatism (EULAR) developed nine different 
recommendations for BS management and care based on the best available evidence and 
expert opinion (Hatemi et al., 2008a). The EULAR recommendations are discussed in 
chapter 1, section 1.2.7. 
 
New and promising treatment modalities including biological agents such as interferon 
alpha 2 a (INF-α2a) and tumour necrosis factor alpha (TNF-α) inhibitors were suggested in 
the literature (Pipitone et al., 2006). INF-α2a has immunomodulatory properties leading to 
a decrease in the circulating gama delta (γδ) T cells, enhanced human leukocyte antigen 
(HLA) 1 expression on peripheral blood mononuclear cells (PBMC), and inhibited T cell 
adhesion to endothelial cells (Treusch et al., 2004). The TNF-α inhibitors are either 
monocolonal antibodies such as infliximab and adalimumab, or fusion protein receptors 
such as etanercept. Infliximab and etanercept have been reported to have an effective 
therapeutic outcome in the treatment of BS (Melikoglu et al., 2005, Ohno et al., 2004).  
 
Oral tolerization with the 336-351 sequence of heat shock protein (HSP) 60 linked to 
recombinant cholera B-toxin was studied in a phase I/II clinical trial with promising results 
in a small cohort of BS patients. Following the oral tolerization, 3 out of 5 patients 
remained free of relapsing uveitis for 10–18 months subsequent to stopping all treatment 
(Stanford et al., 2004). However, this study needs to be supplemented by a phase III trial 
before adopting this technique in the clinical treatment of patients suffering from BS.  
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This part of the thesis is a hospital-based study analysing the clinical picture of BS patients 
in the UK cohort, aiming at a better understanding of this syndrome in a country outside the 
“Silk Road” boundaries. The clinical picture and treatment protocol of BS patients who 
were enrolled in two tertiary referral centres in the UK were analysed in the period between 
January 2006 and August 2012, and compared to the published data from other countries.  
 
3.3 METHODOLOGY 
3.3.1 ETHICAL APPROVAL 
Ethical approval was granted by the East London and The City Research Ethics Committee 
(Reference P/03/122) to study BS aetiology as a part of the immunoregulation at the 
mucosal barrier programme. Subsequently, ethical approval has been granted for St 
Thomas’ Hospital independently. 
 
3.3.2 CLINICAL CENTRES  
 The BS patients were recruited from two main centres in London, St Thomas’ Hospital and 
Royal London Hospital. These centres subsequently became a Centre of Excellence for the 
management and care of BS patients. Both centres are multi-disciplinary in nature, 
embracing the following specialities: Oral Medicine, Ophthalmology, Rheumatology, and 
Immunology. The centres work in close association with the International Society of 
Behçet’s Disease (ISBD).  
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3.3.3 PATIENT DIAGNOSIS 
For the purpose of research standardization, all BS patients enrolled in this study were 
diagnosed according to the International Study Group (ISG) classification and diagnostic 
criteria for BS (Lancet, 1990). The BS patients’ inclusion criteria, exclusion criteria, and 
stratification are detailed in chapter 2, section 2.1.2.2. All patients aged 18 years old and 
over were invited to take part in the study. A written invitation was handed to them and the 
study was explained fully to each patient who wished to participate. A consent form was 
filled in and signed (Appendix 1). Disease signs and activity were recorded in each clinical 
appointment, along with the overall disease activity and the current treatment protocol, on 
the clinician’s observation form for disease activity (Appendix 2). 
 
3.3.4 CLINICAL DATABASE 
A clinical database was developed in order to record demographic data, date of clinical 
assessment, disease symptoms, and disease activity in relation to each clinical sign. The 
overall disease status was recorded to differentiate between inactive and relapsed cases. 
Furthermore, the treatment plan along with any changes in the current treatment protocol 
was recorded for each clinical visit.  
 
3.3.5 STATISTICAL ANALYSIS 
Data were analysed using Prism software (GraphPad, USA). Mean and percentages were 
used as descriptive statistics.  
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3.4 RESULTS  
3.4.1 MALE/FEMALE RATIO  
A total of 153 BS patients, diagnosed according to the ISG criteria for BS classification and 
diagnosis, were registered on the clinical database in the period between January 2006 and 
August 2012 (Lancet, 1990). About 32% of those patients were male and 68% were female 
with male/female (M/F) ratio of 0.5:1 (Figure 3.1).  
 
 
Figure 3.1: Gender of the UK’s BS patients (M/F: 49/104). 
 
3.4.2 ETHNIC BACKGROUND 
About two-thirds of the BS patients identified themselves as European. They reported no 
known ancestors from the “Silk Route” area (93/1153: 60.8%). Only 7.8% classified 
themselves as Turkish (11/120: 9.1%). The percentage of African, Asian, mixed Asian and 
European, and other ethnic origins were as follows: 3.3%, 3.3%, 1.3% and 1.3% 
respectively. About a quarter of the BS patients did not disclose their ethnic background 
68% 
32% 
Gender of BS patients in the UK  
Female 
Male 
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(Tables 3.1 and Figure 3.2). The mean age at analysis was 42.85 years of age (mean age: 
42.84 ± 11.65; range: 18–77 years old).  
 
Table 3.1: The ethnic background of the BS patient cohort in the UK. 
ETHNIC ORIGIN NUMBER OF CASES PERCENTAGE 
African 5 3.3% 
Asian 5 3.3% 
European 93 60.8% 
Asian/European 2 1.3% 
Turkish 12 7.8% 
Others 2 1.3% 
Not specified  34 22.2% 
 
 
 
Figure 3.2: The ethnic origin of BS patients in the UK.  
 
3.4.3 DISEASE SYMPTOMS  
BS patients were diagnosed according to the ISG criteria for BS patient classification and 
diagnosis. Therefore, a total of 100% of the BS patients had a history of recurrent oral 
ulceration of a major, minor or herpetiform nature, while 85.6% had dermatological lesions 
3% 3% 
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such as folliculitis (85.6%) or erythema nodosum-like lesions (82.4%), 79.1% had 
rheumatological manifestations, 73.9% had genital ulceration, and 68.6% had ocular 
involvement. Only 15% of the BS patient cohort had neurological manifestations, and 
10.5% had vascular involvement (Table 3.2).  
 
Table 3.2: Clinical manifestations of the UK’s cohort of BS patients (n=153). 
ORGAN INVOLVEMENT n % 
Oral ulcer 153/153 100% 
Genital ulcer 113/153  73.9% 
Folliculitis 131/153 85.6% 
Erythema nodosum-like lesion 126/153 82.4% 
Cutaneous involvement 131/153 85.6% 
Ocular involvement 105/153 68.6% 
Rheumatologic involvement 121/153 79.1% 
Vascular involvement 16/153 10.5% 
Neurologic involvement 23/153 15% 
n: number; UK: United Kingdom; %: percentage 
 
3.4.4 TREATMENT PROTOCOL 
Treatment protocol was variable based on the subset of BS signs and symptoms according 
to the EULAR recommendation for the management of BS patients (Hatemi et al., 2008a). 
Patients were prescribed multiple medications in 73.9% of the cases (113/153) while only 
15.7% of the cases were treated by single medication (24/153) and a further 10.5% did not 
need to be actively treated at the time of their presentation to the BS patients’ specialist 
clinic (16/153). A total of 3.3% of the UK’s BS patient cohort were treated with topical 
corticosteroid as the sole treatment (5/153) while 53.6% were treated with topical 
corticosteroid as part of their multiple therapies (82/153). Colchicine was the most frequent 
treatment, used in 54.2% of the BS patient cohort (83/153), followed by topical 
corticosteroid therapy (82/153: 53.6%) then azathioprine (67/153: 43.8%) (Table 3.3). 
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Systemic corticosteroid was mostly used as emergency treatment during relapsed episodes 
only (58/153: 37.9%), while mycophenolate, ciclosporin, anti-TNF, and methotrexate were 
used in a small number of patients as follows: 15.7%, 5.9%, 2%, and 1.3% respectively 
(Table 3.3). 
 
Table 3.3: The different treatment modalities used to manage the UK’s cohort of BS 
patients (n=153). 
TREATMENT PROTOCOL n % 
Systemic corticosteroid 58/153 37.9% 
Colchicine 83/153 54.2% 
Azathioprine 67/153 43.8% 
Mycophenolate 24/153 15.7% 
Ciclosporin 9/153 5.9% 
Anti-TNF 3/153 2% 
Methotrixate 2/153 1.3% 
Topical corticosteroid treatment 82/153 53.6% 
Triple therapy mouthwash (topical antifungal, antibacterial, 
and corticosteroid treatment)  
23/153 15% 
Topical treatment only 5/153 3.3% 
No treatments 16/153 10.5% 
n: number; TNF: Tumor Necrosis Factor; UK: United Kingdom; %: percentage 
 
3.5 DISCUSSION AND CONCLUSION  
A cohort of 153 BS patients was successfully recruited. All patients in the cohort were 
diagnosed according to the ISG criteria to ensure research standardization by strictly 
including well-defined cases only (ISG, 1992, Lancet, 1990). The disease was classically 
described as having a greater predilection for men than women in the ancient “Silk Road” 
countries, whereas the trend is reversed in Western Europe and the USA (Evereklioglu, 
2005, Zouboulis et al., 1997). Our study confirms this pattern as the M/F ratio was 0.5:1.0 
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in the UK BS patient cohort. BS patients in Korea, Israel, Spain, and Sweden have a similar 
M/F ratio to that of the UK cohort (Table 3.4).  
 
Table 3.4: M/F ratio of the UK BS patient cohort compared to the published data from 
other countries [source: (Davatchi et al., 2010b)].  
COUNTRY  M/F RATIO REFERENCE 
Brazil  1.00:1.19 (Sachetto et al., 2011) 
China 1.34:1.00 (Wang et al., 2010) 
Germany  1.40:1.00 (Zouboulis et al., 1997) 
Greece 1.40:1.00 (Vaiopoulos et al., 2010) 
India 1.80:2:00 Reviewed in (Davatchi et al., 2010b) 
Iran  1.19:1.00 (Davatchi et al., 2010c) 
Iraq 3.00:1.00 (Al-Rawi and Neda, 2003) 
Israel 0.64:1.00 (Krause et al., 2007) 
Italy 1.00:1.00 (Salvarani et al., 2007) 
Japan  0.98:1.00 (Kaneko et al., 2003) 
Korea 0.63:1.00 (Yi et al., 2009) 
Morocco 2.00:1.00 Reviewed in (Davatchi et al., 2010b) 
Portugal 1.00:1.00 (de Souza-Ramalho et al., 1991) 
Russia 3.67:1.00 Reviewed in (Davatchi et al., 2010b) 
Saudi Arabia 3.40:1.00 Reviewed in (Davatchi et al., 2010b) 
Spain 0.50:1.00 (Gonzalez-Gay et al., 2000) 
Sweden 0.67:1.00 (Ek and Hedfors, 1993) 
Turkey 1.03:1.00 (Tuzun et al., 1996) 
UK 0.50:1.00 Seoudi PhD thesis  
M/F: male/female; UK: United Kingdom 
 
The most frequent symptoms in the UK BS patient cohort were mucocutaneous, 
rheumatological, and ocular manifestations. The high UK rate of oral ulceration (100%) 
was expected as all BS patients were diagnosed according to the ISG criteria for BS 
diagnosis and classification. The UK rate of genital ulceration (73.9%) was greater than 
that reported in Iran (65%) and Germany (64%), similar to that of the Japan (73%) but less 
than that of China (76%) and Korea (83%).  
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The UK rate of cutaneous involvements (85.6%) was similar to that of Korea (84%), 
slightly less than that reported in Japan (87%), but greater than that reported in Iran (66%), 
China (69%), and Germany (81%) (Table 3.5). Interestingly, the UK rate of ocular 
involvements (68.6%) was similar to that reported in Japan (69%) but greater than that 
reported in Iran (55%), China (35%), Korea (51%), and Germany (53%). Likewise, the UK 
rheumatological manifestations (79.1%) were remarkably higher than those reported in Iran 
(33%), Japan (57%), China (30%), Korea (38%), and Germany (53%).  
 
This study is a hospital-based not population-based study, and as such invites a referral bias 
due to the specialized multi-disciplinary nature of the study centres (Oral Medicine, 
Rheumatology, Ophthalmology, and Immunology clinic). It is logical and indeed expected 
that it is the very complicated cases that are referred to these centres rather than the simple 
ones (Table 3.5). 
 
Table 3.5: The clinical picture of BS patients in the UK cohort compared to the published 
data from other countries [source: (Davatchi et al., 2010b)].  
 CHINA  GERMANY IRAN  JAPAN KOREA UK  
n   1,996 590 5,059 3,316 1,527 153 
Oral ulcer 98% 98% 97% 98% 99% 100% 
Genital ulcer 76% 64% 65% 73% 83% 73.90% 
Folliculitis 31% 62% 57% N/R N/R 85.60% 
Erythema nodosum-like 
lesion 
38% 42% 22% N/R N/R 82.40% 
Cutaneous involvement 69% 81% 66% 87% 84% 85.60% 
Ocular involvement 35% 53% 55% 69% 51% 68.60% 
Rheumatologic 
involvement 
30% 53% 33% 57% 38% 79.10% 
Vascular involvement 7.70% 13% 8.90% 8.90% 1.80% 10.50% 
Neurologic involvement 6.50% 11% 9% 11% 4.60% 15% 
n: number; N/R: not reported; UK: United Kingdom; %: percentage 
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In agreement with the EULAR recommendation, the systemic corticosteroid was mostly 
used as emergency treatment during relapsed episodes only (37.9%). The frequent use of 
colchicine (54.2%) reflected the high rate of rheumatological (79.1%) and dermatological 
manifestations (85.6%) observed in this cohort of BS patients. The use of azathioprine was 
also elevated (43.8%), reflecting the high rate of ocular manifestations (68.6%) recorded in 
BS patients in the UK cohort.  
 
In this BS patient cohort only two patients from the 153 cases had lost their useful eyesight 
as a complication of their disease. This might reflect the success of the treatment protocol 
used. However, it might also reflect the nature of the cohort (68% female and 60.8% 
Caucasian ethnic origin). It was documented previously that male BS patients have a worse 
visual prognosis compared to female patients. In addition, patients with poor vision were 
reported more frequently in countries such as Japan, India, and Iran compared to the UK, 
Tunisia, Germany, Greece, Turkey, and Italy (Kitaichi et al., 2007).  
 
In conclusion, this part of the thesis analysed the different signs and symptoms of BS 
patients in a well-defined cohort. In the UK cohort of BS patients, we observed female 
predilection. The most frequent symptoms were mucocutaneous, rheumatological, and 
ocular manifestations. However, the high rate of ocular and rheumatological involvements 
might highlight a referral bias due to the nature of the study centres. 
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CHAPTER 4 
ORAL HEALTH STATUS AND QUALITY OF LIFE OF BEHÇET’S SYNDROME 
PATIENTS 
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4.1 ABSTRACT 
4.1.1 BACKGROUND 
Identifying patients’ perception of the disease burden helps to direct the clinical and 
research resources in the right direction. Behçet’s syndrome (BS) patients usually suffer 
from recurrent oral ulcerations as the initial sign of the disease; therefore, studying the 
impact of their oral health status on their quality of life (QoL) is crucial.  
 
4.1.2 OBJECTIVES 
This part of the thesis is aimed at identifying the impact of the oral health of Behçet’s 
syndrome (BS) patients from two different countries (UK and Turkey) on their QoL. 
 
4.1.3 METHODS 
The QoL of BS patients in the UK was compared to that of BS patients in Turkey. A total 
of 31 BS patients from the UK (M/F: 13/18, mean age: 41.8±11.5) and 31 BS patients from 
Turkey (M/F: 13/18, mean age: 41.5±10.3) were recruited and studied. Both patient cohorts 
were diagnosed according to the International Study Group (ISG) criteria for BS 
classification and diagnosis and closely matched in age and gender (The Lancet, 1990). The 
oral health status of the UK cohort of BS patients was compared to that of the Turkish 
cohort. Furthermore, the oral health status of 55 BS patients in the UK (M/F: 23/32, mean 
age: 42.6±12.3) was compared to that of 15 healthy control (HC) volunteers (M/F: 9/6, 
mean age: 39.7±13.8) and 6 recurrent aphthous stomatitis (RAS) patients (M/F: 3/3, mean 
age: 46.5±7).  
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4.1.4 RESULTS 
The QoL of BS patients from the UK and Turkey was affected to a similar extent. 
Interestingly, the number of oral ulcers per month was higher in the UK patients; however, 
this might reflect a referral bias as UK patients were seen at two of the main tertiary referral 
centres in the UK for BS management and care. Turkish patients had generally poorer oral 
health status, which can be explained by the lower utilization rate of the dental services. 
The oral health status of BS patients form the UK was poorer than HC volunteers but 
similar to those patients suffering from RAS.  
 
4.1.5 CONCLUSION  
BS negatively affects the QoL and the oral health status. In a syndrome with unknown 
aetiology such as BS that starts with recurrent oral ulceration, studying the oral cavity will 
be a vital stage in identifying the aetiology of the disease and therefore increasing the 
potential for discovering more efficient treatment modalities.  
 
4.1.6 DECLARATION 
The ethical approval application was performed by Professor Fortune. The evaluation and 
diagnosis of patients were undertaken in a consultant-led examination.  
 
The author performed the dental assessment and data analysis of the UK patient and 
volunteer cohorts. She also contributed to data collection, and management of the UK 
patient and volunteer cohorts. The research and clinical team of the Centre for Clinical and 
Diagnostic Oral Sciences contributed to data collection and management of the UK BS 
patients.  
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The dental assessment, data collection, and data analysis of the Turkish BS patient cohort 
was conducted by Dr Mumcu’s team, following the same protocol used in the UK centres. 
Dr Mumcu’s team also contributed to the comparative analysis between the Turkish and the 
UK BS patient cohorts.  
4.2 INTRODUCTION 
Establishing patients’ perception of their disease burden and its effect on their quality of 
life (QoL) is crucial in informing clinical decision-making and improving management 
strategies. It also identifies areas of need, aiming to redirect the clinical and research 
resources in patient-focused directions (McGrath et al., 2003, Mumcu et al., 2006, Mumcu 
et al., 2007a). The health-related QoL can be identified by using either a generic 
questionnaire or a disease-specific questionnaire (Bernabe et al., 2010, Gilworth et al., 
2004, Touma et al., 2011). The impact of a particular symptom on the QoL can also be 
examined using a symptom related QoL questionnaire (Mumcu et al., 2006, Mumcu et al., 
2007a, Onal et al., 2010).  
 
Behçet’s syndrome (BS) is one of the chronic diseases characterized by vasculitis affecting 
different vessels in almost all body organs, causing multi-systemic symptoms such as 
mucocutaneous, gastrointestinal, musculoskeletal, neurological, ophthalmic, and vascular 
involvements (Bernabe et al., 2010, Escudier et al., 2006, Kitaichi et al., 2007). Previous 
studies examined the QoL of BS patients by using generic and disease-specific instruments 
and highlighted the considerable negative impact of the syndrome (Bernabe et al., 2010, 
Gilworth et al., 2004).  
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Active oral ulcerations are amongst the most important and very early symptoms in BS 
(Davatchi et al., 2010c, Mumcu et al., 2006). Therefore, the oral health-related QoL of BS 
patients was also examined by two different instruments, namely the oral health impact 
profile 14 (OHIP-14), and the United Kingdom oral health-related quality of life (OHQoL-
UK) (McGrath et al., 2003, Mumcu et al., 2006, Mumcu et al., 2007a) (Tables 4.1 and 4.2). 
However, this part of the thesis is the first study to examine the oral health-related QoL of 
BS patients from the UK and compare it to patients from Turkey. 
 
Poor oral health was previously observed in BS patients with a possible cause or effect 
relationship (Karacayli et al., 2009). Nevertheless, this part of the thesis is the first study to 
compare the oral health of BS patients to healthy control (HC) volunteers and recurrent 
aphthous stomatitis (RAS) patients.  
 
Table 4.1: Questions in the OHIP-14. 
BECAUSE OF PROBLEMS WITH YOUR TEETH, DENTURE OR MOUTH HAVE 
YOU 
had trouble pronouncing words? 
felt your sense of taste has worsened? 
had painful aching in the mouth? 
found it uncomfortable to eat any foods? 
been self-conscious? 
felt tense? 
had an unsatisfactory diet? 
had to interrupt meals? 
found it difficult to relax? 
been a bit embarrassed? 
been irritable with other people? 
had difficulty doing your usual jobs? 
felt life in general was less satisfying? 
been totally unable to function? 
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Table 4.2: Questions in the OHQoL-UK. 
WHAT EFFECT, IF ANY, DO YOUR TEETH, GUMS, MOUTH OR DENTURE 
HAVE ON YOUR 
comfort? 
breath odour? 
eating? 
appearance? 
general health? 
speech? 
smiling/laughing? 
ability to relax/sleep? 
confidence? 
mood? 
carefree manner? 
personality? 
social life? 
romantic relationships? 
work/usual activities? 
finances? 
 
 
4.3 METHODOLOGY 
4.3.1 PATIENT COHORTS  
There are three groups in this part of the thesis, namely the BS patient cohorts (UK and 
Turkey), the RAS patients and the HC volunteers. Patients and volunteers were recruited 
and classified according to the protocol detailed in chapter 2, section 2.1.2.  
 
4.3.2 DATA ACQUISITION 
Data was recorded in two different data collection forms: QoL questionnaire and oral health 
status questionnaire. 
 
4.3.2.1 QUALITY OF LIFE QUESTIONNAIRE 
The OHIP-14 is one of the internationally validated and widely used oral health-related 
quality of life (OHRQol) indicators. It reflects the patient’s own views about their health 
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and oral status by using a 14-item questionnaire to measure self-reported functional 
limitation, discomfort and disability related to the investigated oral condition.  
 
A 5-point Likert-type scale is used to score 14 different items, such as the effect of the 
disease on the physical function of the mouth and in particular on speaking, taste sensation, 
food intake, and movement. The OHIP-14 also investigates the effect of the disease on the 
psychosocial symptoms and psychological wellbeing of the patients. Its scores range from 0 
to 56, with score 0 indicating no impact of the disease on oral health while score 56 
indicates severe impact on all aspects of oral health (Appendix 3).  
 
4.3.2.2 ORAL HEALTH STATUS QUESTIONNAIRE  
Oral assessment was carried out by a trained dentist and evaluated by dental and 
periodontal indices including the decayed, missing, filled teeth (DMFT) index, plaque 
index (PI), gingival index (GI), sulcus bleeding index (SBI), periodontal probing depth 
(PPD) and attachment level (AL) (Appendix 4). 
 
4.3.3 STATISTICAL ANALYSIS  
A statistical power calculation using the StatMate 2 program (GraphPad, USA) and based 
on the previous published literature investigating the QoL by using OHIP-14 indicated that 
a sample size of 30 in each group has a 95% power to detect a difference between means of 
13.46 with a significant level (alpha) of 0.05 (two tailed) (Mumcu et al., 2007a). For the 
purpose of the oral health assessment, a statistical power calculation based on the previous 
published literature investigating BS patients’ oral status by using similar dental indices 
indicated that a sample size of 6 in each group has a 95% power to detect a difference 
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between means of 4.14 with a significant level (alpha) of 0.05 (two tailed) (Karacayli et al., 
2009). The author aimed to investigate the maximum sample size achievable during the 
time of the PhD course and using the available resources. 
 
Data were analysed using Prism software (GraphPad, USA). Mean, standard deviation (SD) 
and standard error of mean (Sem) were used in the descriptive statistics. Non-parametric 
tests such as the Mann-Whitney-U test, Kruskal-Wallis test, and Spearman correlation test 
were used in this study due to the non-normal distributed data. P value of less than 0.05 was 
considered significant. 
 
4.4 RESULTS  
4.4.1 QUALITY OF LIFE  
No significant difference was found in OHIP-14 scores between patients from the UK 
(22.7±14.4) and Turkey (20.4±14.3) (Mann-Whitney, p=0.709). In addition, OHIP-14 
subscale scores looking at physical, psychosocial, and psychological symptoms were 
similar in patients from the UK (8.7±5.2, 8.3±5.5 and 5.7±4.3 respectively) and Turkey 
(7.01±5.7, 6.6±5.5 and 7.1±4.9 respectively) (Mann-Whitney, p=0.219, p=0.311 and 
p=0.248 respectively) (Tables 4.3 and 4.4). 
 
Table 4.3: OHIP-14 scores: a comparison between the BS patient cohort from the UK and 
the cohort from Turkey.  
 UK PATIENTS (n=31) TURKISH PATIENTS (n=31) 
  Mean SD Mean  SD 
OHIP-14 Score 22.7 14.4 20.2 14.3 
n: number; OHIP-14: oral health impact profile-14; SD: standard deviation; UK: United 
Kingdom.  
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Table 4.4: Oral ulcer-related subscales in OHIP-14: a comparison between the BS patient 
cohort from the UK and the cohort from Turkey. 
 UK PATIENTS 
(n=31) 
TURKISH PATIENTS 
(n=31) 
 Mean  SD Mean  SD 
Subscale 1 (Physical symptoms) 8.7 5.2 7.01 5.7 
Subscale 2 (Psychosocial symptoms) 8.3 5.5 6.6 5.5 
Subscale 3 (Psychological 
symptoms) 
5.7 4.3 7.1 4.9 
n: number; OHIP-14: oral health impact profile-14; SD: standard deviation; UK: United 
Kingdom. 
 
The overall disease severity score was similar in both groups (Turkey: 4.91.6 versus UK: 
5.11.8) (Mann-Whitney, p=0.983). The healing times of oral ulcers and oral ulcer-related 
pain were also similar in patients from the UK (8.6±5.2 days and 50.5±36.2 respectively) 
and Turkey (7.2±2.1 days and 42.7±40.7 respectively) (Mann-Whitney, p>0.05). However, 
the number of oral ulcers per month was significantly higher in the UK patients (3.3±2.8) 
compared to the Turkish patients (1.5±2.5) (Mann-Whitney, p=0.014) (Table 4.5). The 
OHIP-14 score correlated with the healing time of oral ulcers in the UK patients (r=0.4, 
p=0.04) and the number of oral ulcers in patients from Turkey (r=0.4, p=0.012). 
 
Table 4.5: Disease severity score and oral ulcer-related factors in the BS patient cohort 
from the UK and the corhort from Turkey. 
 UK PATIENTS  
(n=31) 
TURKISH PATIENTS 
(n=31) 
  Mean SD Mean SD 
Number of oral ulcers  3.3 2.8 1.5 2.5 
Healing time of oral ulcers in days  8.6 5.2 7.2 2.1 
Oral ulcer-related pain in 100 mm VAS  50.5 36.2 42.7 40.7 
Disease severity score  5.1 1.8 4.9 1.6 
SD: standard deviation; VAS: visual analogue scale. 
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4.4.2 ORAL HEALTH STATUS  
4.4.2.1 COMPARATIVE STUDY OF THE UK AND TURKISH BS COHORTS  
The number of filled teeth (1.1±1.6) and the frequency of tooth brushing (1.01±0.7) were 
significantly lower in BS Turkish patients when compared to those from the UK (5.6±4.2 
and 1.9±0.6 respectively) (Mann-Whitney, p<0.0001). However, the scores of the SBI and 
PPD were higher in Turkish patients (1.7±1.2 and 2.7±0.6 respectively) than in the patients 
from the UK (1.1±0.7 and 2.1±0.4) (Mann-Whitney, p=0.004 and p<0.0001 respectively) 
(Tables 4.6).  
 
Table 4.6: Oral health and related factors in the UK and Turkish cohorts of BS patients.  
 UK PATIENTS  
(n=31) 
TURKISH PATIENTS 
(n=31) 
Oral health and related factors Mean SD Mean SD 
Carious teeth  0.6 0.9 1.1 1.8 
Extracted teeth  3.4 3.3 4.5 4.4 
Filled teeth  5.6 4.2 1.1 1.6 
Total number of teeth  24.6 5.6 23.4 4.4 
PI  0.9 0.8 1.3 1.2 
GI 1.1 0.8 1.6 1.2 
SBI 1.1 0.7 1.7 1.2 
PPD 2.1 0.4 2.7 0.6 
AL 3.3 1.01 3.9 1.5 
Frequency of tooth brushing  1.9 0.6 1.01 0.7 
Last dental visit (months)  5.1 7.2 28.6 23.7 
AL: attachment level; BS: Behçet’s syndrome; GI: gıngıval index; PPD: periodontal 
probing depth; PI: plaque index; SD: standard deviation; SBI: sulcus bleeding index. 
 
The period of time since the last dental visit was significantly less for the UK’s BS patients 
than for those from Turkey (5.17.2 months versus 28.623.7 months) (Mann-Whitney, 
p<0.0001) (Tables 4.7 and 4.8). No significant correlation was observed between OHIP-14 
and the scores of dental and periodontal health and the time since the last dental visit in 
either of the patient groups. 
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4.4.2.2 ORAL HEALTH STATUS IN THE UK’S BS PATIENTS COMPARED TO 
THE CONTROLS 
The oral health status was studied in a cohort of 55 BS patients (F/M: 32/23, mean age: 
42.6±12.3) and compared to that of 15 HC volunteers (F/M: 6/9, mean age: 39.7±13.8) and 
6 RAS patients (F/M: 3/3, mean age: 46.5±7). The oral health status was assessed using the 
DMFT, PI, GI, SBI, PPD, and AL.  
 
Using non-parametric statistics, Mann-Whitney to compare two groups and Kruskal-Wallis 
to compare three groups, the BS patient cohort showed a statistically higher DMFT score 
compared to the HC volunteers but there was no statistically significant difference between 
BS patients and RAS patients (Mann-Whitney, p=0.0162 and p=0.9585 respectively) 
(Figures 4.1 and Table 4.7). 
 
There was a statistically significant increase in the GI score observed for the BS patient 
cohort compared to the HC volunteers but there was no statistically significant difference 
between BS patients and RAS patients (Mann-Whitney, p=0.0056 and p=0.7870 
respectively). The same pattern was observed in relation to SBI, PPD and AL (SBI: Mann-
Whitney; p=0.0002 and p=0.1488 respectively), (PPD: Mann-Whitney, p=0.039 and 
p=0.3891 respectively), (AL: Mann-Whitney, p=0.015 and p=0.3351 respectively). 
However, there was no statistically significant difference in PI between BS patients, HC 
volunteers and RAS patients (Kruskal-Wallis, p=0.2756). Oral hygiene was good in the 
three groups, with PI ranged between 0 and 2.4 for all three investigated groups (Figure 4.1 
and Table 4.7).  
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Figure 4.1: Oral health status of BS patients compared to RAS patients and HC volunteers. 
Attachment level (AL), decayed, missing, filled teeth (DMFT) index, gingival index (GI), 
plaque index (PI), periodontal probing depth (PPD), and sulcus bleeding index (SBI) were 
investigated in all groups. 
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Table 4.7: Oral health status in the UK cohort of BS patients compared to RAS patients and 
HC volunteers. 
 BS (n=55) HC (n=15) RAS (n=6) 
Indices Mean SD Mean  SD Mean SD 
DMFT 9.18 7.31 4.81 7.56 8.83 4.54 
PI 0.93 0.78 0.52 0.52 0.56 0.84 
GI 1.17 0.59 0.81 0.42 1.18 0.40 
SBI 1.01 0.55 0.27 0.46 0.67 0.52 
PPD 1.99 0.43 1.58 0.36 1.98 0.05 
AL 2.79 0.75 1.79 0.66 2.26 0.30 
AL: attachment level; BS: Behçet’s syndrome; DMFT: decayed; missing, filled teeth; GI: 
gingival index; n: number; PI: plaque index; PPD: periodontal probing depth; RAS: 
recurrent aphthous stomatitis; SBI: sulcus bleeding index; SD: standard deviation. 
 
4.5 DISCUSSION AND CONCLUSION 
The presence of discomfort, pain, poor oral function, and dissatisfaction with oral health are 
the main areas for impaired oral QoL (McGrath et al., 2003). The OHIP-14 was used in this 
part of the thesis as a tool to compare 31 cases of BS in the UK to an equal number of cases 
in Turkey. This questionnaire was previously validated and proven to be a reliable tool in 
oral disease as a patient-centred outcome measure (McGrath et al., 2003, Mumcu et al., 
2006, Mumcu et al., 2007a).  
 
BS negatively affected the QoL of patients from the UK to a similar extent to those from 
Turkey. In a recent study, BS was proven to affect the QoL similarly to other chronic 
conditions such as multiple sclerosis and arthritis. The symptoms of the disease exhibited a 
negative impact on the QoL, with the strongest impact related to joint problems followed 
by neurological symptoms, pathergy reaction, and stomach and bowel problems (Bernabe 
et al., 2010). 
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It is documented in the literature that the dental and periodontal treatment were associated 
with a short-term flare up of oral ulceration; however, it was thought that good oral hygiene 
along with frequent dental maintenance can deliver a long-term benefit by decreasing the 
frequency and number of oral ulcerations or even decreasing the prevalence of the disease 
(Direskeneli and Mumcu, 2010, Karacayli et al., 2009). The role of the oral pathogen 
and/or commensals in the patho-aetiology of BS was questioned and investigated in the 
literature. However, to date there is no proven causative correlation (Fortune, 2003, Lehner, 
1997).  
 
In this part of the thesis, we observed an increase in the number of oral ulcers in BS 
patients from the UK. However, this might reflect a referral bias as the UK patients were 
seen at two of the main tertiary referral centres in the UK for BS patient management and 
care, where the most complicated cases are expected to be referred. The SBI and PPD 
scores in the Turkish BS cohort were higher than those in the BS patient cohort from the 
UK. This fact proved that BS patients in Turkey had generally poorer oral health, which 
can be explained by the lower utilization rate of dental services.  
 
We also observed statistically higher DMFT, GI, SBI, PPD, and AL scores in the UK BS 
patient cohort compared to HC volunteers. However, there were no statistical differences 
between BS and RAS patients in all the measured indices. This can be due to the difficulty 
of maintaining good oral hygiene during the recurrent attacks of oral ulceration or possibly 
a status of increased susceptibility to oral pathogens in both disease groups (BS and RAS). 
Nevertheless, the PI was low in all the examined groups from the UK, highlighting 
favourable oral hygiene awareness and/or the availability of dental care. The fact that the 
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oral health status of BS and RAS patients was poorer than in HC volunteers despite the 
equal PI might implicate a possible impairment in the immune responses to oral pathogens 
and/or commensals in both BS and RAS patients, leading to more susceptibility to dental 
and periodontal disease.  
 
The results of the QoL study are published in The Journal of Oral Pathology and Medicine 
(Mumcu et al., 2009c) (Appendix 5). 
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CHAPTER 5 
ORAL MUCOSAL EXPRESSION OF TOLL-LIKE RECEPTORS 2 AND 4  
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5.1 ABSTRACT 
5.1.1 BACKGROUND 
Toll-like receptors (TLRs) are pattern recognition receptors (PRR) playing a pivotal role in 
sensing exogenous pathogen and endogenous danger signals. Furthermore, their role in the 
pathogenesis of inflammatory and immune-related diseases is gradually being unravelled. 
Behçet's syndrome (BS) is one of the immune-related diseases with enhanced inflammatory 
reaction as the characteristic pathological feature, but its aetiology remains unknown. The 
activation or desregulation of the innate immune response was hypothesized in BS in 
response to a yet unknown environmental factor such as one of the oral pathogens or 
commensals. 
 
5.1.2 OBJECTIVES 
This part of the thesis aimed at investigating the expression and function of TLR2 and 
TLR4 in BS, given that jointly these two receptors are capable of identifying most of the 
oral microbial commensals and pathogens.  
 
5.1.3 METHODS 
A total of 87 subjects were included in this study: 55 BS patients, 24 healthy control (HC) 
volunteers and 8 recurrent aphthous stomatitis (RAS) patients. Non-lesional oral mucosal 
brush biopsies were collected. Total ribonucleic acid (RNA) was purified and analysed by 
real time polymerase chain reaction (qPCR) for the presence of messenger ribonucleic acid 
(mRNA) of TLR2 and TLR4 along with their splice variants. Peripheral blood mononuclear 
cells (PBMC) from BS patients and healthy individuals were treated in vitro with different 
TLR2 and TLR4 agonists to assess the function of these pattern recognition receptors. 
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5.1.4 RESULTS 
TLR2b, TLR2d, TLR2e, TLR4.3, and TLR4.4 are significantly elevated in relapsed BS 
patients. A significant defect in the response to cognate agonists of TLR1/2 heterodimer 
and TLR4 was also observed in the whole cohort of BS patients. 
    
5.1.5 CONCLUSION 
The expression of unusual splice variants of TLR2 and TLR4 might explain the observed 
defect in the function of these receptors in BS patients.  
 
5.1.6 DECLARATION 
The ethical approval application was performed by Professor Fortune. The evaluation and 
diagnosis of patients were undertaken in a consultant-led examination.  
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5.2 INTRODUCTION 
The most serious consequences of Behçet’s syndrome are blindness, catastrophic 
gastrointestinal bleeding or large vessel disease, especially when presenting in untreated 
young adults (Yazici and Esen, 2008). The lack of a universally recognized diagnostic 
laboratory test results in the diagnosis of BS being based solely on clinical criteria. Oral 
bacterial and viral aetiology have been suggested (Hamza et al., 1990, Lehner et al., 1991, 
Sun et al., 1996, Tojo et al., 2003a, Tojo et al., 2003b) and the evidence points towards both 
genetic and environmental factors as contributors to the disease process (Lehner, 1999).  
 
Pattern recognition receptors (PRRs) are responsible for sensing the presence of 
microorganisms through the recognition of some structures conserved among microbial 
species called the pathogen-associated molecular patterns (PAMPs). They also able to 
recognize endogenous molecules released from damaged cells known as damage-associated 
molecular patterns (DAMPs). There are four different classes of PRR that can broadly be 
classified into two main groups as follows: (1) transmembrane proteins such as toll-like 
receptors (TLRs) and C-type lectin receptors (CLRs); (2) cytoplasmic proteins such as the 
retinoic acid-inducible gene (RIG)-l-like receptors (RLRs) and nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs) (Takeuchi and Akira, 2010). 
 
TLRs form one of the transmembrane proteins groups of the PRR. As such, they act as first 
line of defence against microbes and danger signals. Lipopolysaccharides (LPS) produced 
by gram negative bacteria, peptidoglycans of gram positive bacteria, human and microbial 
heat shock proteins (HSPs), and viruses are all potential ligands for TLRs (Ariza et al., 
2009, Compton et al., 2003, Gay and Gangloff, 2007) (Table 5.1).  
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Table 5.1: The localisation and ligand for the different TLRs [source: (Takeuchi and Akira, 
2010)]. 
TLR LOCALISATION LIGAND ORIGIN OF THE 
LIGAND 
TLR1 Plasma membrane Triacyle lipoprotein Bacteria 
TLR2 Plasma membrane Lipoteichoic acid 
Peptidoglycan 
porins 
Phosphalipomannan 
β-glucans 
Zymosan 
DAMPs (HSP) 
Bacteria, viruses, 
parasites, fungus, 
self 
TLR3 Endolyosome dsRNA Virus 
TLR4 Plasma membrane LPS 
Mannan 
O-linked mannosyl residue 
DAMPs (HSP 
Fibrinogen, fibrinectin 
Hyaluronan) 
Bacteria, viruses, 
fungus, self 
TLR5 Plasma membrane Flagellin Bacteria 
TLR6 Plasma membrane Diacyle lipoprotein 
Zymosan 
Bacteria, fungus, 
viruses 
TLR7 (human 
TLR8) 
Endolysosome ssRNA Viruses, bacteria, 
self 
TLR9 Endolysosome CpG-DNA Viruses, bacteria, 
protozoa, self 
TLR10 Endolysosome Unknown Unknown 
TLR11 Plasma membrane Profilin-like molecule Protozoa 
CpG-DNA: cytosine-phosphate-guanine-deoxyribonucleic acid; DAMP: Damage-
associated molecular patterns; ds: double strand; HSP: heat shock protein; LPS: 
lipopolysaccharides; RNA: ribonucleic acid; ss: single strand; TLR: toll-like receptors 
 
Interestingly, TLR2 and TLR4 jointly are capable of identifying most of the oral microbial 
commensals and pathogens. These receptors are mainly expressed on the cells associated 
with innate immunity such as granulocytes, monocytes, macrophages and dendritic cells. 
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However, expression of some TLRs has been demonstrated on epithelial and endothelial 
cells (Takeda et al., 2003). 
 
Activation of TLRs triggers a cascade of protein kinases that result in a well-characterized 
innate host recognition pathway leading to the nuclear translocation of nuclear factor kappa 
B (NF-κB) and transcription of cytokine-encoding genes (Binder et al., 2004, Takeda et al., 
2003). More interestingly, the activation of different TLRs can result in different reactions 
within the cell and different ligands may induce a relatively more aggressive response when 
bound to the same receptor (Coats et al., 2005).  
 
TLR2 messenger ribonucleic acid (mRNA) has five different splice variants, one of which 
lacks exon II, while TLR4 mRNA is known to have three mRNA splice variants, one of 
which might have inhibitory activity (Haehnel et al., 2002, Jaresova et al., 2007). All TLR2 
mRNA splice variants contain the complete sequence of exon III with no changes in the 
putative open reading frame; however, the differences in the 5´ untranslated sequences 
influence the stability of the mRNA, which can affect the extent of TLR2 protein 
translation. TLR2 mRNA variant e is highly expressed in freshly isolated monocytes and 
the splicing rapidly changes upon adherence to the longer splices (Haehnel et al., 2002). 
Furthermore, the presence of an early stop codon in TLR4 mRNA variant 3 and 4 makes 
them subject to a non-sense decay mechanism that should prevent the production of 
truncated non-functional protein (Brogna and Wen, 2009, Jaresova et al., 2007). 
 
Single-nucleotide polymorphism (SNP) analyses of TLR2 and TLR4 genes were not 
significantly associated with BS in the Caucasian, Turkish, and Tunisian cohorts (Bacanli 
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et al., 2006a, Ben Dhifallah et al., 2009, Durrani et al., 2011, Tomiyama et al., 2009). 
However, one SNP in the TLR4 gene was associated with BS and six other SNPs had an 
effect on its clinical features in the Japanese BS cohort (Meguro et al., 2008). Likewise, the 
TLR4 haplotype TAGCGGTAA was considered as a susceptibility gene for HLA-B51 
positive BS patients and for the complication of arthritis in the Korean cohort (Horie et al., 
2009). 
 
An elevated expression of TLR4 (mRNA and protein) but not TLR2 in the peripheral blood 
mononuclear cells (PBMCs) of BS patients was initially observed, irrespective of the 
disease activity (Kirino et al., 2008). Later on, an elevated expression of TLR2 and TLR4 
mRNA in the PBMCs of active BS patients was highlighted (Do et al., 2008). Interestingly, 
vitamin D was found to suppress the protein and mRNA expression of both receptors (Do 
et al., 2008). Furthermore, decreased TLR2 expression was noted in the PBMCs of BS 
patients after stimulation with HSP60 and LPS (Yavuz et al., 2008). The total expression of 
TLR2 and TLR4 was also found to be elevated in the intestinal and buccal mucosa of BS 
patients and broncho-alveolar lavage (BAL) (Durrani et al., 2011, Hamzaoui et al., 2012, 
Nara et al., 2008). Furthermore, NOD2 expression showed correlation with TLR2 and 
TLR4 in BAL samples from BS patients (Hamzaoui et al., 2012). However, to date no 
study has investigated the differential expression and function of TLR2 and TLR4 splice 
variants in the oral mucosa of BS.  
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5.3 METHODOLOGY  
5.3.1 PATIENT SELECTION AND ETHICAL APPROVAL 
All patients were diagnosed according to the International Study Group (ISG) criteria for 
BS and informed consent was obtained. The patient cohort was recruited from the 
outpatient clinic at the Royal London Hospital and St. Thomas’ Hospital with the 
appropriate local ethical approval. BS patients were stratified according to the overall 
disease activity, following a consultant-led assessment, into the following groups: (1) 
relapsed status (severe disease activity in more than two of the BS symptoms despite 
treatment), (2) minor activity status (some disease activity in less than three of the BS 
symptoms), (3) inactive status (the absence of any symptoms at the time of sampling), (4) 
non-relapsed (minor activity BS group + inactive BS group).  Moreover, the different 
disease activity and the treatment protocol were also examined.  
 
A total of 87 subjects were included in this part of the thesis: 55 BS patients (13 relapsed 
BS, 24 minor activity BS, 18 inactive BS) (F/M: 33/22, mean age: 43.3±13), 24 HC (F/M: 
14/10, mean age: 39.7±13.8) and 8 recurrent aphthous stomatitis (RAS) (F/M: 5/3, mean 
age: 46.5±7). 
  
5.3.2 SAMPLES 
A total of 87 brush biopsies from non-lesional oral mucosa from 13 relapsed BS patients, 
24 minor activity BS, 18 inactive BS, 24 HC volunteers, and 8 RAS patients were collected 
using a nylon bristle cytology brush (Flowgen, UK) (Fedele, 2009). All samples were made 
anonymous according to ethical guidelines. Total RNA and protein were purified 
simultaneously from the same samples according to the Purescript kit protocol (Purescript-
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Gentra, Qiagen, UK). For the purpose of the functional study, a total of 46 blood samples 
from 10 relapsed BS patients, 21 inactive BS patients, and 15 healthy individuals were also 
collected. 
 
5.3.3 EXPRESSION OF TLR2 AND TLR4 mRNA BY qPCR 
Total RNA was transcribed to complementary deoxyribonucleic acid (c-DNA) using the 
high-capacity c-DNA reverse transcription kit (Applied Biosystems, UK) according to the 
manufacturer’s instructions. All samples were tested in a real time polymerase chain 
reaction (qPCR) experiment using TaqMan probes for TLR2 mRNA (general TLR2 probe 
for the common 5´ untranslated region (5´UTR) region of the five transcripts on the 2-3 
exon boundary), TLR4 mRNA (general TLR4 probe for the common 5´UTR region of the 
three transcripts on the 1-2 exon boundary) (Applied Biosystems, UK). 18 S rRNA acted as 
a housekeeping gene for the relative expression analysis (Figures 5.1 and 5.2)  
 
 
Figure 5.1: qPCR of the TLR2 mRNA in general. 
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Figure 5.2: qPCR of the TLR4 mRNA in general. 
 
5.3.4 EXPRESSION OF SPLICE VARIANTS OF TLR2 AND TLR4 mRNA BY 
qPCR 
A total of 35 positive c-DNA samples from the same cohort investigated in the previous 
experiment (11 relapsed BS patients, 12 non-relapsed BS patients, 12 HC volunteers) were 
tested for the presence of the different splice variants of TLR2 mRNA and TLR4 mRNA by 
using specific primers designed and validated in-house (chapter 2, section 2.2.2.2, Table 
2.5). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) acted as a housekeeping gene 
for the relative expression analysis. SYBR Green master mix was used in this analysis 
(Roche Applied Science, UK). and the thermal cycle parameters were as follows: one cycle 
at 95 °C for 5 minutes followed by 45 cycles (melting at 95 °C for 10 seconds, annealing at 
60 °C for 10 seconds and extension at 72 °C for 10 seconds) and one melting analysis cycle 
(95 °C for 5 seconds, 60 °C for 60 seconds, 60 °C to 99 °C gradual heating and finally 
40 °C for 20 seconds). 
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5.3.5 SLOT-BLOT ANALYSIS 
A total of 42 protein samples from 14 relapsed BS patients, 14 non-relapsed BS patients, 
and 14 HC volunteers were quantified by using the NanoDrop spectrophotometer (Labtech, 
UK). 12.5% purified protein samples were prepared in sodium dodecyl sulphate (SDS) 
buffer and analysed according to the protocol detailed in chapter 2, section 2.2.2.3.  
 
5.3.6 WESTERN-BLOT ANALYSIS 
A total of 30 protein samples from the cohort investigated by Slot-blot analysis (8 relapsed 
BS patients, 12 non-relapsed BS patients, and 10 HC volunteers) were prepared for loading 
in the sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
analysed according to the protocol detailed in chapter 2, section 2.2.2.4.  
 
5.3.7 TLR FUNCTIONAL STUDY 
A total of 46 blood samples from 10 relapsed BS patients, 21 non-relapsed BS patients and 
15 healthy individuals were analysed. PBMC were isolated by density gradient 
centrifugation over ficoll-hypaque (F-H) (1700 rpm for 35 minutes) and processed 
according to the protocol detailed in chapter 2, section 2.2.2.5.  
 
5.3.8 STATISTICAL ANALYSIS 
The statistical power was calculated using the StatMate 2 program (GraphPad, USA). 
Based on the average of the standard deviation (SD) of the investigated 4 groups in the 
qPCR pilot study (SD average=0.002207), a sample size of 8 in each group has a 95% 
power to detect a difference between means of 0.0043 with a significant level (alpha) of 
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0.05 (two tailed). The author aimed to investigate the maximum sample size achievable 
during the time of the PhD course and using the available resources. 
 
The GraphPad Prism® statistical package was used in the data analysis (GraphPad 
Software Inc., USA). Mean, median, minimum, maximum, range, SD, standard error of 
mean (Sem), and percentages (%) were used to describe the data. The data were analysed 
by Mann-Whitney-U when comparing quantitative data of two groups, and Kruskal-Wallis 
when comparing quantitative data of more than two groups. Differences in the rate were 
analysed using Chi-square tests. Correlation was analysed by using Spearman test.  
 
 
5.4 RESULTS  
Clinical characteristics and medications used in the treatment protocol are summarized in 
Table 5.2. Of the 55 BS patients, 13 were relapsed, 24 had minor activity, and 18 were 
inactive. Oral activity was observed in 50.9%, followed by rheumatologic involvement 
(38.2%), skin involvement (25.5%), genital ulceration (18.2%), ocular lesions (10.9%), and 
CNS involvement (3.6%).  Colchicine was used in the treatment of 43.6% of BS, followed 
by azathioprine (36.4%), and systemic steroids (34.5%). Topical oral steroid treatment was 
used in 43.6% of BS. 
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Table 5.2: Clinical characteristics of BS patients. 
VARIABLES VALUE 
Clinical characterisations Case number (%) 
Relapsed (activity in more than two of BS symptoms) 13 (23.6) 
Minor activity (activity in less than three of BS symptoms) 24 (42.6) 
Non-relapsed (relapsed group + minor activity group) 42 (76.4) 
Inactive (absence of any activity of BS symptoms) 18 (32.7) 
Oral ulcers 28 (50.9) 
Genital ulcers 10 (18.2) 
Skin lesions 14 (25.5) 
Ocular lesions 6 (10.9) 
Rheumatologic involvement 21 (38.2) 
Vasculitis 0 (0) 
CNS involvements 2 (3.6) 
  
Medications used Case number (%) 
Systemic corticosteroid 19 (34.5) 
Topical corticosteroid 24 (43.6) 
Colchicine 24 (43.6) 
Azathioprine 20 (36.4) 
 
5.4.1 TLR2 AND TLR4 GENE TRANSCRIPTION IN THE ORAL MUCOSA  
The relative expression of TLR2 and TLR4 was measured by qPCR. 18S ribosomal 
ribonucleic acid (rRNA) was used as a housekeeping gene for the relative expression 
analysis. Data from BS patients’ samples were compared to data from RAS patients, and 
HC volunteers. The BS patient cohort was further subdivided into relapsed, minor disease 
activity, and inactive status for further analysis. A sub-analysis was performed to 
investigate the difference in gene transcription in relation to the different system (oral, 
ocular, cutaneous, rheumatological, vascular, etc.) activity of BS patients.  
 
 
5.4.1.1 THE RELATIVE EXPRESSION OF TLR2 AND TLR4 mRNA IN GENERAL 
There was a significant increase in the expression of TLR2 mRNA in relapsed BS patients 
compared to HC volunteers (p=0.0129). Similarly, relapsed compared with inactive BS 
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patients (p=0.0260), relapsed compared with minor activity BS patients (p=0.0396), and 
relapsed compared with non-relapsed BS patients (p=0.0155). Likewise, there was increase 
in the expression of TLR2 in relapsed BS patients compared to RAS patients (p=0.0214). 
However, when HC volunteers were compared with the full cohort of BS patients (relapsed 
and non-relapsed) there was no significant difference (p=0.3107). RAS patients expressed 
higher levels of TLR2 in comparison to HC volunteers; however, the difference was not 
statistically significant (Figure 5.3).   
      
The expression of TLR4 (Figure 5.3) showed a similar pattern with a significant increase in 
expression of relapsed BS patients versus HC volunteers (p=0.0019), relapsed compared to 
inactive BS patients (p=0.0041), relapsed compared with minor activity BS patients 
(p=0.0256), relapsed compared with non-relapsed BS patients (p=0.0043), and relapsed BS 
patients compared to RAS patients (p=0.0024). There was no significant difference in the 
expression of the HC volunteers and the whole of the BS patients cohort for TLR4 
(p=0.3107). RAS patients also expressed higher levels of TLR4 in comparison to HC 
volunteers; however, this was not statistically significant.  The level of expression of TLR4 
appeared higher than TLR2 but again was not significant (Figure 5.3). 
 
Examining the ocular activity showed that ocular active BS patients expressed statistically 
higher levels of TLR2 and TLR4 in their buccal mucosa brush biopsies than ocular inactive 
BS patients (p=0.0389 and p=0.0497 respectively). However the number of the ocular 
active patients was very small (n=4). Furthermore, orally active BS patients expressed 
higher levels of TLR2 and TLR4 in their buccal mucosa brush biopsies in comparison to 
orally inactive BS patients but the differences were not statistically significant. The other 
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systemic activities (skin, genital, rheumatologic...etc) and treatment protocol did not 
significantly affect the expression of TLR2 and TLR4 mRNA (Data not shown).  
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Figure 5.3: The relative expression of TLR2 and TLR4 mRNA (BS: n=55, relapsed BS: 
n=13, non-relapsed BS: n=42, inactive BS: n=18, minor activity BS: n=24, HC: n=24, and 
RAS: n=8). 
 
 
 
TLR4 
TLR2 
185 
 
 
The rate of positivity was high for relapsed BS patients compared with all the other groups 
[TLR2: 76.9% (10/13) and TLR4: 100% (13/13)]. There were no statistical significant 
differences in positivity rate between HC volunteers, non-relapsed BS patients, minor 
activity BS patients, inactive BS patients and RAS patients (Figure 5.4). 
 
 
Figure 5.4: TLR2 and TLR4 mRNA positivity rate in the non-lesional oral mucosa (BS: 
n=55, relapsed BS: n=13, non-relapsed BS: n=42, inactive BS: n=18, minor activity BS: 
n=24, HC=24, RAS=8).  
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TLR2 and TLR4 mRNA positivity rate 
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5.4.1.2 THE RELATIVE EXPRESSION OF TLR2 AND TLR4 mRNA SPLICE 
VARIANTS 
TLR2a and TLR2c expression was broadly similar in all groups. The expression of TLR2b, 
TLR2d, and TLR2e were higher in relapsed BS patients compared to HC volunteers 
(p=0.0321, p=0.0272 and p=0.0134 respectively). However, there were no statistical 
significant difference in the expression levels of TLR2b, TLR2d, and TLR2e between 
relapsed and non-relapsed BS patients (p=0.1985, p=0.1213 and p=0.4887 respectively) 
(Figure 5.5). 
 
The relative expression of TLR4 variant 1, 3 and 4 mRNA was measured in the same 
cohorts. All investigated groups had broadly similar levels of TLR4.1 expression. Relapsed 
BS patients expressed higher levels of TLR4.3 compared to non-relapsed BS patients, and 
HC volunteers (p=0.0127, and p=0.0002 respectively). Likewise, relapsed BS patients 
expressed higher levels of TLR4.4 compared to non-relapsed BS patients, and HC 
volunteers (p=0.0373, and p=0.0127 respectively) (Figure 5.5). 
 
The rate of positivity was high for TLR2 variant a, b, d, and e. However, TLR2 variant c 
was low in all the investigated groups (Figure 5.6). Expression of TLR4 splice variants 3 
and 4 was infrequent in HC volunteers (1/12: 8.3%) and non-relapsed BS patients (3/12: 
25% and 4/12: 33.3% respectively) compared to relapsed BS patients (9/10: 90%) (Figure 
5.7). 
 
Descriptive statistical analysis including mean, median, SD, Sem, and percentages of TLR2 
and TLR4 mRNA and their splice variants is presented in table 5.3 and 5.4.  
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Figure 5.5: The relative expression of TLR2 splice variants a-e and TLR4 splice variants 1, 
3 and 4 (BS: n=22, relapsed BS: n=10, non-relapsed BS: n=12, and HC: n=12). 
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Figure 5.6: TLR2 mRNA splice variants positivity rate (BS: n=22, relapsed BS: n=10, non-relapsed 
BS: n=12, HC: n=12).  
 
 
Figure 5.7: TLR4 mRNA splice variants positivity rate (BS: n=22, relapsed BS: n=10, non-
relapsed BS: n=12, HC: n=12).  
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C) TLR4 mRNA splice variant positivity rate 
189 
 
Table 5.3: mRNA quantification of TLR2 and their splice variants. 
 GROUP  MEDIAN  MINIMUM MAXIMUM MEAN SD Sem %  
TLR2 
mRNA 
Relapsed 
BS  
(n=13) 
3.380e-006 0 0.02693 0.002307 0.007409 0.0020055 76.9% 
(10/13) 
Non-
relapsed 
BS  
(n=42) 
3.047e-008 0 0.0009257 7.211e-005 0.0001943 2.997e-005 50% 
(21/42) 
RAS 
(n=8) 
0 0 0.00014 1.769e-005 4.942e-005 1.747e-005 25%  
(2/8) 
HC 
(n=24) 
1.130e-007 0 0.0001470 7.405e-006 2.986e-005 6.095e-006 50% 
(12/24) 
TLR2a 
mRNA 
Relapsed 
BS  
(n=10) 
0.0020 0.000201 0.0158 0.003802 0.004854 0.001535 100% 
(10/10) 
Non-
relapsed 
BS  
(n=12) 
0.003853 0.000608 0.01225 0.004880 0.003549 0.001053 100% 
(12/12) 
HC 
(n=12) 
0.00177 0.00017 0.0158 0.004390 0.004168 0.0008887 100% 
(12/12) 
TLR2b 
mRNA 
Relapsed 
BS  
(n=10) 
0.6357 0.02212 3.020 0.9266 0.9442 0.2986 100% 
(10/10) 
Non-
relapsed 
BS  
(n=12) 
0.3210 0.007765 2.868 0.5608 0.7785 0.2247 100% 
(12/12) 
HC 
(n=12) 
0.2307 0 0.6077 0.2412 0.2061 0.05949 91.6% 
(11/12) 
TLR2c 
mRNA 
Relapsed 
BS  
(n=10) 
0 0 0.0007 7.000e-005 0.0002214 7.000e-005 10% 
(1/10) 
Non-
relapsed 
BS  
(n=12) 
0 0 0.003875 0.0006435 0.001292 0.0003729 41.7% 
(5/12) 
HC 
(n=12) 
0 0 0.003875 0.0003828 0.0009901 0.0002111 8.3% 
(1/12) 
TLR2d 
mRNA 
Relapsed 
BS  
(n=10) 
0.03328 0.00314 0.4745 0.08407 0.1414 0.04473 100% 
(10/10) 
Non-
relapsed 
BS  
(n=12) 
0.01695 0.000788 0.1448 0.02560 0.03852 0.01112 100% 
(12/12) 
HC 
(n=12) 
0.01164 0 0.0400 0.01466 0.01166 0.003366 91.6% 
(11/12) 
TLR2e 
mRNA 
Relapsed  
BS  
(n=10) 
0.4945 0.1052 1.772 0.5873 0.4992 0.1579 100% 
(10/10) 
Non-
relapsed 
BS  
(n=12) 
0.3628 0.0186 1.473 0.4360 0.3925 0.1133 100% 
(12/12) 
HC 
(n=12)  
0.1750 0.03675 0.4166 0.1892 0.1233 0.03558 100% 
(12/12) 
BS: Behçet’s syndrome; HC: healthy control; RAS: recurrent aphthous stomatitis; SD: standard deviation; Sem: Standard error of 
mean. 
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Table 5.4: mRNA quantification of TLR4 and their splice variants. 
 GROUP  MEDIAN  MINIMUM MAXIMUM MEAN SD Sem %  
TLR4 
mRNA 
Relapsed 
BS  
(n=13) 
0.0004994 9.100e-008 0.1743 0.01634 0.04820 0.01337 71.4% 
(13/13) 
Non-
relapsed 
BS  
(n=42) 
1.084e-007 0 0.02726 0.001322 0.004672 0.0003411 52.3% 
(22/42) 
RAS 
(n=8) 
0 0 0.000749 9.365e-005 0.0002648 9.362e-005 25%  
(2/8) 
HC 
(n=24) 
2.335e-007 0 0.0003347 2.801e-005 8.721e-005 1.780e-005 58.3% 
(14/24) 
TLR4.1 
mRNA 
Relapsed 
BS  
(n=10) 
0.0002295 1.700e-006 0.00254 0.0004641 0.0007582 0.0002398 100% 
(10/10) 
Non-
relapsed 
BS  
(n=12) 
7.730e-005 3.170e-006 0.00102 0.0002262 0.0003056 8.823e-005 100%  
(12/12) 
HC 
(n=12) 
8.060e-005 1.700e-006 0.000751 0.0001697 0.0002351 6.786e-005 100% 
(12/12) 
TLR4.3 
mRNA 
Relapsed 
BS  
(n=10) 
0.00207 0 0.004765 0.002324 0.001709 0.0005405 90% 
(9/10) 
Non-
relapsed 
BS  
(n=12) 
0 0 0.00917 0.001150 0.002753 0.0007948 25% 
(3/12) 
HC 
(n=12) 
0 0 0.001245 0.0001038 0.0003594 0.0001038 8.3% 
(1/12) 
TLR4.4 
mRNA 
Relapsed 
BS  
(n=10) 
0.0003835 0 0.002175 0.0005810 0.0006826 0.0002158 90% 
(9/10) 
Non-
relapsed 
BS  
(n=12) 
0 0 0.001454 0.0002531 0.0004855 0.0001402 33.3% 
(4/12) 
HC 
(n=12) 
0 0 0.0003475 2.896e-005 0.0001003 2.896e-005 8.3% 
(1/12) 
BS: Behçet’s syndrome; HC: healthy control; RAS: recurrent aphthous stomatitis; SD: standard deviation; Sem: Standard error of 
mean. 
 
5.4.1.3 TLR2 AND TLR4 mRNA CORRELATION STUDY 
There was positive correlation between TLR2b and TLR2e in all the investigated groups 
(relapsed BS patients: p=0.0001 and r=0.9758, non-relapsed BS patients: p=0.0139 and 
r=0.6853, HC volunteers: p=0.0004 and r=0.8531). Additionally, TLR2b positively 
correlated with TLR2d and TLR2e (p=0.0220 and r=0.6503 & p=0.0016 and r=0.8042 
respectively) in non-relapsed BS patients (Figure 5.8). 
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Figure 5.8:  TLR2 correlation study (BS: n=22, relapsed BS: n=10, non-relapsed BS: n=12, 
HC: n=12).  
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There was positive correlation between the total TLR4 and TLR4.1 in all the investigated 
groups (relapsed BS patients: p=0.0330 and r=0.6727, non-relapsed BS patients: p=0.0008 
and r=0.8322, HC volunteers: p=0.0004 and r=0.8531). Additionally, TLR4.4 positively 
correlated with total TLR4 (p=0.0289 and r=0.6848) and TLR4.1 (p=0.0330 and r=0.6727) 
(Figure 5.9). 
 
HC
(p=0.0004 & r=0.8531)
0.0000 0.0001 0.0002 0.0003 0.0004
0.0000
0.0002
0.0004
0.0006
0.0008
TLR4
T
L
R
4
.1
Non relapsed BS
(p=0.0008 & r=0.83220
0.00 0.01 0.02 0.03
0.0000
0.0005
0.0010
0.0015
TLR4
T
L
R
4
.1
 
Relapsed BS
(p=0.0029 & r=0.8303)
0.00 0.01 0.02 0.03 0.04
0.000
0.001
0.002
0.003
TLR4
T
L
R
4
.1
Relapsed BS
(p=0.0289 & r=0.6848)
0.00 0.01 0.02 0.03 0.04
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
TLR4
T
L
R
4
.4
Relapsed BS
(p=0.0330 & r=0.6727)
0.000 0.001 0.002 0.003
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
TLR4.1
T
L
R
4
.4
 
Figure 5.9: TLR4 correlation study (BS: n=22, relapsed BS: n=10, non-relapsed BS: n=12, 
HC: n=12). 
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5.4.2 TLR2 AND TLR4 GENE TRANSLATION IN THE ORAL MUCOSA 
Total protein was purified from oral mucosal brush biopsies of 42 subjects (14 relapsed BS 
patients, 14 non-relapsed BS patients, and 14 HC volunteers) for the purpose of TLR2 and 
TLR4 detection by using immunoassays.  
 
5.4.2.1 TLR2 AND TLR4 TOTAL PROTEIN 
Slot-blot analysis of lysates of oral mucosal brush biopsies was carried out for TLR2 and 
TLR4 in 42 samples from 14 relapsed BS patients, 14 non-relapsed BS patients, and 14 HC 
volunteers. There was no statistically significant difference in the expression of the TLR2 
protein between relapsed BS patients, non-relapsed BS patients and HC volunteers 
(Kruskal-Wallis, p=0.2937). There was also no statistically significant difference in the 
expression of the same protein between the whole BS patient cohort, including relapsed and 
non-relapsed presentation, and HC volunteers (Mann-Whitney, p=0.3158) (Table 5.5, and 
Figures 5.10-5.11).  
 
Table 5.5: Slot-blot for TLR2 protein in oral mucosal brush biopsies. 
 NON-RELAPSED BS  
PATIENTS 
RELAPSED  
BS PATIENTS 
BS 
PATIENT 
COHORT 
HC  
VOLUNTEERS 
n 14 14 28 14 
Median 1.030 1.020 1.025 1.150 
Min 1.000 1.000 1.000 1.000 
Max 4.200 1.200 4.200 4.400 
Mean 1.647 1.054 1.350 1.442 
SD 0.9876 0.07239 0.7506 0.9081 
Sem 0.2639 0.01935 0.1419 0.2427 
BS: Behcet’s syndrome; HC: healthy control; SD: standard deviation; Sem: standard error 
of mean; Max: maximum; Min: minimum; n: number. 
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Figure 5.10: TLR2 protein expression in lysate from oral mucosal brush biopsies using 
Slot-blot analysis. A comparative study between 14 non-relapsed BS patients, 14 relapsed 
BS patients, and 14 HC volunteers.  
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                                            1               2                  3                 4                 5                 6 
Figure 5.11: TLR2 Slot-blot for 42 protein samples from oral mucosal brush biopsies of 14 
non-relapsed BS patients, followed by 14 HC volunteers and 14 relapsed BS patients.
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The pattern observed for TLR2 protein was also observed for TLR4 protein. There was 
no statistically significant difference between relapsed BS patients, non-relapsed BS 
patients, and HC volunteers (Kruskal-Wallis, p=0.4673). There was also no statistically 
significant difference in the expression of the same protein between the whole BS 
patient cohort and HC volunteers (Mann-Whitney, p=0.4329) (Table 5.6 and Figures 
5.12–5.13). 
 
Table 5.6: Slot-blot for TLR4 protein in oral mucosal brush biopsies. 
 NON-RELAPSED 
BS  
PATIENTS 
RELAPSED BS  
PATIENTS 
BS 
PATIENT  
COHORT 
HC  
VOLUNTEERS 
n 14 14 28 14 
Median 1.000 1.040 1.005 1.000 
Min 1.000 1.000 1.000 1.000 
Max 1.400 1.800 1.800 1.900 
Mean 1.077 1.156 1.116 1.153 
SD 0.1322 0.2310 0.1890 0.3069 
Sem 0.03534 0.06174 0.08202 0.08202 
BS: Behcet’s syndrome; HC: healthy control; SD: standard deviation; Sem: standard 
error of mean; Max: maximum; Min: minimum; n: number. 
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Figure 5.12: TLR4 protein expression in lysate from oral mucosal brush biopsies using 
Slot-blot analysis.  
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Figure 5.13: TLR4 Slot-blot for 7 protein samples from oral mucosal brush biopsies.  
A1, B1, C1, D1, E1, F1 and G1: 7 different samples from BS patients.  
A2, B2, C2, D2, E2, F2 and G2: 1:5 dilutions of the same samples. 
A3, B3, C3, D3, E3, F3 and G3: negative control samples. 
 
5.4.2.2 TLR2 AND TLR4 PROTEIN ISOFORMS  
Western-blot analysis of protein lysates from oral mucosal brush biopsies was carried 
out for TLR4 in 20 BS patients (8 relapsed BS patients and 12 non-relapsed BS 
patients) and 10 HC volunteers. TLR4 showed heterogeneous bands with 90% of HC 
volunteers showing a band at ~90kDa. The 70kDa band was also strong in 90% of 
samples from HC volunteers, while the 50kDa band appeared in 50% of relapsed BS 
patients’ samples. Additionally, 75% of the relapsed BS patients’ samples had a band at 
about 35kDa and 12.5% had a band on 25kDa. There was a significantly higher 
expression of 70kDa band in the HC volunteers compared to BS patients (relapsed and 
non-relapsed) (Chi-square, p=0.0107), while band 35kDa was significantly highly 
expressed in relapsed BS patients (Chi-square, p=0.0097) (Table 5.7 and Figure 5.14).  
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The TLR2 protein expression also appeared to be somewhat heterogeneous despite a 
constant amount of protein loading in all cases of 1 µg/ml. Three main bands were 
observed for TLR2 at about 90 kDa, 50 kDa and 30 kDa (Figure 5.14).  
 
Table 5.7: TLR4 Western-blot. 
TLR4 WESTERN-
BLOT 
BAND SIZE 
RELAPSED BS  
(n=8) 
NON-
RELAPSED BS 
 (n=12) 
HC 
VOLUNTEERS 
(n=10) 
≈90 kDa 87.5% (7/8) 83% (10/12) 90% (9/10) 
≈70 kDa 75% (6/8) 50% (6/12) 90% (9/10) 
≈50 kDa 50% (4/8) 33% (4/12) 40% (4/10) 
≈35 kDa 75% (6/8) 50% (6/12) 40% (4/10) 
≈25 kDa 12.5% (1/8) 8.3% (1/12) 30% (3/10) 
BS: Behcet’s syndrome; n: number; HC: healthy control.  
 
 
 
 
Figure 5.14: Western-blot for TLR4 and TLR2 protein. TLR4 Western-blot 
demonstrated 5 different bands at 90, 70, 50, 35 and 25 kDa, while TLR2 Western-blot 
showed 3 main bands at 90, 50 and 30 kDa. 
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5.4.3 TLR2 AND TLR4 FUNCTION IS DAMPENED IN BS PATIENTS 
A total of 46 blood samples from 10 relapsed BS patients, 21 non-relapsed BS patients, 
and 15 healthy individuals were analysed. PBMC were treated with the different 
cognate agonist for TLR1/2 heterodimer, TLR2, TLR4, and TLR2/6 heterodimer. The 
level of spontaneous secretion of TNF-α was quantified along with its post treatment 
levels (R&D Systems, UK). The spontaneous tumour necrosis factor alpha (TNF-α) 
secretion was elevated in relapsed BS patients PBMC supernatant; however, this 
difference was not statistically significant (Figure 5.15). All three groups responded 
equally to phytohaemagglutinin (PHA) treatment. After the treatment with the different 
TLRs’ cognate agonists, PBMC from the whole BS patient cohort (relapsed and non-
relapsed) failed to respond to TLR4 agonist efficiently compared to healthy individuals 
(Mann-Whitney, p= 0.0093). Also, there was observed decrease in the response to 
TLR1/2 agonist by BS PBMC (Mann-Whitney, P=0.0500) (Figure 5.16). 
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Figure 5.15: The spontaneous TNF-α secretion in relapsed BS patients PBMC 
supernatant, non-relapsed BS patients, and HC volunteers. 
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Figure 5.16: TNF-α secretion by BS patients and HC volunteers PBMC upon 
stimulation with PHA and TLRs agonists.  
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5.5 DISCUSSION AND CONCLUSION  
Enhanced inflammatory reaction is a recognized characteristic pathological feature of 
BS with well-recorded high serum pro-inflammatory cytokine levels such as TNFα and 
interleukin 6 (IL6) (Evereklioglu et al., 2002). These cytokines can be triggered by the 
TLRs’ cascade that leads to the translocation of NF-κB and transcription of cytokine-
encoding genes after binding to a challenging antigen, either endogenous or exogenous 
(Gay and Gangloff, 2007). Furthermore, oral bacterial and viral aetiology was suggested 
in the literature for BS (Hamza et al., 1990, Lehner et al., 1991, Sun et al., 1996, Tojo et 
al., 2003b). Interestingly, TLR2 and TLR4 jointly are capable of sensing most of the 
oral microbial commensals and pathogens. Therefore, the aim of this part of the thesis 
was to study the differential expression of TLR2, TLR4, and their splice variants in 
relation to BS. The author investigated the oral mucosa in particular because it is 
deemed to be an important site of the disease activity for BS, based on the fact that most 
BS patients experience recurrent episodes of oral ulceration and they are considered to 
be the initial sign of the disease in more than 80% of patients (Davatchi et al., 2010b).  
 
The results of this part of the thesis indicate that TLR2 and TLR4 mRNA expression 
increases in the oral mucosa of BS patients during the relapsed phase, highlighting the 
importance of these markers in monitoring the disease activity. This is consistent with 
another study that showed elevated expression of TLR2 and TLR4 in the PBMCs of 
active BS patients (Do et al., 2008).  
 
Given the higher levels of TLR2 and TLR4 in relapsed disease, one of their ligands may 
play an important role in the pathogenesis of BS. However, it is also possible that 
multiple antigens contribute to the activity of the disease, with some of them acting as 
shared ligand for both TLR2 and TLR4.  
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This part of the thesis is the first study to investigate the relative expression of the 
different mRNA splice variants of TLR2 and TLR4, and it points towards possible 
innate immune abnormalities in BS patients. Interestingly, TLR2 mRNA variant b, 
which is known to be able to transcribe to the full-length protein, was high in relapsed 
BS patients’ oral mucosa. Furthermore, TLR2 mRNA variant d, one of the unusual 
splice variant possibly affecting the stability of the mRNA, was also predominantly 
elevated in relapsed BS patients’ oral mucosa. The elevated TLR2 mRNA variant e in 
relapsed BS patients’ oral mucosa was of great importance as this fact highlights the 
high monocyte infiltration in their non-lesional oral mucosa. 
 
The upregulation of the unusual mRNA splice variants of TLR4 may lead to incomplete 
protein translation. TLR4 mRNA splice variant 3 and 4 were significantly elevated in 
the whole BS patient cohort. TLR4 variant 3 has extra exon (compared to splice variant 
1), which results in a frameshift and an early stop codon; the translated protein from this 
splice variant is expected to be significantly truncated and a candidate for nonsense 
decay. Interestingly, TLR4 mRNA splice variant 4 lacks an exon (compared to variant 
1), resulting in a frameshift and an early stop codon; the translated protein of this splice 
variant is also expected to be significantly truncated and a candidate for nonsense decay.  
 
Interestingly, the correlation study pointed toward a positive correlation between 
TLR2b (known to translate to full length protein) and TLR2e (known to be expressed 
by fresh monocytes) in all investigated groups. It is documented in the literature that 
TLR activation can induce chemokine production and leukocyte recruitment (Parker et 
al., 2004). However contradictory observations were also documented pointing towards 
inhibition of leukocyte chemotaxis following TLR activations by a high concentrations 
of their agonists (Yi et al., 2012). 
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The dampened response of BS PBMC TLR4 upon stimulation with its agonist is one of 
the novelties of this part of the thesis and could explain the higher level of TLR4 variant 
3 and 4 in relapsed BS patients. In addition, the decrease in the BS PBMC response 
upon treatment with TLR1/2 agonist might highlight a defect in the heterodimer 
formation between these two receptors. The results are consistent with the available 
literature indicating the decrease in TLR2 expression in PBMCs upon treatment with 
LPS and HSP (Yavuz et al., 2008). 
 
Examination of the slot-blot data suggests that protein expression of TLR2 and TLR4 is 
not raised during relapsed BS compared to the non-relapsed phase. This appears to 
highlight a defect in the translation of the mRNA that was expected in view of the 
elevated level of expression of the unusual mRNA splice variants of TLR2 and TLR4. 
However, it is not unprecedented for protein and mRNA levels of the same gene/protein 
to show a poor correlation in the same tissue (Dixon et al., 2004).  
 
In the Western-blot analysis for TLR2 and TLR4, the author consistently observed 
multiple bands despite the use of protease inhibitor cocktail tablets (Roche Applied 
Science, UK) to remove the potential for protein degradation. Koch et al. (2007) also 
demonstrated by Western-blot the presence of 5 protein bands for TLR4 around the 
sizes 130, 110, 72, 50, 26 kDa. His interpretation was that the band at 130 kDa 
represents a glycosylated TLR4 isoform, expressed at the cell surface, and the band at 
110 kDa represents a partially glycosylated form, which is unable to translocate to the 
surface. However, the bands at lower molecular weights may represent translation 
products of the TLR4 mRNA splice variants that contain an early stop codon (Koch et 
al., 2007, Ohnishi et al., 2003). These mRNA splice variants should be candidates for 
the non-sense decay mechanism, preventing them from being translated into truncated 
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non-functional protein. Therefore, we believe that the abundance of band 35kDa of 
TLR4 in relapsed BS patients may indicate either a defect in the non-sense decay 
mechanism or enhanced proteolysis in this cohort.  
 
We conclude that there is a shift towards expressing some of the unusual mRNA splice 
variants of TLR2 and TLR4 by BS patients’ oral mucosa, which explains the observed 
defect in TLR4 and TLR1/2 heterodimer function and indicates abnormalities in the 
innate immune response to oral microbes in this syndrome. However, the exact protein 
product of the TLR2 and TLR4 mRNA splice variants is not completely understood, 
which in turn invites further research to investigate the function of these splices in 
health and disease  
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CHAPTER 6 
THE ORAL MICROBIOME OF BEHÇET’S SYNDROME PATIENTS 
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6.1 ABSTRACT 
6.1.1 BACKGROUND  
Behçet’s syndrome (BS) is one of the devastating vasculitides with unknown aetiology. 
Currently, there is a consensus that the complex interplay between the commensal 
microbial community and the abnormal immune response is a fundamental root cause 
triggering the complex clinical presentation of BS. 
 
6.1.2 OBJECTIVES 
This study investigates the oral microbiome in BS patients and compares it to recurrent 
aphthous stomatitis (RAS) patients and healthy control (HC) volunteers. 
 
6.1.3 METHODS 
Eighty-one saliva samples and oral swabs from BS patients and controls were cultured 
and bacteria were identified by matrix-assisted laser desorption/ionisation-time of flight 
(MALDI-TOF). Molecular identification of cultured Mycobacterium was established. 
Salivary viral load and the serum immunoglobulin G (IgG) of the different herpes 
viruses were quantified from a further 89 saliva samples and matched serum samples. 
 
6.1.4 RESULTS 
Sixty different oral bacteria, five fungi and four mycobacteria were identified. 
Simultaneously, the presence of six different herpes viruses was inspected. The oral 
mucosal and salivary microbial profile was variable between individuals in the same 
group and between individuals in different groups. The orally active BS patients’ oral 
mucosa showed the highest microbial community complexity and diversity compared to 
all the other investigated groups. Salivary shedding of Epstein-Barr virus (EBV) was 
statistically significantly higher in BS patients compared to HC volunteers, independent 
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of their oral disease activity (Mann-Whitney, p=0.0057). Furthermore, the 
cytomegalovirus (CMV) IgG expression was significantly deficient in BS patients’ 
serum samples compared to RAS patients and HC volunteers (Kruskal-Wallis, 
p=0.0450). 
 
6.1.5 CONCLUSION 
The lower level of expression of CMV IgG could be caused by a defect in the cross-talk 
between innate and adaptive immune responses, given the previously mentioned defect 
in the toll-like receptor (TLR) 1/2 heterodimer function that act as an initial receptor to 
sense CMV. This in turn will lead to a status of increased susceptibility to CMV 
infection.  
 
Despite the uncertainty about whether the reported differences in the microbiome of BS 
patients are of a causative or reactive nature, these differences might prove to be of 
great importance as restoring the balance of the microbial community is expected to 
promote rapid recovery from oral ulcerations and potential better control of the 
immunological response.  
 
6.1.6 DECLARATION 
The ethical approval application was performed by Professor Fortune. The evaluation 
and diagnosis of patients were undertaken in a consultant-led examination.  
 
The author has performed all data analysis in this chapter. She also contributed to 
sample collections, sample processing, experimental assays, data collection, and data 
management. The research and clinical team of the Centre for Clinical and Diagnostic 
Oral Sciences contributed to sample collection, data collection and data management.  
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The Barts and the London NHS Medical Microbiology unit guided the author in the 
MALDI-TOF analysis. The National Mycobacterium Reference Laboratory kindly 
funded the mycobacterial analysis and guided the author throughout its stages. The 
Barts and The London NHS virology unit guided the author in the real time Polymerase 
Chain Reaction (qPCR) and immunoassays for the herpes viruses.  
 
6.2 INTRODUCTION 
Investigating the aetiology and pathogenesis of chronic diseases is challenging but it 
can yield crucial information to help create new treatment modalities. The role of the 
oral bacteria in the pathogenesis of many life threatening systemic diseases such as 
brain abscess, endocarditis and glomerulonephritis is well documented in the literature. 
Recently, the importance of oral and gut commensals in the pathogenesis of immune-
related diseases has been highlighted in autoimmune encephalomyelitis, rheumatic 
arthritis, pancreatic diseases, and inflammatory bowel diseases (Docktor et al., 2012, 
Farrell et al., 2012, Liao et al., 2009, Mueller et al., 2009, Ochoa-Reparaz et al., 2009, 
Wolf and Curtis, 2008). Furthermore, oral tolerization and probiotic therapy were 
suggested as treatment modalities with their potential benefit in treating immune-related 
diseases and some oral ulcerative diseases (Stanford et al., 2004, Sun et al., 2009, Tasli 
et al., 2006). 
 
Behçet’s syndrome (BS) is a multi-systemic immune-related disease characterized by 
recurrent oral ulcers as the initial sign of the disease in more than 80% of the cases 
(Davatchi et al., 2010b). Because of this observation, it is thought that the oral 
environment may play a very important role in its aetiology and pathogenesis. To date, 
the consensus is that the disease is triggered by a profound inflammatory response to an 
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undefined environmental factor in a genetically susceptible host, but as yet the aetiology 
remains poorly understood (Lehner, 1999). 
 
A bacterial aetiology was suggested in the literature a long time ago. The uncommon 
serovars of Streptococcus sanguis KTH1 and KTH3 were thought to be a potential 
aetiological factor in BS based on their frequent isolation from this group of patients. 
Furthermore, BS patients showed marked skin reactivation to these antigens and there 
were lymphoproliferative responses observed against KTH1 and KTH3 whole cell 
antigen. However, in subsequent studies there were no differences in the uncommon 
serovars KTH1 and KTH3 biochemical properties compared to Streptococcus oralis 
isolated from healthy control (HC) volunteers, therefore, it was reclassified as 
Streptococcus oralis (Lehner et al., 1991, Narikawa et al., 1995).  
 
The cross reactivity of bacterial heat shock proteins (HSP) with their mammalian 
counterparts was also studied in relation to BS patients (Lehner et al., 1991). The serum 
antibody titre and delayed-type hypersensitivity against Streptococcal antigens were 
reported as significantly higher in BS patients than in those of the controls. Therefore, it 
was suggested that hypersensitivity to Streptococcal species may act as a trigger for the 
inflammatory response (Kaneko et al., 1997, Kaneko et al., 2008). Indeed, an oral 
tolerization with the peptide (p36-351) of HSP60 was investigated in a phase I/II 
clinical trial, with promising results (Stanford et al., 2004).  
 
In a recent study, Staphylococcus aureus, Moraxella, and Streptococcus were found to 
colonize the conjunctiva of BS patients significantly more than in a HC group (Gunduz 
et al., 2008). Likewise, Staphylococcus aureus and Prevotella spp. were more 
commonly isolated from the skin lesions of BS patients (Hatemi et al., 2004). 
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Furthermore, treatment of eight BS patients suffering from active mucocutaneous 
symptoms with azithromycin for four weeks was reported to be effective in decreasing 
folliculitic lesions and speeding up the healing of oral ulcers (Mumcu et al., 2005). In 
another study, minocycline successfully reduced the frequency of clinical symptoms in 
BS patients and indeed reduced the in vitro production of the pro-inflammatory 
cytokines by their peripheral blood mononuclear cells (PBMCs) when stimulated with 
Streptococcal antigen (Kaneko et al., 1997). Moreover, probiotic treatment in the form 
of Lactobacillus brevis CD2 lozenges seemed to be beneficial in controlling the oral 
ulceration of BS patients in a pilot study (Tasli et al., 2006)  
 
A viral aetiology was also postulated more than fifty years ago by Hulusi Behçet. Later, 
Denman et al. (1980) and then Eglin et al. (1982) showed by in situ DNA-DNA 
hybridization that at least part of the herpes simplex virus (HSV) 1 genome is 
transcribed in mononuclear cells of some patients with BS (Denman et al., 1980, Eglin 
et al., 1982, Gray, 1950). However, administration of high doses of acyclovir in 
association with plasma exchanges failed to produce positive treatment results and 
treatment with acyclovir alone failed to alleviate the frequency and severity of oro-
genital ulceration or other BS features in a randomized, double-blind, placebo-
controlled, crossover trial (Davies et al., 1988). 
 
In other studies, the level of immunoglobulin (Ig) G antibody against HSV1 was found 
to be significantly increased in patients who had BS but there was no HSV1 DNA found 
in peripheral blood leukocytes and oral smears from the same cohort (Nomura et al., 
1998). Also, there was no statistically significant increase in HSV1 DNA observed in 
the saliva of BS patients compared to HC volunteers (Lee et al., 1996). 
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In addition to HSV1, the human cytomegalovirus (CMV) has been studied in relation to 
BS. CMV DNA was detected in biopsy specimens from the oral mucosa of BS patients 
(Sun et al., 1996). In another study, the mean titre of IgG and IgA antibodies to CMV 
was significantly lower in BS patients than in HC volunteers. However, the number of 
subjects having IgM antibody against CMV was similar in BS patients and HC 
volunteers (Lee et al., 2005). Nevertheless, these studies have not been substantiated.  
 
Epstein-Barr virus (EBV) was also suggested as a potential cause of BS. EBV DNA was 
isolated in the pre-ulcerative stage of oral ulceration of patients with BS and recurrent 
aphthous stomatitis (RAS) in a very small cohort (Sun et al., 1998). 
 
To date, the oral microbial profile of BS patients has not been fully identified. This part 
of the thesis is attempting to fill that gap in the literature by investigating the oral 
microbiome of the BS patient cohort in the UK and comparing it to HC volunteers and 
RAS patients. We also investigated the oral microbial profile of BS during orally active 
and inactive phases of the disease, and in ulcer sites compared to non-ulcer sites in the 
same patients.  
 
6.3 MATERIALS AND METHODS 
 
6.3.1 PATIENT COHORTS AND SAMPLE COLLECTIONS  
The International Study Group (ISG) criteria were employed to diagnose and stratify all 
BS patients. Informed consent was obtained with appropriate local ethical approval. BS 
patients were stratified according to the oral activity of the disease into orally active 
(presented with oral ulceration at the time of sample collection) and orally inactive 
disease status. A total of 89 subjects were invited to this part of the study [54 BS (M/F: 
19/35 mean age: 44±11), 28 HC (M/F: 13/15, mean age: 34±10.5) and 7 RAS (M/F: 
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3/4, mean age: 49.7±8)]. Out of those, 14 BS patients and 3 RAS patients had oral 
ulcerations at the time of sampling. None of these investigated subjects showed any 
signs of oral infection, nor were they treated with any topical or systemic antimicrobials 
at the time of sampling or during the week before sampling. 
 
Eighty-one samples (45 oral swabs (Copan, UK) from ulcerated and non-ulcerated oral 
mucosa and 36 unstimulated saliva samples) from 10 orally active BS patients, 10 orally 
inactive BS patients, 10 HC volunteers, and 6 RAS patients (50% orally active) from 
the above-mentioned cohorts were cultured and bacteria were identified by matrix-
assisted laser desorption/ionisation-time of flight (MALDI-TOF). Molecular 
identification of cultured Mycobacterium was established from another 81 samples from 
the same patient and volunteer cohorts (45 brush biopsies (Flowgen Bioscience, UK) 
from ulcerated and non-ulcerated oral mucosa and 36 unstimulated saliva samples).  
 
Herpes viruses’ nucleic acid was quantified using real time polymerase chain reaction 
(qPCR) with specific primers in 89 saliva samples, while the specific IgG response to 
the different herpes viruses was measured by quantitative immunoassays in matching 
serum samples from the same cohorts of patients and volunteers.  
 
6.3.2 ORAL MICROBIAL ANALYSIS 
Oral mucosal swabs and salivary samples were diluted in sterile saline at 10
-2
 and 10
-4
 
and cultured on 7 different culture media: blood agar, chocolate agar, colistin nalidixic 
acid agar, MacConkey agar, gonococcus agar, Sabouraud agar and fastidious anaerobic 
agar. Blood agar, chocolate agar and gonococcus agar plates were incubated at 37 °C 
for 48 hours in a CO2 enriched environment. Colistin nalidixic acid agar, MacConkey 
agar and Sabouraud agar plates were incubated at 37 °C for 48 hours in an O2 enriched 
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environment. The fastidious anaerobic agar plates were incubated at 37 °C for 7 days in 
an anaerobic environment. Bacteria grown on blood agar plates were quantified in 
colony-forming units. Isolated colonies were re-cultured in the same culture 
environments to purify them before peptide isolation.  
 
Peptides were purified by the acetonitrile precipitation method according to the 
manufacturer’s instructions (Bruker Daltonics, Germany). MALDI-TOF analysis using 
the MALDI Biotyper was conducted in a 96 target plate by applying 1 μl of each 
peptide sample to a different target followed by 1 μl of the crystallised molecules in the 
MALDI matrix, to protect the peptides and help in the ionisation process by the laser 
beam (Bruker Daltonics, Germany).  
 
MALDI-TOF applied nitrogen-pulsed laser ionisation to the peptide samples to ionise 
and separate them based on their mass/charge ratio. The resulting spectra formulated the 
protein finger print (2,000–20,000 Dalton range) which was then compared to a 
database of known spectra to identify and type the different bacteria being analysed. A 
match factor for each sample was automatically calculated by the MALDI Biotyper 
based on the number and amplitude of the peaks that matched. A score of 1.7 or above 
was considered a reliable identification of the investigated microorganism.  
 
6.3.3 MYCOBACTERIAL ANALYSIS 
For the purpose of mycobacterial analysis, all investigated brush biopsy samples were 
decontaminated using the 3% oxalic acid decontamination method while all saliva 
samples were treated with the 2% sodium hydroxide and N-acetyl-L-cysteine 
decontamination method.  
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All samples were cultured on Lowenstein-Jensen (LJ) slopes and mycobacterial growth 
indicator tubes (MGIT) following the manufacturer’s instructions (Becton Dickinson 
Diagnostic Instrument Systems, USA). MGIT bottles were incubated on the MGIT 
instrument which reads each tube hourly and triggers an alarm when growth is detected 
(Becton Dickinson Diagnostic Instrument Systems, USA). All samples were allowed to 
be incubated for 6 weeks.  
 
An isolated mycobacterium was identified by the PCR and DNA-DNA hybridization 
technique using the GenoType Mycobacterium CM kit following the manufacturer’s 
instructions (Hain Lifescience, Germany). 
 
6.3.4 q PCR FOR HERPES VIRUSES 
6.3.4.1 NUCLEIC ACID PURIFICATION FROM THE SALIVA SAMPLES 
To investigate HSV1, HSV2, EBV, CMV, varicella zoster virus (VZV), and human 
herpes virus (HHV) 8, nucleic acid in 300 μl of all the saliva samples was 
simultaneously purified, along with 6 water samples as negative control. All samples 
were processed by the BioRobot MDx workstation using a QIAamp DNA extraction kit 
following the manufacturer’s protocol (Qiagen, UK). This method utilized the selective 
binding properties of a silica-based membrane. Purified DNA samples were then eluted 
in elusion buffer (AE) and were free from protein, nucleases and other contaminants or 
inhibitors. All samples were subsequently spiked with phocine herpes virus (PHV) 
DNA to act as internal control during qPCR test.  
 
6.3.4.2 HSV1, HSV2 AND VZV qPCR 
Multiplex real time amplification of HSV1, HSV2, and VZV DNA using glycoprotein 
B-specific primers was performed as described in chapter 2, section 2.2.3.4.  
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6.3.4.3 CMV qPCR 
 Real time amplification of CMV DNA using glycoprotein B-specific primers was 
performed according to the previously published method (Mattes et al., 2005).  
 
6.3.4.4 EBV qPCR 
 Real time amplification of EBV DNA using glycoprotein B-specific primers was 
performed as described in chapter 2, section 2.2.3.4.  
 
6.3.4.5 HHV8 qPCR 
Primers, probes, PCR conditions, and cycles were adopted from the previously 
published method (Stamey et al., 2001).  
 
6.3.4.6 PHV qPCR 
 Real time amplification of PHV DNA using glycoprotein B-specific primers was 
performed as internal control. The conditions of the PCR were described in chapter 2, 
section 2.2.3.4.  
 
6.3.5 IMMUNOASSAYS 
6.3.5.1 HSV1 ELISA 
To detect the presence of HSV1 IgG antibodies, a 100 μl of the 1/101 diluted serum 
samples were added to the recombinant-Gg1-antigen coated wells and then processed 
according to the enzyme-linked immunosorbent assay (ELISA) manufacturer’s 
instructions (Biokit, Spain). The samples were tested in duplicates along with seven 
control samples to validate the assay. According to the manufacturer’s instructions, the 
mean absorbance of the low positive control was calculated and considered to be the 
cut-off value. The samples’ absorbance was then divided by the cut-off value to give a 
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ratio absorbance/cut-off which is proportional to the concentration of the HSV1 IgG 
antibodies in each investigated specimen (Biokit, Spain). 
 
6.3.5.2 HSV2 ELISA  
The HSV2 IgG ELISA method is similar to HSV1 IgG ELISA apart from the fact that 
the wells were coated with recombinant-gG2-antigen instead of recombinant-gG1-
antigen (Biokit, Spain). 
 
6.3.5.3 VZV ELISA  
The VZV IgG ELISA method is similar to HSV1 and HSV2 IgG ELISA but the wells 
were coated with VZV antigen from partially purified extract of human fibroblast 
infected with VZV, strain ELLEN (ATCC) (Diamedix, USA). To determine the ELISA 
unit (EU)/ml, the following formula was used following the manufacturer’s instructions 
(absorbance of calibrator x absorbance of sample = EU/ml of sample).  
 
6.3.5.4 CMV ELFA 
An automated quantitative two-step enzyme immunoassay sandwich method with a 
final fluorescent detection, enzyme-linked fluorescent assay (ELFA), was employed to 
detect CMV IgG (bioMérieux, France). All of the assay steps were performed 
automatically by vitek immuno-diagnostic assay system (VIDAS) instrument according 
to the manufacturer’s instructions (bioMérieux, France). The instrument, using 
calibration curves that are stored by the machine, automatically calculated the results 
and expressed them in AU/ml.  
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6.3.5.5 EBV CLIA  
The quantification the IgG antibodies to EBV viral capside antigen (VCA) in the serum 
samples was performed on the LIAISON Analyzer using chemiluminescent 
immunoassay (CLIA) following the manufacturer’s instructions (DiaSorin, Italy). The 
samples were tested in duplicates, along with the calibrator and control samples to 
validate the assay. The analyser automatically calculated the antibody concentrations 
and expressed them as U/ml.  
 
6.3.5.6 HHV8 IFA  
A semi-quantification of the IgG antibodies to HHV8 in the serum samples was 
investigated by utilizing indirect fluorescent assay (IFA) following the manufacturer’s 
instructions (Advanced Biotechnologies, Columbia). The investigated samples were 
scored in relation to the positive and negative controls. Results were blindly recorded by 
two different investigators and then checked for consistency and re-evaluated if there 
were any discrepant results between the two investigators. 
 
6.3.6 STATISTICAL ANALYSIS 
The statistical power was calculated using the StatMate 2 program (GraphPad, USA). 
For the purpose of the viral analysis, the statistical power calculation was based on the 
previously published information about the prevalence of HSV1 in London in people of 
the age of 30 or above (54%) (Smith and Robinson, 2002). A sample size of 12 in each 
group has 95% power to detect an increase of 0.5 with a significant level (alpha) of 0.05 
(two tailed). However, one can use an unequal number in the samples of each of the 
investigated groups without losing any statistical power if the total number of 
investigated subjects is increased proportionally. For example, the statistical power 
from investigating a sample size of 12 in three different groups (total number 
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investigated 36) will be equal to investigating a sample size of 54 in one group, 28 in 
another, and 7 in the third group (total number investigated 89). 
 
Due to the extent and cost of the analysis performed for each sample for the 
bacteriological and mycobacterial identification, the author investigated a sample size in 
concordance with other published papers investigating the human oral microbiome 
(Farrell et al., 2012, Dang et al., 2012).  
 
The GraphPad Prism® statistical package was used in the data analysis (GraphPad 
Software Inc., USA). Mean, median, minimum, maximum, range, standard deviation 
(SD), standard error of mean (Sem) and percentages (%) were used to describe the data. 
The data were analysed by Mann-Whitney-U when comparing quantitative data of two 
groups, and Kruskal-Wallis when comparing quantitative data of more than two groups. 
Differences in the rate were analysed using Chi-square tests. Non-parametric 
multivariate analysis of variance (MANOVA) with Bonferroni post tests when 
comparing multiple variants in relation to different groups were also used.  
 
6.4 RESULTS  
6.4.1 ORAL MUCOSAL AND SALIVARY MICROBIAL LOAD  
There was no statistically significant difference in the microbial load colonizing the oral 
mucosa of orally active BS patients, orally inactive BS patients, RAS patients and HC 
volunteers (Kruskal-Wallis, p=0.2283). However, there was a slight increase in the 
bacterial load colonizing the ulcerative mucosa of orally active BS patients compared to 
the non-ulcerative mucosa of the same patients, but this difference was not statistically 
significant (Mann-Whitney, p=0.4595) (Figures 6.1 and 6.2).  
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Figure 6.1: The oral mucosal microbial load of orally active BS patients, orally inactive 
BS patients, RAS patients, and HC volunteers.  
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 Figure 6.2: The oral mucosal microbial load of ulcerated oral mucosa and non-ulcerated 
oral mucosa of orally active BS patients.  
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There was no statistically significant difference in the salivary microbial load of orally 
active BS patients, orally inactive BS patients, and RAS patients (Kruskal-Wallis, 
p=0.1216). There was an observed decrease in the salivary microbial load of RAS 
patients compared to HC volunteers. However, this difference was not statistically 
significant. Nevertheless, the salivary microbial load of the orally inactive BS patients 
was significantly decreased compared to HC volunteers (Mann-Whitney, p=0.0185) 
(Figure 6.3).  
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Figure 6.3: The salivary microbial load of orally active BS patients, orally inactive BS 
patients, RAS patients, and HC volunteers.  
 
6.4.2 ORAL AND SALIVARY MICROBIAL COMPLEXITY  
There was no statistically significant difference in the oral mucosal complexity in the 
four investigated groups (Kruskal-Wallis, p=0.1378). However, there was a noticeable 
increase in the complexity of the bacteria isolated from the ulcerative mucosa of orally 
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active BS patients compared to all the other groups investigated. Moreover, there was a 
noticeable increase in the complexity of the bacteria isolated from the ulcerative mucosa 
of orally active BS patients compared to the non-ulcerative mucosa of the same patients, 
but this difference was not statistically significant (Mann-Whitney, p=0.5532) (Figures 
6.4 and 6.5).  
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Figure 6.4: The oral mucosal microbial complexity in orally active BS patients, orally 
inactive BS patients, RAS patients, and HC volunteers.  
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Figure 6.5: The oral mucosal microbial complexity of ulcerated and non-ulcerated sites 
of orally active BS patients.  
 
Looking at the salivary microbial complexity in orally active BS patients, orally inactive 
BS patients, RAS patients, and HC volunteers, there was no statistically significant 
difference in the four investigated groups (Kruskal-Wallis, p=0.1555) (Figure 6.6). 
Mucosal Microbial Complexity of Orally Active BS patients
U
lc
er
at
iv
e 
m
uc
os
a
N
on
-u
lc
er
at
iv
e 
m
uc
os
a
0
2
4
6
8
10
Groups
N
u
m
b
e
r
 o
f 
b
a
c
te
r
ia
l 
sp
e
c
ie
s 
is
o
la
te
d
222 
 
Salivary Microbial Complexity
O
ra
lly
 A
ct
iv
e 
B
S
O
ra
lly
 I
na
ct
iv
e 
B
S
R
A
S
H
C
0
5
10
15
Groups
N
u
m
b
e
r
 o
f 
b
a
c
te
r
ia
l 
sp
e
c
ie
s 
is
o
la
te
d
 
Figure 6.6: The salivary microbial complexity of orally active BS patients, orally 
inactive BS patients, RAS patients, and HC volunteers.  
 
6.4.3 ORAL MUCOSAL MICROBIAL ANALYSIS 
The taxonomic proportion of species that were detected in the oral mucosal samples of 
subjects in each patient group were analysed from 905 successfully isolated, purified 
and identified microorganisms obtained by MALDI-TOF analysis from 81 different 
samples. Each sample was bacteriologically cultured on 7 different culture media and 
allowed to be incubated on 3 different growth environments to maximize the possibility 
of identifying all the culturable bacteria in each sample. From these 80 samples, 60 
different oral bacteria and 5 fungi were identified to the species level. There was great 
variability between individuals in each group and also between individuals in different 
groups. Interestingly, variability was also noticed in different sites (ulcerated and non-
ulcerated mucosa) in the same individual.  
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The microbial profile of the non-ulcerated mucosa in orally active BS patients was the 
most variable with 31 different bacterial species in 14 different bacterial genera 
identified as follows: Actinomyces odontolyticus, Candida albicans, Capnocytophaga 
sputigena, Corynebacterium durum, Gemella haemolysans, Kingella denitrificans, 
Kocuria palustris, Lactobacillus fermentum, Lactobacillus sp., Neisseria cinerea, 
Neisseria flavescens, Neisseria mucosa, Neisseria perflava, Prevotella melaninogenica, 
Rothia aeria, Rothia dentocariosa, Rothia mucilaginosa, Staphylococcus aureus, 
Staphylococcus epidermidis, Streptococcus australis, Streptococcus constellatus, 
Streptococcus gordonii, Streptococcus mutans, Streptococcus oralis, Streptococcus 
mitis, Streptococcus pseudopneumoniae, Streptococcus salivarius, Streptococcus 
sanguinis, Streptococcus vestibularis, Veillonella atypica, and Veillonella dispar. 
Rothia dentocariosa was statistically significantly more likely to colonize the non-
ulcerated mucosa of orally active BS patients compared to the ulcerated mucosa of 
orally active BS patients, ulcerated mucosa of RAS patients, and the oral mucosa of HC 
volunteers (MANOVA, p<0.05) (Figure 6.7).  
 
In total, 14 different genera were represented in the oral microbiome of the non-
ulcerated sites in orally active BS patients. In contrast, only 9 genera were detected in 
the HC volunteers’ oral mucosal microbiome. The oral microbiome of the non-ulcerated 
sites in orally active BS patients included all the genera detected in HC volunteers as 
well as Actionmyces, Candida, Haemophilus, Lactobacillus, and Prevotella. Neisseria 
and Veillonella were isolated more frequently from HC volunteers (Chi-square, 
p=0.0159: 88.9% vs 75% and p<0.0001: 22.2 vs 12.5% respectively) while Rothia 
showed higher representation in the non-ulcerated mucosa of orally active BS patients 
(Chi-square, p<0.0001: 87.5% vs 44.4%) (Figure 6.8).  
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The microbial profile of the ulcerated mucosa in orally active BS patients was slightly 
less diverse than that of the non-ulcerated mucosa, with 23 different bacterial species in 
12 different bacterial genera identified as follows: Actinomyces naeslundii, 
Capnocytophaga ochracea, Capnocytophaga sputigena, Corynebacterium durum, 
Gemella haemolysans, Haemophilus parainfluenzae, Kingella denitrificans, Neisseria 
cinerea, Neisseria flavescens, Neisseria macacae, Propionibacterium acnes, Rothia 
aeria, Rothia dentocariosa, Rothia mucilaginosa, Staphylococcus aureus, Streptococcus 
anginosus, Streptococcus cristatus, Streptococcus mutans, Streptococcus oralis, 
Streptococcus mitis, Streptococcus pseudopneumoniae, Streptococcus salivarius, and 
Streptococcus sanguinis. Rothia dentocariosa was statistically significantly less likely 
to colonize the ulcerated mucosa of orally active BS patients compared to the non-
ulcerated mucosa of orally active BS patients (MANOVA, p<0.05). Interestingly, 
colonization of the ulcerative mucosa of BS patients with Streptococcus salivarius was 
statistically significantly higher than of the ulcerative mucosa of RAS patients 
(MANOVA, p<0.05) (Figure 6.7).  
 
In total, 12 different genera were represented in the oral microbiome of the ulcerated 
sites in orally active BS patients. In contrast, only 9 genera were detected in the HC 
volunteers’ oral mucosal microbiome. The oral microbiome of the ulcerated sites in 
orally active BS patients included all the genera detected in HC volunteers as well as 
Actinomyces, Kocuria, and Propionibacterium. Neisseria and Veillonella were isolated 
more frequently from HC volunteers (Chi-square, p<0.000: 188.9% vs 63% and 
p<0.0001: 22.2 vs 13% respectively) while Rothia showed higher representation in the 
ulcerated mucosa of orally active BS patients (Chi-square, p=0.0069: 75% vs 44.4%) 
(Figure 6.8). However, the proportion of Rothia denticariosa in relation to the other 
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species of Rothia was less than that seen in the non-ulcerated sites of orally active BS 
patients (Figure 6.9). There was a noticeable shift towards Rothia mucilaginosa (50%) 
as it was isolated more frequently than Rothia denticariosa (37.5%) from the ulcer sites 
of orally active BS patients.  
 
The microbial profile of the oral mucosa in orally inactive BS patients was similar in 
complexity to that of those showing oral activity with 25 different bacterial species in 9 
different bacterial genera identified as follows: Actinomyces naeslundii, Candida 
africana, Candida albicans, Candida dubliniensis, Gemella haemolysans, Kingella 
denitrificans, Neisseria flavescens, Neisseria macacae, Neisseria mucosa, Neisseria 
perflava, Prevotella melaninogenica, Rothia aeria, Rothia dentocariosa, Rothia 
mucilaginosa, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus 
anginosus, Streptococcus australis, Streptococcus constellatus, Streptococcus gordonii, 
Streptococcus mutans, Streptococcus oralis, Streptococcus mitis, Streptococcus 
salivarius, and Streptococcus vestibularis.  
 
In total, 9 different genera were represented in the oral mucosal microbiome of the 
orally inactive BS patients; they included all the genera detected in HC volunteers, 
(excluding Capnocytophaga, Corynebacterium, and Veillonella) as well as 
Actionmyces, Candida, and Prevotella. Neisseria and Veillonella were isolated more 
frequently from HC volunteers (Chi-square, p=0.0009: 88.9% vs 44.4% and p<0.0001: 
22.2 vs 0% respectively) while Rothia showed higher representation in the oral mucosa 
of orally inactive BS patients (Chi-square, p<0.0001: 77.8% vs 44.4%) (Figure 6.8).  
 
The microbial profile of the oral mucosa in HC volunteers was less diverse in 
comparison to the oral microbial profile of BS patients of both orally active and orally 
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inactive status, with 16 different bacterial species in 9 different bacterial genera 
identified as follows: Capnocytophaga haemolytica, Corynebacterium durum, Gemella 
haemolysans, Kingella denitrificans, Neisseria flavescens, Neisseria mucosa, Rothia 
aeria, Rothia dentocariosa, Rothia mucilaginosa, Staphylococcus aureus, 
Staphylococcus epidermidis, Streptococcus anginosus, Streptococcus australis, 
Streptococcus gordonii, Streptococcus mitis, Streptococcus salivarius, and Veillonella 
parvula (Figure 6.7). 
 
The microbial profile of the oral mucosa of RAS patients was less diverse in 
comparison to the oral microbial profile of BS patients of both orally active and orally 
inactive status, with 17 different bacterial species in 9 different bacterial genera 
identified as follows: Actinomyces naeslundii, Capnocytophaga ochracea, Haemophilus 
influenzae, Haemophilus parainfluenzae, Lactobacillus gasseri, Lactobacillus 
paracasei, Neisseria flavescens, Rothia dentocariosa, Rothia mucilaginosa 
Staphylococcus hominis, Staphylococcus epidermidis, Streptococcus cristatus, 
Streptococcus gordonii, Streptococcus mutans, Streptococcus oralis, Streptococcus 
mitis, and Streptococcus salivarius. Similarly to the pattern observed in BS patients’ 
oral mucosa, Rothia dentocariosa was statistically significantly more likely to colonize 
the non-ulcerated mucosa of RAS patients compared to the ulcerative mucosa of RAS 
patients (MANOVA, p<0.05). Likewise, Streptococcus mitis was statistically 
significantly more likely to colonize the non-ulcerated mucosa of RAS patients 
compared to ulcerative mucosa of RAS patients (MANOVA, p<0.05) (Figure 6.7). 
 
In total, 9 different genera were represented in the microbiome of oral mucosa of RAS 
patients and they matched only 5 genera from those that were detected in HC volunteers 
(Capnocytophaga, Neisseria, Rothia, Staphylococcus, and Streptococcus). 
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Corynebacterium, Gamella, Kingella and Veillonella were missing from the RAS non-
ulcerated oral mucosal microbiome. However, Actionmyces, Haemophilus, 
Lactobacillus, and Prevotella appeared to replace them. Neisseria and Veillonella were 
isolated more frequently from HC volunteers (Chi-square, p<0.0001: 88.9% vs 25% and 
p<0.0001: 22.2 vs 0% respectively) while Rothia showed slightly higher representation 
in the oral mucosa of RAS patients (Chi-square, p=0.0564: 50% vs 44.4%) (Figure 6.8).  
 
There was an observed increase in the colonization of orally active BS patients’ 
ulcerated oral mucosa sites with Streptococcus sanguinis compared to HC volunteers’ 
oral mucosa (Chi-square, p<0.0001: 25% vs 0%). A much more diverse range of 
Streptococcus species was isolated from BS patients’ oral mucosa, with 10 different 
species isolated from the non-ulcerated oral mucosa of orally active BS patients, 8 
different species isolated from the ulcerated oral mucosa of orally active BS patients, 
and 10 different species isolated from the non-ulcerated oral mucosa of orally inactive 
BS patients. On the other hand, only 5 different Streptococcus species were isolated 
from the oral mucosa of HC volunteers, and 6 from the oral mucosa of RAS patients.  
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Figure 6.7: The taxonomic proportion of the oral mucosal microbiome at the species 
level in orally active BS patients, orally inactive BS patients, HC volunteers, and RAS 
patients. A much more diverse oral microbial profile was observed in BS patients’ oral 
mucosa.  
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Figure 6.8: The taxonomic proportion of the oral mucosal microbiome at the genus level 
in orally active BS patients, orally inactive BS patients, HC volunteers, and RAS 
patients. A much more diverse oral microbial profile was observed in BS patients’ oral 
mucosa.  
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Figure 6.9: Rothia in ulcer sites of orally active BS patients. The proportion of Rothia 
denticariosa in relation to the other species of Rothia was less than that seen in the non-
ulcerated sites. Data presented in percentages.  
 
6.4.4 SALIVARY MICROBIAL ANALYSIS 
The taxonomic proportion of species that were detected in the salivary samples of 
subjects in each patient group were analysed. Similarly to the pattern observed in the 
oral mucosal microbial analysis, there was great variability between individuals in each 
group and also between individuals in different groups.  
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The salivary microbial profile of orally active BS patients was complex, with 29 
different bacterial species in 14 different bacterial genera identified as follows: 
Actinomyces naeslundii, Actinomyces odontolyticus, Candida albicans, Candida 
metapsilosis, Candida parapsilosis, Capnocytophaga ochracea, Capnocytophaga 
sputigena, Escherichia coli, Gemella haemolysans, Haemophilus parainfluenzae, 
Kingella denitrificans, Kocuria rhizophila, Neisseria flavescens, Neisseria perflava, 
Prevotella buccae, Prevotella oralis, Rothia aeria, Rothia dentocariosa, Rothia 
mucilaginosa, Staphylococcus aureus, Staphylococcus capitis, Staphylococcus 
epidermidis, Streptococcus anginosus, Streptococcus australis, Streptococcus cristatus, 
Streptococcus mitis, Streptococcus salivarius, Streptococcus sanguinis, and Veillonella 
parvula (Figure 6.10).  
 
In total, 14 different genera were represented in the salivary microbiome of the orally 
active BS patients. In contrast, only 9 genera were detected in the saliva of HC 
volunteers. The salivary microbiome of the orally active BS patients included all the 
genera detected in HC volunteers (except Haemophilus) as well as Actinomyces, 
Candida, Echerichia, Gamella, Kocuria, and Prevotella. Neisseria were isolated more 
frequently from HC volunteers (Chi-square, p<0.0001: 100% vs 66.7%) while 
Staphylococcus showed higher representation in the orally active BS patients’ saliva 
(Chi-square, p=0.0002: 55.6% vs 33%) (Figure 6.11).  
 
The salivary microbial profile of orally inactive BS patients was slightly less complex 
compared to the orally active BS patients, with 24 different bacterial species in 11 
different bacterial genera identified as follows: Abiotrophia defectiva, Candida 
africana, Candida albicans, Candida dubliniensis, Capnocytophaga ochracea, Kingella 
denitrificans, Lactobacillus paracasei, Lactobacillus rhamnosus, Neisseria flavescens, 
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Neisseria mucosa, Neisseria perflava, Prevotella buccae, Rothia aeria, Rothia 
dentocariosa, Rothia mucilaginosa, Staphylococcus aureus, Streptococcus anginosus, 
Streptococcus australis, Streptococcus cristatus, Streptococcus gordonii, Streptococcus 
mitis, Streptococcus salivarius, Streptococcus sanguinis, and Veillonella atypica (Figure 
6.10).  
 
Topical and/or systemic steroid treatment rate was 68% in BS patients who had 
Candida albicans isolated from their saliva at the time of the sampling (Chi-square, 
p=0.0038). Therefore, unsurprisingly, Candida albicans was statistically significantly 
more isolated from the saliva of orally inactive BS patients compared to HC volunteers 
and RAS patients (MANOVA, p>0.05). 
 
In total, 11 different genera were represented in the salivary microbiome of the orally 
inactive BS patients. In contrast, only 9 genera were detected in the saliva of HC 
volunteers. The salivary microbiome of the orally inactive BS patients included all the 
genera detected in HC volunteers (except Haemophilus) as well as Abiotrophia, 
Candida, and Prevotella. Neisseria were isolated more frequently from HC volunteers 
(Chi-square, p<0.0001: 100% vs 63.6%) (Figure 6.11).  
 
The salivary microbial profile of HC volunteers included 25 different bacterial species 
in 9 different bacterial genera identified as follows: Capnocytophaga haemolytica, 
Capnocytophaga ochracea, Haemophilus parainfluenzae, Kingella denitrificans, 
Lactobacillus paracasei, Neisseria elongata, Neisseria flavescens, Neisseria mucosa, 
Neisseria perflava, Rothia aeria, Rothia dentocariosa, Rothia mucilaginosa, 
Staphylococcus aureus, Staphylococcus capitis, Staphylococcus epidermidis, 
Streptococcus anginosus, Streptococcus australis, Streptococcus dysgalactiae, 
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Streptococcus gordonii, Streptococcus oralis, Streptococcus peroris, Streptococcus 
mitis, Streptococcus salivarius, Veillonella atypica, and Veillonella parvula (Figure 
6.10). 
 
The salivary microbial profile of RAS volunteers was less complex than the salivary 
microbial profile of BS patients and HC volunteers, with 18 different bacterial species 
in 10 different bacterial genera identified as follows: Actinomyces naeslundii, 
Actinomyces odontolyticus, Haemophilus parainfluenzae, Klebsiella oxytoca, 
Lactobacillus paracasei, Neisseria flavescens, Neisseria perflava, Neisseria subflava, 
Prevotella nigrescens, Rothia dentocariosa, Staphylococcus pasteuri, Staphylococcus 
warneri, Streptococcus anginosus, Streptococcus gordonii, Streptococcus mitis, 
Streptococcus salivarius, Streptococcus sanguinis, and Veillonella atypica (Figure 
6.11).  
 
There was an observed increase in the salivary Streptococcus sanguinis in orally active 
BS patients (44.4%) compared to orally inactive BS patients (9.1%) (Chi-square, 
p<0.0001), RAS patients (0%) (Chi-square, p<0.0001), and HC volunteers (20%) (Chi-
square, p<0.0001). Contradicting the pattern observed in the oral mucosal microbial 
analysis, the salivary Streptococcus species were similar in diversity in orally active BS 
patients (6 different species), orally inactive BS patients (7 different species), HC 
volunteers (8 different species), and RAS patients (5 different species).  
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Figure 6.10: The taxonomic proportion of the salivary microbiome at the species level 
in orally active BS patients, orally inactive BS patients, HC volunteers, and RAS 
patients.  
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Figure 6.11: The taxonomic proportion of the salivary microbiome at the genus level in 
orally active BS patients, orally inactive BS patients, HC volunteers, and RAS patients.  
 
6.4.5 MYCOBACTERIAL ANALYSIS 
Two different species of non-tuberculous mycobacteria (Mycobacterium gordona and 
Mycobacterium chelonae) were isolated from saliva samples of four orally active BS 
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patients. Mycobacterium avium intracellulare was isolated from one orally inactive BS 
patient’s saliva. There was no mycobacterium isolated from any of the brush biopsies of 
orally active and orally inactive BS patients. Mycobacterium gordonii and 
Mycobacterium Kansasii were isolated from two HC volunteers’ saliva samples. 
Mycobacterium gordonii was isolated from one orally inactive RAS patient’s saliva 
sample.  
 
6.4.6 HERPES VIRUS ANALYSIS  
6.4.6.1 HSV1 
There was no statistically significant difference in the HSV1 IgG level of expression 
between BS patients, RAS patients, and HC volunteers (Kruskal-Wallis, p=0.6697). 
Mean and standard deviation were as follows: BS patients (0.87 ratio absorbance/cut-off 
± 0.92), RAS patients (0.75 ratio absorbance/cut-off ± 0.89), and HC volunteers (0.96 
ratio absorbance/cut-off ± 0.98). There was also no statistically significant difference in 
the prevalence of HSV1 infection between the three investigated groups, with positivity 
rate ranges between 46% and 57% (Chi-square, p=0.2892) (Table 6.1). Only one BS 
patient’s saliva was positive for HSV1 by qPCR.  
 
6.4.6.2 HSV2 
There was no statistically significant difference in HSV2 IgG level of expression 
between BS patients, RAS patients, and HC volunteers (Kruskal-Wallis, p=0.9297). 
Mean and standard deviation were as follows: BS patients (0.16 ratio absorbance/cut-off 
± 0.36), RAS patients (0.21 ratio absorbance/cut-off ± 0.45), and HC volunteers (0.12 
ratio absorbance/cut-off ± 0.22). There was also no statistically significant difference in 
the prevalence of HSV2 infection between BS patients and HC volunteers (Chi-square, 
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p=0.2507) and BS patients compared to RAS patients (Chi-square, p=0.2507) (Table 
6.1). The salivary HSV2 viral load was negative for all three groups.  
 
6.4.6.3 VZV 
There was no statistically significant difference in the VZV IgG level of expression 
between BS patients, RAS patients, and HC volunteers (Kruskal-Wallis, p=0.6054). 
Mean and standard deviation were as follows: BS patients (98.7 EU/ml ± 35.1), RAS 
patients (91.9 EU/ml ± 50.6), and HC volunteers (106.8 EU/ml ± 38.5). There was also 
no statistically significant difference in the prevalence of VZV infection between the 
three investigated groups, with positivity rate ranges between 86% and 100% (Chi-
square, p=0.6978) (Table 6.1). The salivary VZV viral load was negative for all three 
groups. 
  
6.4.6.4 CMV 
There was a statistically significant decrease in the CMV IgG level of expression in BS 
patients’ samples compared to those of RAS patients and HC volunteers (Kruskal-
Wallis, p=0.0450). Mean and standard deviation were as follows: BS patients (30.67 
AU/ml ± 35.2), RAS patients (55.6 AU/ml ± 46.8) and HC volunteers (48.32 AU/ml ± 
37.9) (Figure 6.12). Nevertheless, there was no statistically significant difference in the 
prevalence of CMV infection between the three investigated groups, with a positivity 
rate as follows: BS patients (50%), RAS patients (71%) HC volunteers (64%) (Chi-
square, p=0.2206) (Table 6.1). The salivary CMV viral load was negative for all three 
investigated groups. 
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Figure 6.12: CMV IgG level of expression.  
 
6.4.6.5 EBV 
There was no statistically significant difference in the EBV IgG level of expression 
between BS patients, RAS patients, and HC volunteers (Kruskal-Wallis, p=0.9742). 
Mean and standard deviation were as follows: BS patients (412.3 U/ml ± 285.0), RAS 
patients (399.4 U/ml ± 345.8), and HC volunteers (403.2 U/ml ± 255.5). There was also 
no statistically significant difference in the prevalence of EBV infection between the 
three investigated groups, with positivity rate ranges between 86% and 96% (Chi-
square, p=0.1181) (Table 6.1).  
 
Interestingly, there was a statistically significant increase in salivary shedding of EBV 
in the saliva of the BS patients compared to HC volunteers (Mann-Whitney, p=0.0057). 
However, there was no statistically significant difference between BS patients and RAS 
patients (Chi-square, p=0.4407). Mean and standard deviation of the absolute shedding 
of the virus were as follows: BS patients (2.3 log ± 2.3), RAS patients (1.4 log ± 2.1), 
and HC volunteers (0.89 log ± 1.7) (Figure 6.13). There was also a statistically 
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significant increase in the positivity rate in the BS patients (55%) compared to HC 
volunteers (25%) (Chi=square, p<0.0001), but not RAS patients (43%) (Chi=square, 
p=0.0926) 
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Figure 6.13: The salivary shedding of EBV.  
 
There was no statistically significant difference in the EBV salivary shedding of orally 
active BS patients (n=14) compared to orally inactive BS patients (n=40) (Mann-
Whitney, p=0.135). Mean and standard deviation of the absolute shedding of the virus 
were as follows: orally active BS patients (1.8 log ± 2.4) and orally inactive BS patients 
(2.8 log ± 2.4). There was also no statistically significant difference in the positivity rate 
in orally active BS patients (43%) compared to orally inactive BS patients (65%) (Chi-
square, p=0.1348) (Figure 6.14).  
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Figure 6.14: The salivary shedding of EBV in orally active BS patients compared to 
orally inactive BS patients.  
 
6.4.6.6 HHV8 
There was no statistically significant difference in the HHV8 IgG level of expression 
between BS patients, RAS patients, and HC volunteers (Kruskal-Wallis, p=0.3150) 
(Figure 6.15). The HHV8 immunoassay used in this study is a semi-quantitative assay, 
as mentioned before in section 6.3.5.6. Six BS patients’ samples and one HC 
volunteer’s sample gave nonspecific binding and therefore were excluded from the 
analysis (Figure 6.16). The prevalence of the HHV8 is reported in table 6.1. Salivary 
HHV8 qPCR was negative for all three investigated groups.  
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Figure 6.15: HHV8 IgG level of expression.  
 
 
Figure 6.16: Nonspecific binding of HHV8 infected cells to molecules in the serum 
samples of a BS patient (IFA). 
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Table 6.1: Prevalence of herpes virus infections in BS patients, RAS patients, and HC 
volunteers. 
 BS (n=54) RAS (n=7) HC (n=28) 
HSV1 (29/54) 53.7% (14/28) 50% (3/7) 42.9% 
HSV2 (5/54) 9% (1/7) 14% (1/28) 4% 
CMV (27/54) 50% (5/7) 71% (19/28) 64% 
EBV (48/54) 89% (6/7) 85.7% (27/28) 96.4% 
VZV (54/54) 100% (6/7) 85.7% (28/28) 100% 
HHV8 (14/44) 32% (3/7) 42% (13/27) 48% 
CMV: cytomegalovirus; EBV: Epstein-Barr virus; HHV8: human herpes virus 8; 
HSV1: herpes simplex virus 1; HSV2: herpes simplex virus 2; VZV: varicella voster 
virus.  
 
6.4.6.7 VALIDATION OF THE IMMUNOASSAY 
All samples were analysed in duplicate. Negative control, positive control and calibrator 
samples were tested each time along with the investigated samples. In order to validate 
the results, the value of these control samples was checked against the validation range 
suggested by the manufacturer’s instructions. For the HHV8 IFA, the slide was blindly 
evaluated by two different investigators followed by re-evaluation of the discrepant 
samples. 
 
6.4.6.8 VALIDATION OF THE qPCR 
All extracted DNA from clinical samples and negative control samples was spiked with 
PHV as an internal control, according to the method described in chapter 2, section 
2.2.3.4. Samples were then tested by qPCR for the presence of PHV. All samples were 
positive for PHV, which excluded the presence of PCR inhibitors in the reaction. 
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6.5 DISCUSSION AND CONCLUSION  
It is estimated that the human oral cavity may be inhabited by about 700 different 
aerobic and anaerobic bacterial species, which produce a huge number of different 
pathogen-associated molecular patterns (PAMPs) such as peptides and polysaccharides 
that can interact with each other and the host immunity to maintain a stable symbiotic 
microenvironment during health (Bik et al., 2006, Paster et al., 2001). If this balance is 
disturbed, the symbiotic relationship will shift to allow the induction of a pathogenic 
process leading to various disease symptoms.  
 
It is well appreciated that the human microbiome includes a “core” microbiome which 
is common between most individuals and a “variable” microbiome that evolves in 
response to lifestyle, and phenotypic and genotypic differences (Bik et al., 2006, 
Turnbaugh et al., 2007). The bacterial genera and species that dominate the mouth vary 
considerably between healthy individuals. However, in general the healthy human 
mouth is inhabited by nine main bacterial phyla (Firmicutes, Proteobacteria, 
Bacteroidetes, Actionbacteria, Fusobacteria, TM7, Spirochaetes, and Synergistes) (Bik 
et al., 2010). On the genera level, Streptococcus is known to be the most abundant 
genus, followed by Haemophilus, Neisseria, Prevotella, Veillonella, and Rothia (Figure 
6.17).  
 
Interestingly, recently there are data indicating that the oral microbiome changes 
considerably in certain chronic diseases such as pancreatic disease and inflammatory 
bowel disease, offering the potential for using the salivary microbiome as useful non-
invasive biomarkers (Docktor et al., 2012, Farrell et al., 2012). In addition, there is 
some evidence of the impact of the human immunodeficiency virus (HIV) infection and 
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its treatment with antiretroviral medication on the community structure of the oral 
microbiome (Dang et al., 2012).  
 
 
 Figure 6.17: Oral community members. The inner circle highlights the bacterial genera 
found in 100% of the investigated subjects in the 2010 study by Bik et al. The genera in 
the second circle were present in 51%–99% of subjects, followed by the third circle 
(21%–50%) and the fourth circle (1%–20%) [source: (Bik et al., 2010)].  
 
This part of the thesis is the first study to investigate the oral and salivary microbiome 
of BS patients in great depth. There is some evidence in the literature pointing towards a 
possible increase in the Streptococcus load and the existence of an unfavourable shift in 
the cutaneous and conjunctival flora (Gunduz et al., 2008, Hatemi et al., 2004, Isogai et 
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al., 1990, Lehner et al., 1991). The author observed a decrease in the oral mucosal 
microbial load in orally active BS patients, although there was a tendency for increased 
complexity and diversity within the microbial community isolated from these patients. 
The phyla Actinobacteria including the genera Rothia, Actinomyces, and 
Propionibacterium was represented more frequently in BS patients and RAS patients 
compared to HC volunteers. On the other hand, Neisseria and Veillonella were more 
represented in HC volunteers. Furthermore, the ulcer sites of orally active BS patients 
and RAS patients seemed to be less able to support the growth and multiplication of 
Rothia dentocariosa.  
 
Interestingly, the ulcer sites of BS patients seemed to be colonized with Streptococcus 
more frequently than the ulcer sites of RAS patients. Also the complexity of the 
Streptococcus community was enhanced in the oral mucosa of BS patients in general. In 
concordance with the published study investigating the bacterial diversity in aphthous 
ulcers, Prevotella was isolated more frequently in RAS patients’ oral mucosa (Marchini 
et al., 2007). Indeed, the genera Prevotella was also more frequently isolated from BS 
patients. There was also an increase in the salivary Candida albicans in BS patients. 
However, it is evidenced in the literature that the topical and systemic application of 
corticosteroid can decrease the salivary total IgA; therefore it is not unprecedented to 
observe an increase in Candida albicans colonization in a patient cohort that is 
frequently treated with topical and systemic preparations of corticosteroid (68%) 
(Fukushima et al., 2005).  
 
There was no statistically significant difference in the prevalence of HSV1, HSV2, 
VZV, and HHV8 in BS patients compared to HC volunteers and RAS patients. 
Moreover, the salivary viral load of these viruses was negative in the three investigated 
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groups, apart from only one BS patient who was positive for HSV1. These results 
contradict some of the earlier studies especially regarding HSV1 prevalence, but the 
validated methodology used in this study along with the bigger cohort substantiate the 
previous published results (Denman et al., 1980, Eglin et al., 1982, Lee et al., 1996, 
Nomura et al., 1998). In addition, our results are supported by the fact that BS was not 
successfully treated by administration of high doses of acyclovir in association with 
plasma exchanges or treatment with acyclovir alone (Davies et al., 1988). 
 
There was a statistically significant decrease in the level of expression of CMV IgG in 
the serum samples of BS patients. This result is in concordance with the previously 
published study (Lee et al., 2005). Interestingly, the prevalence of CMV in our BS 
patients was only 50%, while a much higher prevalence of the CMV infection was 
reported from countries along the “Silk Route”, reaching 97% in those aged between 17 
and 40 (Uyar et al., 2008). The initial sensing of CMV is suggested to be through toll-
like receptor (TLR) 1/2 heterodimer (Sato et al., 2006). Given the known influence of 
TLR on the adaptive immune response modulation, it is very possible that the observed 
decrease in the CMV IgG is a consequence of the previously mentioned potential 
dysfunction of the TLR1/2 heterodimer in BS patients (Palm and Medzhitov, 2009). 
Therefore, a status of increased susceptibility to CMV infection is expected in those 
patients. 
 
The prevalence of EBV in BS patients was comparable to that of HC volunteers and 
RAS patients. However, the salivary viral load of BS patients was significantly higher 
compared to HC volunteers, but similar to RAS patients. Interestingly, the initial 
sensing of EBV is suggested to be through TLR2 independently from TLR1 or TLR6 
(Trinchieri and Sher, 2007). It is also documented that the released EBV-encoded 
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dUTPase from infected cells into the extracellular environment acts as a ligand for 
TLR2, resulting in the classical signalling cascade of TLRs activating nuclear factor 
kappa B (NFκβ) and inducing the production of pro-inflammatory cytokines such as 
interleukin 6 (IL6) and tumour necrosis factor alpha (TNFα) (Ariza et al., 2009). IL6 in 
turn supports the latent infection and persistence of EBV through its potent activation 
effect on signal transducer and activator of transcription (STAT) 3 gene signalling that 
regulates the Epstein-Barr nuclear antigen (EBNA) 1 transcription, which plays a 
crucial role in the maintenance of the EBV episome in infected cells (Tsao et al., 2012). 
Interestingly, enhanced inflammatory reaction is a recognized pathological feature of 
BS with well-recorded high serum pro-inflammatory cytokine levels such as TNFα and 
IL6 (Evereklioglu et al., 2002). 
 
In conclusion, the lower level of expression of CMV IgG is of great interest as it 
correlates with the previously investigated defect in the TLR1/2 heterodimer function 
that acts as the initial receptor sensing CMV. Furthermore, despite the uncertainty about 
whether the reported differences in the microbiome in health and disease are of a 
causative or reactive nature, restoring the balance of these differences might prove to be 
of great importance in treating the oral ulceration and controlling the immunological 
response in BS patients and RAS patients.  
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CHAPTER 7 
 DISCUSSION 
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Behçet’s syndrome (BS) is a multi-systemic immune-related disease with major 
systemic involvement which may result in blindness, stroke, and major vascular 
accident (Davatchi et al., 2010b). It is a debilitating chronic disease that severely affects 
patients’ quality of life (QoL) (Fortune, 2003, Mumcu et al., 2009b, Bernabe et al., 
2010). However, it was not clear from the available literature whether the cross-cultural 
differences could modify the impact of this disease on patients’ quality of life (QoL). 
Moreover, the effect of the oral health status on the patients’ perception of their disease 
burden was of particular interest.  
 
Although, BS is markedly prevalent in areas surrounding the old “Silk Road” trading 
routes in the Middle East and Central Asia (Davatchi et al., 2010b), recently it was 
documented in the literature that its prevalence in other areas around the world is greater 
than previously thought (Yazici et al., 2008). Furthermore, the prevalence of BS in the 
UK was estimated to be 0.65/100,000 (Chamberlain, 1977, Dejaco et al., 2009). Indeed, 
the author documented that over a 6-year period there were 153 well-defined BS 
patients enrolled at two of the UK’s centres for the management and care of BS patients. 
Therefore, increasing the awareness of the disease among health care professionals and 
the public is mandatory.  
 
BS patients most frequently suffer from recurrent oral ulceration, which is usually the 
initial sign of the disease. Because of this observation, it is thought that the oral 
environment may play a very important role in the aetiology and pathogenesis of the 
disease (Davatchi et al., 2010b). To date the consensus is that BS is triggered by a 
profound inflammatory response to an undefined environmental factor in a genetically 
susceptible host (Lehner, 1999). Therefore, in well-defined cohorts, investigating the 
inter-relationship between the oral microbiome and the relevant aspects of the innate 
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and adaptive immune response was considered a key to understanding the capacity of 
these patients to respond to microbial insult.  
 
This thesis focused on four main areas: (1) studying the different symptoms of BS 
patients along with the treatment protocol used in two of the main centres for BS 
patients’ management and care in the UK; (2) investigating the oral health status and 
QoL of BS patients from two different ethnic origins; (3) examining the capacity of the 
BS patients’ oral mucosa for expressing the different splice variants of toll-like 
receptor2 (TLR2) and toll-like receptor4 (TLR4); and (4) identifying the oral 
microbiome of BS patients. 
 
7.1 DISCUSSION 
7.1.1 BEHÇET’S SYNDROME PATIENT COHORT IN THE UK 
The most frequent symptoms in the UK BS patient cohort were mucocutaneous, 
rheumatological, and ocular manifestations. Oral ulceration was reported in 100% of 
investigated cases for the reason that all BS patients were diagnosed according to the 
International Study Group (ISG) criteria (Lancet, 1990). The UK rate of genital 
ulceration (73.9%) was greater than that reported in Iran (65%) and Germany (64%), 
similar to that of Japan (73%), but less than that of China (76%) and Korea (83%). 
Interestingly, the UK rate of ocular involvements (68.6%) was similar to that reported in 
Japan (69%), but greater than that reported in Iran (55%), China (35%), Korea (51%), 
and Germany (53%). Likewise, the UK rheumatological manifestations (79.1%) were 
remarkably higher than those reported in Iran (33%), Japan (57%), China (30%), Korea 
(38%), and Germany (53%) (Sachetto et al., 2011, Salvarani et al., 2007, Calamia et al., 
2009, Davatchi et al., 2010c, Davatchi et al., 2010b, El Menyawi et al., 2008).  
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The systemic corticosteroid was mostly used as emergency treatment during relapsed 
episodes only (37.9%). The frequent use of colchicine (54.2%) reflected the high rate of 
rheumatological (79.1%) and dermatological manifestations (85.6%) observed in this 
cohort of BS patients. The use of azathioprine was also elevated (43.8%), reflecting the 
high rate of ocular manifestations (68.6%) recorded in BS patients in the UK. Only two 
patients from the 153 cases had lost their useful eyesight as a complication of their 
disease. This might reflect the success of the treatment protocol used. However, it might 
also reflect the nature of the cohort (68% female and 60.8% of Caucasian ethnic origin). 
Indeed, it was documented previously that male BS patients have a worse visual 
prognosis compared to female patients. In addition, poor vision was reported more 
frequently in relation to BS patients in countries such as Japan, India and Iran compared 
to those from the UK, Tunisia, Germany, Greece, Turkey, and Italy (Kitaichi et al., 
2007). 
  
7.1.2 ORAL HEALTH STATUS AND QUALITY OF LIFE ANALYSIS OF 
BEHÇET’S SYNDROME PATIENTS 
The oral health impact profile 14 (OHIP-14) that was used in this part of the thesis was 
previously validated and proven to be a reliable tool in oral disease as a patient-centred 
outcome measure (McGrath et al., 2003, Mumcu et al., 2006, Mumcu et al., 2007a). By 
using this tool, it was proven that the oral health status of BS negatively affects the QoL 
of patients from the UK to a similar extent to those from Turkey. It was also 
documented in the previously published literature that BS affects the QoL similarly to 
other chronic conditions such as multiple sclerosis and arthritis (Bernabe et al., 2010).  
 
An increase in the number of oral ulcers in BS patients from the UK was observed 
compared to patients from Turkey. However, this might reflect a referral bias as the UK 
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patients were recruited from two of the main tertiary referral centres in the UK for BS 
patient management and care, where the most complicated cases are expected to be 
referred. The sulcus bleeding index (SBI) and periodontal probing depth (PPD) in the 
Turkish BS cohort were higher compared to the BS patient cohort from the UK. This 
fact can be explained by the reported lower utilization rate of dental services by the 
Turkish BS patients. 
 
A statistically higher score in all the oral health indices except the plaque index (PI) was 
observed in the UK BS patient cohort compared to healthy control (HC) volunteers. On 
the other hand, there were no statistical differences between BS and recurrent aphthous 
stomatitis (RAS) patients in all the measured indices. This can be due to the difficulty in 
maintaining good oral hygiene during the recurrent attacks of oral ulceration or possibly 
a status of increased susceptibility to oral pathogens in both disease groups (BS and 
RAS). However, the fact that the oral health status of BS and RAS patients was poorer 
than HC volunteers, despite the equal PI, might implicate a possible impairment in the 
immune responses to oral pathogens and/or commensals in both disease groups, leading 
to more susceptibility to dental and periodontal disease.  
 
7.1.3 ORAL MUCOSAL EXPRESSION OF TOLL-LIKE RECEPTORS 2 AND 4 
TLR2 and TLR4 messenger ribonucleic acid (mRNA) expression increases significantly 
in the oral mucosa of BS patients during the relapsed phase. This result is consistent 
with another study that showed elevated expression of TLR2 and TLR4 in the 
peripheral blood mononuclear cells (PBMCs) of active BS patients (Do et al., 2008).  
 
An investigation into the different mRNA splice variants of TLR2 and TLR4 concluded 
with the following points. (1) TLR2 mRNA variant b, which is known to be able to 
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translated to the full-length protein, was particularly high in relapsed BS patients’ oral 
mucosa. (2) TLR2 mRNA variant d, one of the unusual splice variant possibly affecting 
the stability of the mRNA, was predominantly elevated in relapsed BS patients’ oral 
mucosa. (3) TLR2 mRNA variant e was also elevated in relapsed BS patients’ oral 
mucosa, potentially highlighting the high monocyte infiltration in the non-lesional oral 
mucosa of these patients. (4) TLR4 mRNA splice variant 3 was significantly elevated in 
relapsed BS patients’ oral mucosa; this splice variant has extra exon (compared to splice 
variant 1), which results in a frameshift and an early stop codon, and the translated 
protein from this splice variant is expected to be significantly truncated and a candidate 
for nonsense decay. (6) TLR4 mRNA splice variant 4 was also elevated in relapsed BS 
patients’ oral mucosa. TLR4 mRNA splice variant 4 lacks an exon (compared to variant 
1), resulting in a frameshift and an early stop codon; the translated protein of this splice 
variant is also expected to be significantly truncated and a candidate for nonsense decay.  
 
The total protein expression of TLR2 and TLR4 was not raised during relapsed BS 
compared to the non-relapsed phase, confirming the expected defect in the translation 
due to the observed elevated level of expression of the unusual mRNA splice variants of 
TLR2 and TLR4. The protein characterization also established the presence of multiple 
isoforms for TLR2 and TLR4. At the same time, the abundance of band 35kDa of TLR4 
in relapsed BS patients may indicate either a defect in the non-sense decay mechanism 
or enhanced proteolysis in this cohort.  
 
The decrease in the BS PBMCs’ response upon treatment with TLR1/2 agonist might 
highlight a defect in the heterodimer formation between these two receptors. These 
results are consistent with a published study illustrating the decrease in TLR2 
expression in PBMCs upon treatment with lipopolysaccharide (LPS) and heat shock 
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protein (HSP) (Yavuz et al., 2008). In addition, the dampened response of BS PBMC 
TLR4 upon stimulation with its agonist could be explained by the higher level of TLR4 
mRNA variant 3 and 4 in relapsed BS patients.  
 
7.1.4 THE ORAL MICROBIOME OF BEHÇET’S SYNDROME PATIENTS 
There was an observed decrease in the oral mucosal microbial load in orally active BS 
patients although there was a tendency for increased complexity and diversity within the 
microbial community isolated from these patients, with an observed shift towards 
Actinobacteria phyla including Rothia, Actinomyces, and Propionibacterium, and 
Bacteroidetes phyla, in particular Prevotella. Moreover, some of the very common 
commensal bacteria such as Neisseria, and Veillonella were more represented in HC 
volunteers than in BS patients. This shift might explain the previously observed less 
favourable oral health status in BS patients compared to HC volunteers despite the fact 
that their PI was very similar. It is also worth mentioning that a very similar oral health 
status was observed in RAS patients; however, RAS patients’ oral microbiome was less 
diverse despite showing a very similar microbiological shift compared to BS patients. 
Furthermore, the ulcer site of orally active BS patients and RAS patients seemed to be 
less able to support the growth and multiplication of Rothia dentocariosa.  
 
In concordance with the previously published data, the ulcer sites of BS patients seemed 
to be colonized with Streptococcus more frequently than the ulcer sites of RAS patients. 
Also, the complexity of the Streptococcus community was enhanced in the oral mucosa 
of BS patients in general (Isogai et al., 1990, Lehner et al., 1991).  
 
TLR1/2 heterodimer plays an important role in the initial sensing of cytomegalovirus 
(CMV) and the consequent modulation of the adaptive immune response efficiently to 
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defend the host against this infection. Therefore, the observed defect in this heterodimer 
function in relation to BS patients can explain the recorded decrease in the CMV IgG in 
the same patient cohort (Palm and Medzhitov, 2009, Sato et al., 2006).  
 
The persistent shedding of salivary Epstein-Barr virus (EBV) in BS patients during both 
phases of oral activity (orally active and orally inactive periods) can aid in 
understanding the disease process. Knowing the process that preserves EBV and 
promotes latency in the host cells, one can appreciate the complex nature of the 
interaction between the microbial insult and the human immune defence. If this 
interaction is faulty or exaggerated, a pathological process is expected to be initiated. 
The initial sensing of EBV is through TLR2 independently from TLR1 or TLR6; this in 
turn will lead to the classical signalling cascade of TLRs, inducing the production of 
interleukin 6 (IL6) as one of the pro-inflammatory cytokines that support latent 
infection and persistence of EBV. Interestingly, enhanced inflammatory reaction is a 
recognized pathological feature of BS with a well-recorded high IL6 (Ariza et al., 2009, 
Evereklioglu et al., 2002, Trinchieri and Sher, 2007, Tsao et al., 2012). 
 
7.2 SIGNIFICANCE  
7.2.1 BEHÇET’S SYNDROME PATIENT COHORT IN THE UK 
This part of the thesis highlighted that BS is actually not as rare in western countries as 
was previously thought as there were 153 well-defined cases of BS patients enrolled at 
only two centres for the management and care of BS patients in the UK. This fact in 
turn will be useful in resource allocation and decision-making. Increasing the awareness 
of BS clinical diagnosis and management among health care professionals is crucial to 
allow early diagnosis and prevent its possible detrimental complications such as 
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blindness (Chamberlain, 1977, Jankowski et al., 1992, Mahr et al., 2008, Yazici et al., 
2008). 
  
7.2.2 ORAL HEALTH STATUS AND QUALITY OF LIFE ANALYSIS OF 
BEHÇET’S SYNDROME PATIENTS 
Establishing patients’ perception of their oral disease burden and its effect on their QoL 
is crucial in informing clinical decision-making and improving management strategies. 
It also identifies areas of need, aiming to redirect the clinical and research resources in a 
patient-focused direction (McGrath et al., 2003, Mumcu et al., 2006, Mumcu et al., 
2007a). This part of the thesis highlighted the fact that the oral health status of BS 
patients negatively affects their QoL, independently from any cross-cultural and ethnic 
differences. This fact emphasizes the importance of increasing the resources directed 
towards improving the oral health status for those patients and also towards researching 
the aetiology of the disease, aimed at discovering new and more effective treatment 
strategies.  
 
7.2.3 ORAL MUCOSAL EXPRESSION OF TOLL-LIKE RECEPTORS 2 AND 4 
The significant increase in TLR2 and TLR4 mRNA expression in the oral mucosa of BS 
patients during the relapsed phase can be very valuable in two main areas: (1) the 
potential future utilization of these markers to monitor the disease activity; and (2) the 
possibility of informing future research directions in unravelling the aetiology of the 
disease, as it is possible that one of the TLR2 and TLR4 ligands is playing a key role in 
the aetiopathogenesis of BS.  
 
Additionally, the observed shift towards expressing some of the unusual mRNA splice 
variants of TLR2 and TLR4 by BS patients’ oral mucosa might explain the defect in 
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TLR4 and TLR1/2 heterodimer function and indicates the potential presence of some 
abnormalities in the innate immune response to oral microbes in this syndrome.  
 
7.2.4 THE ORAL MICROBIOME OF BEHÇET’S SYNDROME PATIENTS 
Traditional microbiological techniques are available to examine the oral microbiome 
including culturing and biochemical identification; however, these techniques are 
laborious and pricey and do not easily lend themselves to systematic analysis of large 
patient cohorts. Studies have tended to be restricted to certain microbial genera, thereby 
limiting the investigation of the oral microbiome and ignoring the other genera that act 
as dependent and independent variants (Mumcu et al., 2009a, Narikawa et al., 1995). 
This part of the thesis is the first attempt to date to examine the whole microbiome in 
relation to BS patients and to fill this gap in the literature.  
 
The two main points concluded from this part of the study might prove to be of great 
significance in understanding the disease process and modifying the future clinical 
management of BS patients. (1) Despite the uncertainty about whether the reported 
differences in the microbiome in health and disease are of a causative or reactive nature, 
restoring the balance of these differences might prove to be of great importance in 
treating the oral ulceration and controlling the immunological response in BS patients 
and indeed in RAS patients. (2) The observed abnormalities in salivary shedding of 
EBV and the adaptive immune response to CMV correlate well with the documented 
defect in TLR2 function and in unravelling some areas of the BS disease process.  
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7.3 LIMITATIONS 
7.3.1 BEHÇET’S SYNDROME PATIENT COHORT IN THE UK 
The ISG criteria were used to classify and diagnose all cases enrolled in this study. 
While the ISG criteria are a very useful tool to ensure that only well-defined cases are 
enrolled in the research study, the tool has its limitations. It is unable to diagnose cases 
where patients have fewer than three episodes of recurrent oral ulceration per year, do 
not have oral ulceration, or develop oral ulceration later in their disease (Chang and 
Kim, 2003). 
 
This study is a hospital-based not population-based study, and as such invites a referral 
bias due to the specialized multi-disciplinary nature of the study centres (Oral Medicine, 
Rheumatology, Ophthalmology, and Immunology clinic). It is logical and indeed 
expected that it is the very complicated cases that are referred to these centres rather 
than the simple ones. 
 
7.3.2 ORAL HEALTH STATUS AND QUALITY OF LIFE ANALYSIS OF 
BEHÇET’S SYNDROME PATIENTS 
Again, the UK part of this study is hospital-based at specialized multi-disciplinary 
centres (Oral Medicine, Rheumatology, Ophthalmology, and Immunology clinic), 
which invited referral bias. The Turkish part of the study was also hospital-based, but in 
a Rheumatology clinic. Therefore, a difference in the severity of the cases was expected. 
Despite these differences, the reported impact of the oral health status on the QoL was 
similar in both cohorts.  
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7.3.3 ORAL MUCOSAL EXPRESSION OF TOLL-LIKE RECEPTORS 2 AND 4 
The sample sizes in certain assays were small; however, a statistical power calculation 
based on the pilot study proved that a sample size of 8 in each group has a 95% power 
to detect a difference between means of 0.0043 with a significant level (alpha) of 0.05 
(two tailed) (StatMate 2: GraphPad, USA). 
 
The exact protein product of the TLR2 and TLR4 mRNA splice variants is not 
completely understood, which in turn invites further research to investigate the function 
of these splices in health and disease.  
 
7.3.4 THE ORAL MICROBIOME OF BEHÇET’S SYNDROME PATIENTS 
Real time polymerase chain reaction (qPCR) using specific primers, matrix-assisted 
laser desorption/ionisation-time of flight (MALDI-TOF) mass spectrometry, denaturing 
gradient gel electrophoresis (DGGE), cloning and sequencing, next-generation 
sequencing, and the human oral microbial identification microarray (HOMIM) are 
different techniques that can be used to facilitate systematic mining of the oral 
microbiome (Bik et al., 2010, Colombo et al., 2009, Eigner et al., 2009, Paster et al., 
2001, Socransky et al., 2004, Wade, 2011). Considering the advantages and 
disadvantages of each method, MALDI-TOF was chosen in this part of the thesis for its 
quick and accurate identification of most culturable microorganisms and for its ability 
to give accurate typing information. MALDI-TOF identifies the viable culturable 
bacteria, fungi and mycobacteria, but with two limitations: (1) unculturable oral bacteria 
are not recognized by this technique; and (2) Streptococcus mitis is usually 
misidentified as Streptococcus pneumonia (Risch et al., 2010). However, the author 
tried to overcome the second limitation by performing optochin susceptibility and bile 
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solubility tests to check the identification accuracy of any microorganism reported as S. 
pneumoniae by MALDI-TOF (Kok et al., 2011). 
 
Due to the extent and cost of the analysis performed for each sample for the purpose of 
bacteriological and mycobacterial identification, the sample size in the MALDI-TOF 
analysis and the mycobacterial analysis was relatively small, although from well-
defined cohorts. Therefore, it is crucial to interpret these results carefully as a 
preliminary indication of the impact of BS and RAS on the community structure of the 
oral microbiome. In fact, variation in diet, oral hygiene and sampling time are factors 
that can significantly affect the oral microbial community structure in a single patient 
and/or healthy individual (Dewhirst et al., 2010). 
 
7.4 SCOPE FOR THE FUTURE 
7.4.1 BEHÇET’S SYNDROME PATIENT COHORT IN THE UK 
A population-based study to determine the prevalence of BS in the UK will be of great 
importance. In addition, a more detailed data collection sheet to capture more 
information about the different signs and symptoms of the disease, such as the nature of 
ocular involvements (anterior segment or posterior segment), will be valuable. 
  
7.4.2 ORAL HEALTH STATUS AND QUALITY OF LIFE ANALYSIS OF 
BEHÇET’S SYNDROME PATIENTS 
Similar cross-cultural comparative studies investigating BS patients’ QoL using a 
generic questionnaire or disease-specific questionnaire will be of interest to highlight 
the impact of other symptoms of the disease on the QoL of patients from different 
ethnic and cultural backgrounds (Bernabe et al., 2010, Touma et al., 2011, Gilworth et 
al., 2004). A population-based study will be more useful in controlling the confounding 
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factors and referral bias created in hospital-based studies. However, these types of 
studies are costly and control of the quality of diagnosis of the enrolled patients is 
difficult.  
 
7.4.3 ORAL MUCOSAL EXPRESSION OF TOLL-LIKE RECEPTORS 2 AND 4 
Investigating the presence of the TLR2 and TLR4 mRNA splice variants in other 
immune-related diseases as well as in different cell types is of great importance. 
Furthermore, studying the properties of the translated protein from each mRNA splice 
variant will help in understanding their biological functions. It is also important to 
establish if these isoforms affect the protein expression on the cell surface, and indeed 
their capability of forming certain heterodimers and interacting with other receptors and 
adaptor molecules.  
 
Outside the PhD project, the author is currently trying to understand the interaction 
between TLR2 and TLR1 or TLR6 on the surface of the PBMCs isolated from BS 
patients during the different disease activity, by using flow cytometry-based 
fluorescence resonance energy transfer (FRET) analysis. 
 
7.4.4 THE ORAL MICROBIOME OF BEHÇET’S SYNDROME PATIENTS 
The differences in the oral microbial community structure of ulcerated and non-
ulcerated mucosa of BS patients are of great interest, as restoring the balance of the 
microbial community can promote rapid recovery from oral ulceration. Supplementing 
these data with a molecular analysis of the unculturable bacteria by using HOMIM 
analysis and/or next-generation sequencing will ensure the complete identification of 
the oral microbiome of BS, including unculturable microorganisms, during the different 
oral activities of the disease.  
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Indeed the author has collected all the required samples for the molecular analysis as 
follows: saliva samples and swabs from ulcerated and non-ulcerated BS oral mucosa 
from BS patients during orally active and orally inactive phases of the disease. Samples 
have also been collected from RAS patients and HC volunteers, with informed consent 
under the ethical approval for this study of the disease. Microbial deoxyribonucleic acid 
(DNA) was isolated using a DNA isolation kit (Gentra, Qiagen, UK). All samples were 
checked for the presence of DNA by NanoDrop spectrophotometer (Labtec, UK) and 
for the presence of bacterial DNA by using general bacterial primers for 16S ribosomal 
DNA gene. The samples have been stored at -80° ready for the HOMIM and/or next-
generation sequencing analysis. The author also has applied for funding to support this 
analysis, hoping to embark on it during her postdoctoral training.  
 
7.5 CONCLUSION 
BS is a devastating chronic disease affecting patients’ QoL. The oral health status of 
these patients has a negative effect on their QoL. Investigating the oral environment is a 
very important research area that can unravel the mysterious disease aetiology and 
pathogenesis of BS, allowing the future discovery of new, more useful treatment 
modalities. Indeed, in this thesis the author has highlighted that the higher level of 
expression of some of the unusual splice variants of TLR2 and TLR4 mRNA in the oral 
mucosa might explain the observed functional defect in TLR1/2 heterodimer and TLR4, 
which in turn can be expected to cause a failure in the adaptive immune response 
modulation resulting in the observed decrease in the expression of CMV IgG and the 
increased susceptibility to oral infections (Figure 7.1). Furthermore, it is envisaged that 
the reported discrepancy in the oral microbiome of BS patients can be targeted in the 
future by probiotics to restore the balance of the oral microbial community, leading to 
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Evidence of abnormal 
innate immunity 
•↑ TLR2b 
•↑ TLR2d 
•↑ TLR2e 
•↑ TLR4.3 
•↑ TLR4.4 
•↓ TLR2/1 heterodimer function 
•↓ TLR4 function 
Evidence of abnormal 
adaptive immunity 
• ↓ CMV IgG 
Unbalanced oral 
microbiome and 
increase susceptibility 
to oral infections 
•↑ Actinobacteria phyla 
•↑ Bacteroidetes phyla 
•↑ EBV 
•↓ Neisseria 
•↓ Veillonella 
Poor oral health status 
•↑  Decayed, missing, filled teeth index 
•↑ Gingival index 
•↑  Sulcus bleeding index 
•↑ Periodontal probing depth 
•↑ Attachment level 
better oral health which in turn will potentially enable a better control of the BS immune 
response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
# 
 
 
 
 
 
 
 
 
Figure 7.1: Schematic presentation of the main findings of this thesis in relation to BS 
patients.  
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APPENDIX (3) QUALITY OF LIFE QUESTIONNAIRE 
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INSTRUCTIONS:  
This set of questions asks for your views about your health and oral health. This 
information will helps keep track of how you feel and how well you are able to do your 
usual activities. Answer every question by marking the answer as indicated. If you are 
unsure about how the answer a question please give the best answer you can.   
 
OHIP 
Because of problems with 
your teeth, denture or mouth 
have you  
Never Hardly 
ever 
Occasionally Fairly 
often 
All 
the 
times 
1. Had trouble pronouncing 
words 
0 1 2 3 4 
2. Felt sense of taste has 
worsened 
0 1 2 3 4 
3. Had painful aching in 
the mouth 
0 1 2 3 4 
4. Found it uncomfortable 
to eat any food 
0 1 2 3 4 
5. Have been self-
conscious 
0 1 2 3 4 
6. Felt tense 0 1 2 3 4 
7. Had an unsatisfactory 
diet 
0 1 2 3 4 
8. Had to interrupt meals 0 1 2 3 4 
9. Found it difficult to relax 0 1 2 3 4 
10. Have been a bit 
embarrassed 
0 1 2 3 4 
11. Have been irritable with 
other people 
0 1 2 3 4 
12. Had difficulty doing 
unusual jobs 
0 1 2 3 4 
13. Felt life in general was 
less satisfactory 
0 1 2 3 4 
14. Have been totally unable 
to function 
0 1 2 3 4 
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